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Zusammenfassung 
 
Die vorliegende Dissertation befasst sich mit der Anwendung von quantenchemischen 
Berechnungen zur Untersuchung von zytostatischen Ruthenium-Komplexen. In den letzten 
Jahren wurden quantenchemische Methoden erfolgreich auf dem Gebiet der 
krebshemmenden Metallkomplexe angewendet.  
 
Zu dem Zeitpunkt meiner Doktorarbeit waren die krebshemmenden Ruthenium-
Verbindungen nicht ausreichend aus quantenchemischer Sicht untersucht worden, deshalb 
habe ich mit einem sorgfältigen Methodenvergleich begonnen. Gasphasen-Berechnungen 
wurden auf dem DFT-Niveau mit Hilfe der ubiquitären B3LYP-Funktional durchgeführt und 
die Leistungsfähigkeit der von zur Verfügung stehenden Solvatisierungsmethoden für die 
Berechnung von Standardredoxpotentialen (SRP) wurde verglichen. Demzufolge habe ich die 
SRP-Werte von Ru(III/II)-Paaren berechnet, deren elektrochemisches Verhalten in der 
Literatur bereits beschrieben wurde. Ein Vergleich mit experimentellen Werten hat 
beträchtliche Fehler bei bestimmten Kombinationen von Solvatisierungsmethoden und Solut-
Hohlraum ergeben. Zum Beispiel, der absoluter Fehler (mean unsigned eehler, MUE) mit der 
PCM/UA0-Kombination, die eine Methode der Wahl in Gaussian 03 darstellt, beträgt 0.23 V 
(5.4 kcal/mol). Die Poisson-Boltzmann Finite-Element-Methode (PBF), implementiert in 
Jaguar 7 zusammen mit Standard-Hohlraum, liefert geringfügig bessere Ergebnisse mit MUE 
von 0.16 V (3.7 kcal/mol). Da die betrachteten Redox-Paare eine Ladung von +3/+2 bis –1/-2 
tragen und die Voraussage von Solvatisierungsenergien am schwierigsten für hochgeladene 
Ionen ist, finden diese Ergebnisse Anwendung auch bei DFT-Studien von Reaktionen anderer 
Metall-Komplexe, die in der Katalyse, Biologie und Medizin involviert sind. 
 
Das erfolgreichste Berechnungsverfahren wurde wie angegeben für das Studium von 
vier potentiellen tumorhemmenden Ruthenium(III)-Komplexen verwendet (Abbildung): 1 – 
trans-tetrachlorido(dimethylsulfoxid)imidazolruthenat(III) (NAMI-A), 2 – trans-
tetrachloridobis(1H-imidazol)ruthenat(III) (ICR), 3- trans-tetrachloridobis(1H-
pyrazol)ruthenat(III), und 4 – trans-tetrachloridobis(1H-indazol)ruthenat(III) (KP1019) und 
deren reduzierte Analoga. Elektronische Aspekte, die deren elektrochemisches Verhalten 
bestimmen, wurden untersucht mit Hilfe der Energy Decomposition Analysis und lassen die 
entscheidende Rolle von π-Elektronen-Akzeptor-Charakter von DMSO- und Indazol-
Liganden bei der Stabilisierung der Ru(II)-Spezies erkennen. Der Einfluss der Elektronen-
Donor-Eigenschaften von Protein- und DNA-Modellen mit Direktbindung zum Metall, des 
mittleren pH-Wertes, und der dielektrischen Konstante auf die SRP-Werte wurde untersucht. 
Zusätzlich gibt die Studie Aufschluss über den mechanistischen Verlauf des Aquations-
Prozesses. In Übereinstimmung mit den verfügbaren experimentellen Daten und im 
Gegensatz zu einem Teil der früher publizierten quantenchemischen Berechnungen (die für 
den Aquations-Prozess einen Interchange-Mechanismus von assoziativem Charakter 
annehmen (Ia)), habe ich eine Bevorzugung des stark dissoziativen Interchange-
Mechanismus festgestellt (Id). Darüber hinaus habe ich zum ersten Mal den limitierenden 
dissoziativen Mechanismus (D) für die Aquation von Ru(II)-Analoga untersucht und dessen 
Bevorzugung gegenüber dem Austauschmechanismus festgestellt. Der Aquations-Prozess 
wurde ausführlich untersucht durch die Erstellung der Energie-Profile bis zum zweiten 
Aquationsschritt. Die Bedeutung von Aquationsprodukten, Mono- und cis-Diaquakomplexen, 
als Vorstufen bei der biologischen Wirkung wurde ausgewertet. Die Kinetik und 
Thermodynamik von Reaktionen in Bezug auf die Biomodelle wurde berechnet und keine 
klare Bevorzugung für Stickstoff- oder Schwefelproteinbindungsstellen gefunden. Bei der 
Bindung zu isolierten Purin-Basen als Modell für die Reaktion mit DNA wurde eine 
kinetische Präferenz für die Bindung zu Guanin gegenüber Adenin in reduzierten cis-Diaqua-
Komplexen nachgewiesen; mit Stabilisierung der charakteristischen Übergangszustand durch 
Wasserstoffbrücken - ähnlich wie bei Reaktionen von Cisplatin. Die Wasserstoffbindung 
zwischen O6 von Guanin und dem cis-Aqua-Liganden stabilisiert die Reaktionsprodukte in 
beiden Oxidationszuständen. Die mögliche Beteiligung von Ru(III)-Komplexen am Redox-
Kreislauf in den Krebszellen, der eine Produktion von reaktiven Hydroxyl-Radikalen 
katalysieren kann, wurde ebenfalls erörtert. 
 
Die quantenchemischen Berechnungen wurden angewendet, um die elektronischen 
Aspekte der Elektrochemie von krebshemmenden Gallium- und Eisenkomplexen mit redox-
aktiven α-N-Thiosemicarbazonen zu beschreiben. Die intuitive Annahme, dass die Reduktion 
von einer Verbindung nach der Bindung zu einem Metallion erleichtert wird, scheint nur 
dann gültig zu sein, wenn der freie Ligand, in unserem Fall Thiosemicarbazonat, als 
Referenz-Substanz betrachtet wird, wobei ein Proton die Reduktion von Thiosemicarbazon 
stärker begünstigt als das Fe(II)-Ion mit seiner d6-Low-Spin-Konfiguration. Die berechneten 
Redoxpotentiale korrelieren sowohl mit den berechneten Hirshfeld-Partialladungen auf dem 
Thiosemicarbazon-Rest dieser Verbindungen, als auch mit den Energieniveaus  deren 
LUMO-Orbitale. 
 
Die potentiell krebshemmenden Ruthenium(III)-Verbindungen: 
 1 – trans-tetrachlorido(dimethylsulfoxid)imidazolruthenat(III) (NAMI-A), 2 – trans-
tetrachloridobis(1H-imidazol)ruthenat(III) (ICR), 3- trans-tetrachloridobis(1H-
pyrazol)ruthenat(III), und 4 – trans-tetrachlorido-bis(1H-indazol)ruthenat(III) (KP1019) 
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Summary 
 
This thesis focuses on the applications of the computational chemistry methods for the 
study of ruthenium(III) potential anticancer complexes. Since recently the computational 
chemistry has emerged the vast area of anticancer metallo-drugs research with great success. 
Particularly the outstanding contributions were made in the revealing the factors governing 
the mode of action of cisplatin (the most successful product of the medicinal inorganic 
chemistry for cancer treatment). 
 
At the moment of starting my thesis, the ruthenium(III) anticancer compounds were 
neglected by computational chemists, therefore I began with a careful methodological 
benchmarking. The gas phase calculations were performed at DFT level by using the 
ubiquitous B3LYP functional and the performances of available solvation methods in the 
computations of the standard redox potentials (SRPs) have been compared. For this purpose I 
have calculated SRP values of Ru(III/II) pairs that were electrochemically characterized in 
the literature. Comparison with experimental data revealed substantial errors in some of the 
combinations of solvation method and solute cavity. For example, the overall mean unsigned 
error (MUE) with the PCM/UA0 combination, which is the popular default in Gaussian 03, 
amounts to 0.23 V (5.4 kcal/mol). The Poisson-Boltzmann finite element method (PBF) 
implemented in Jaguar 7 together with the default cavity performs slightly better, with the 
overall MUE being 0.16 V (3.7 kcal/mol). Because the redox pairs considered bear molecular 
charges from +3/+2 to −1/−2 and the prediction of solvation free energies is most challenging 
for highly charged species, these results may be used also for DFT studies of the reactions of 
other metal complexes involved in catalysis, biology, and medicine. 
 
In this way revealed, the most successful computational setup has been used for 
exploration of the chemical behavior of four potential anticancer ruthenium(III) species 
(Chart): 1 - trans-tetrachlorido(dimethylsulfoxide)imidazoleruthenate(III) (NAMI-A), 2 - 
trans-tetrachloridobis(1H-imidazole)ruthenate(III) (ICR), 3 - trans-tetrachloridobis(1H-
pyrazole)ruthenate(III), and 4 - trans-tetrachloridobis(1H-indazole)ruthenate(III) (KP1019) 
and their reduced analogs. The electronic aspects governing their electrochemical behavior 
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have been investigated by using the bond energy decomposition analysis revealing the 
decisive role of π-electron acceptor character of DMSO and indazole ligands in stabilization 
of Ru(II) species. Influence of the electron donor properties of the protein and DNA models 
directly bound to the metal, the medium pH and dielectric constant on the SRPs were 
examined. Furthermore, the study sheds light into the mechanistic insights of the aquation 
process. In agreement with experimental data available and contrary to part of the previous 
computational works (which study the aquation of the Ru(III) species to proceed via an 
interchange mechanism of associative character (Ia)) I found the preference for strong 
dissociative character of the interchange mechanism (Id). Moreover, for the first time I have 
studied the limiting dissociative mechanism (D) of the aquation of Ru(II) analogs and have 
found it to be prefered over the interchange mechanism. The aquation process was 
investigated in detail by drawing the energy profiles up to the second aquation step. The 
importance of aquation products, mono- and cis-di-aqua complexes, as precursors for the 
biological actions is analyzed. The kinetics and thermodynamics of reactions towards 
biomodels have been computed and no clear preference for either nitrogen or sulfur protein 
binding sites was found. In the binding to isolated purinic nucleobases, to model the reaction 
with DNA, the kinetic preference for binding guanine over adenine is found for the reduced 
cis-di-aqua complexes; the characteristic transition structures being stabilized by a hydrogen 
bonding pattern similar to cisplatin reactions. The hydrogen bond between guanine O6 and 
cis-aqua ligand stabilizes the reaction products in both oxidation states. The possible 
involvement of Ru(III) complexes in the redox cycling inside the cancer cell that can catalyze 
the generation of reactive hydroxyl radicals is discussed as well.  
 
The quantum chemical calculations were used to describe the electronic aspects of 
electrochemistry of antineoplastic gallium and iron complexes with redox non-innocent α-N-
heterocyclic thiosemicarbazones. The intuitive assumption that the reduction of a compound 
is facilitated when it binds to a metal ion appears to be valid only if the free ligand, in our 
case the thiosemicarabazonate, is considered as the reference compound, whereas a proton 
promotes the reduction of the thiosemicarbazone more strongly than does the iron(II) ion 
with its d6 low-spin electron configuration. The computed redox potentials correlate both 
with the calculated Hirshfeld partial charges on the thiosemicarbazone moieties in these 
compounds and with the energy levels of their LUMOs. 
 7 
 
Potential anticancer ruthenium(III) species: 
 1 - trans-tetrachlorido(dimethylsulfoxide)imidazoleruthenate(III) (NAMI-A), 2 - trans-
tetrachloridobis(1H-imidazole)ruthenate(III) (ICR), 3 - trans-tetrachloridobis(1H-
pyrazole)ruthenate(III), and 4 - trans-tetrachloridobis (1H-indazole) ruthenate(III) (KP1019) 
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I. Introduction 
 
I.1. Cancer Therapy 
 
Roughly one person in eight in the world will die of cancer.1 The disease is 
characterized by the disturbances of the most fundamental rules of behavior of the cells in a 
multicellular organism. As a result of the failure of growth or division regulatory systems, the 
affected cells proliferate boundlessly and colonize tissues normally reserved for other cells.2 
The methods of cancer treatment include surgery, radiation therapy, chemotherapy, and 
immunotherapy. The choice of therapy depends upon the cancer type and the stage of the 
disease, as well as the general condition of the patient. Complete removal of the affected 
tissue with least harm to the rest of the body is the treatment goal. The surgery alone is 
effective mainly in the cases of benign tumors (their cells do not have the ability to invade the 
surrounding tissue, and stay clustered together in a single mass). In contrast, the malignant 
tumors have the tendency to invade adjacent tissue or to spread through the bloodstream and 
lymphatic vessels to form metastasis at other sites of the body, which often limits surgery 
effectiveness. In such cases the surgery is combined with other methods, and frequently with 
chemotherapy.  
 
The modern era of cancer chemotherapy3 started when the war gas sulfur mustard was 
used in patients in 1931 (abandoned because of high toxicity). The second generation 
mustard, nitrogen mustard, was tested in the 1940s subsequently in lymphoma treatment first 
in mice and then in a patient. The result was a dramatic reduction in the patient's tumor 
masses. Although this effect lasted only a few weeks, this was the first step to the realization 
that cancer could be treated by pharmacological agents. Since then, a number of drugs (which 
act as alkylating agents, antimetabolites, mitotic inhibitors, antibiotics or hormones) were 
approved and largely used in the cancer chemotherapy.4 Among them metal-based anticancer 
drugs play a crucial role. Three platinum complexes, cisplatin, carboplatin, and oxaliplatin, 
which act as alkylating-like agents, are used in about 50% of all tumor therapies, displaying 
significant therapeutic activity in a series of solid tumors.5 Chemotherapy acts by killing 
rapidly dividing cells, one of the main properties of cancer cells. Consequently, the fast-
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dividing cells of the body, such as the cells of the bone marrow, digestive tract and hair 
follicles, are affected, giving rise to a range of side effects. Common side effects associated 
with chemotherapy include: immunosuppression, anemia and myelosuppression (caused by 
partial or total destruction of bone marrow), mucositis (inflammation of the lining of the 
digestive tract), nausea and vomiting, nephrotoxicity, diarrhea or constipation, and alopecia 
(hair loss). The effectiveness of chemotherapy is often limited by general toxicity to other 
tissues in the body. The understanding of the mode of action of the anticancer drugs at 
molecular level is essential to rational drug development.  
 
I.2. Computational Chemistry 
 
Along with physiologists, the chemists actively participate in the mode of action 
assessment of the drugs. This is possible due to the vast chemical experience and the diversity 
of physico-chemical methods available for investigation of the microscopic world. Predicting 
properties of the molecular systems by computer simulations is one of the relatively new 
methods successfully adopted by chemists. The medium for scientific research in 
computational chemistry is the computer’s processor, the methods are physical models, and 
the tools are mathematical algorithms. The in silico experiments are nowadays used to 
determine the spatial structures of the molecules, and the obtained electronic information is 
directly compared with a variety of spectroscopic data (Infrared, Raman and NMR). But most 
important the computers improve continuously the accuracy in the prediction of microscopic 
and macroscopic chemical systems behavior otherwise not accessible, or often too expensive 
for conventional methods. For example computationally can be investigated the reaction 
intermediates and transition states, which, being crucial species in chemical processes but 
having a very short lifetime, are difficult to observe experimentally. Thus, experimentally 
proposed and theoretically possible competing reaction mechanisms can be rigorously 
investigated by computation chemists. In the humans fight against cancer computational 
chemistry already proves its distinctive value. The hydrolysis of the most successful metallo-
drug cisplatin6 was rigorously investigated,7 along with the factors governing its in vivo 
binding preferences and reactivity.8 The theoretical predictions correlate very well with 
experimental findings. Despite the fact that ruthenium(III) complexes9 are known for years to 
have similar or even better anticancer potency than cisplatin, at the moment of starting my 
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thesis systematic computational investigation of the ruthenium(III) anticancer drugs was not 
carried out.  
 
The work is focused on the elucidation of the chemical behavior at molecular level of 
two ruthenium(III) complexes NAMI-A10 (imidazolium [trans-
tetrachlorido(dimethylsulfoxide)imidazoleruthenate(III)]) and KP101911 (indazolium [trans-
tetrachloridobis(1H-indazole)ruthenate(III)]) (Chart 1) which successfully completed phase I 
clinical trials.12 Chapter II has been entirely dedicated to the basic theoretical and 
computational concepts used in the study. In chapter III the systematic benchmarking of the 
available solvation models by predicting redox potentials of ruthenium(III) complexes is 
presented. In chapter IV, by using carefully benchmarked method, an in silico four-species-
evolution approach which includes trans-tetrachloridobis(1H-imidazole)ruthenate(III) (ICR) 
and trans-tetrachloridobis(1H-pyrazole)ruthenate(III) to rationally connect NAMI-A and 
KP1019 has been used to investigate the behavior of potential ruthenium(III) anticancer 
drugs. In this sense, along with aquation, the reactions of the selected compounds with 
biological protein and DNA models have been investigated, in both the kinetic and 
thermodynamic aspects. In chapter V an example of the use of the computational methods to 
analyze the electrochemistry of some metal complexes with non-innocent α-N-heterocyclic 
chalcogensemicarbazones is presented.  
 
Chart 1. NAMI-A and KP1019, successful Ru(III) anticancer complexes in clinical trials. 
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II. Theory 
 
The chapter presents the basic concepts of the total energy calculation methods, in 
particular DFT, an overview of the solvation computational models, and shortly the structure 
optimization techniques used in molecular modeling. More information is available in 
excellent introductory manuals on the theory and applications of computations in chemistry 
and physics.1 
 
II.1. Total Energy Calculation 
 
The ground state properties of a molecular system are determined by the interactions 
between the electrons and nuclei and to describe these interactions it is necessary to use 
quantum mechanics. The nuclear Hamiltonian, Ĥn, and the electronic Hamiltonian, Ĥe, fully 
describe the molecular system in the Schrödinger equation: 
 
 Ψ=Ψ+ EHH en )ˆˆ(  (1) 
 
where E is the total energy, Ψ = Ψ(x1, x2, ..., xn) is the wave function, and Ĥ is the 
Hamiltonian operator. Because the fundamental interaction at the atomic level is the 
electrostatic Coulomb interaction, along with kinetic component describing the particles 
motion, the Hamiltonian contains the electrostatic components. The electronic Hamiltonian 
has the form: 
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where the three terms are the electron’s kinetic energy, and electrostatics: the electron-nuclei 
and the electron-electron interaction. Despite the fact that the interactions make this equation 
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impossible to solve completely, manageable equations are obtained by using approximations. 
The adiabatic or Born-Oppenheimer approximation assumes that the electrons respond 
instantaneously to heavy nuclei motion and thus the total wavefunctions can be factorized 
into separate wavefunctions for the electrons and the nuclei respectively: 
 
 neT ΨΨ=Ψ *  (3) 
 
The contributions to the electronic energy Ee of an N-electron molecular system 
consisting of α type nuclei, in the HF methods are:  
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where ET is the kinetic energy of electrons, EV represents nuclei-electrons electrostatic 
interaction, and EJ is classic electrostatic interaction between electrons. The last two 
components describe the electron correlation: a pure quantum phenomenon that take into 
account the interactions between electrons, others than motion and classical electrostatics. EX 
is the electron exchange component of energy (so called Fermi correlation) describes the 
correlation between electrons with parallel spin. This prevents the parrallel-spin electrons 
from being found at the same point in space. On the other hand, the second quantum term EC 
(Coulomb correlation) describes the correlation between the spatial positions of electrons 
with opposite spin due to their Coulomb repulsion. The Coulomb correlation energy is not 
possible to describe within the Hartree-Fock HF approach. Numerically this term is equal to 
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the difference between the exact total energy of the system and the energy calculated at HF 
level using a complete basis set. 
 
II.2. Density Functional Theory 
 
The basis for the Density Functional Theory (DFT) is the proof by Hohenberg and 
Kohn2 that the ground state electronic energy is determined completely by the electron 
density ρ(r). While DFT is conceptually and computationally very similar to Hartree–Fock 
theory, it became popular due to results quality, and computational accessibility of large 
electronic systems. The significance of the Hohenberg–Kohn theorem is perhaps best 
illustrated by comparing it with the wave function approach. While the complexity of a wave 
function increases exponentially with the number of electrons, the electron density has the 
same number of variables, independent of the system size. A wave function for an N-electron 
system contains 4N variables: three spatial and one spin coordinate for each electron. The 
electron density being the square of the wave function, integrated over N−1 electron 
coordinates, has each spin density depending on three spatial coordinates, independent of the 
number of electrons (eq. 5). Although it has been proven that different density yields a 
different ground state energy, the functional connecting these two quantities is not known. 
The goal of DFT methods is to design functionals connecting the electron density with the 
energy.  
 
 ∫ Ψ= NN drdrrrrNr ...),...,()( 2
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II.2.1. The Energy Functional and Energy Calculations in DFT 
 
According to Kohn and Sham3 the energy functional E[ρ(r)] can be written as: 
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where ET is the kinetic energy of non-interacting electrons followed by the energy 
contribution from the interaction of electrons with the external nuclear potential V(r), the 
electron-electron interaction term, and the last term EXC[ρ(r)] represents the exchange-
correlation functional. Using the electron density as a parameter, there is a variational 
principle analogous to that in wave mechanics, i.e. given an approximate electron density ρ(r) 
(assumed to be positive definite everywhere) that integrates to the number of electrons, the 
energy given by this density is an upper bound to the exact ground state energy, provided that 
the exact functional is used: 
 
 [ ] [ ])()(00 rErEE ρρ ≤=  (7) 
 
The total energy functional for the interacting many-particle system can be transformed into a 
set of one-particle equations, called the Kohn-Sham (KS) equations. By using a set of one-
electron orbitals:  
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and Lagrange multipliers for constraining the system to a fixed number of atoms, the KS are:  
 
 19 
 iiieff rV ϕεϕ =



+∇− )(
2
1 2
 (9) 
 
The effective potential Veff(r) (eq. 10) has a contribution from the nuclei-electron interaction, 
while the electron-electron interaction is divided into the Hartree term and the correlation 
potential VXC(r).  
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The problem of finding the ground state of a molecule becomes a mean field problem 
where non-interacting electrons are moving in an effective potential of other electrons. Eq. 9 
is solved self-consistently and the ground state electron density is determined by eq. 8. The 
self-consistent scheme is an iterative process to obtain the correct electron density of the 
molecular ground state. This is achieved by assigning trial wave functions which are used to 
calculate first the electron density ρ(r), by eq. 8, then Veff by eq. 10 and Veff are then inserted 
into the Kohn-Sham equations. New trial wave functions are generated by solving the KS 
equations and the procedure is repeated until the convergence is achieved. The sum over the 
occupied one-electron energies εi has to be corrected with a Coulomb and an exchange-
correlation term to give the correct total energy: 
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II.2.2. The Exchange-Correlation Functional 
 
Theoretically, the Kohn-Sham equations yield the exact ground-state energy by using 
the exact forms of EXC and VXC. However, these two quantities are only approximate 
challenging the scientists to carefully choose the available functionals for their specific 
purpose. The diversity of the functional forms to derive the exchange correlation energy 
determines the difference between various DFT methods. 
 
The simplest model is the Local Density Approximation (LDA), where the electron 
density is assumed to be slowly varying, such that the density can be locally treated as a 
uniform gas: homogeneous electron gas, also known as jellium, is a quantum mechanical 
model of interacting electrons within an infinite volume of space and neutralized with a 
uniformly distributed background positive charge. For a spin-unpolarized system, a local 
density approximation for the exchange-correlation functional is written as: 
 
 [ ] ∫= drrrrE XCLDAXC ))(()()( ρερρ  (12) 
 
where ρ(r) is the electronic density and εxc is the exchange-correlation energy function of the 
density alone. The exchange-correlation energy is decomposed into exchange and correlation 
terms linearly: 
 
 CXXC EEE +=  (13) 
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The exchange term takes on a simple analytic form for the homogeneous electron gas: 
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The correlation energy is calculated by Quantum Monte Carlo methods. Although the 
LDA method is based on a very crude model, it provides results which are in general 
comparable or even better than those calculated by methods based on the Hartree-Fock 
approximation. Improvements over the LDA approach must consider a non-uniform electron 
gas.  
 
In methods based on the Generalized Gradient Approximation (GGA), the 
dependence of exchange-correlation energy on the local density gradient is used along with 
the local electron density: 
 
 [ ] ∫ ∇= drrrrrE XCGGAXC ))(),(()()( ρρερρ  (15) 
 
Various GGA functionals use different representations of εxc functions. Although 
there are cases when LDA perform better than GGA, the later improve considerable the 
description of some molecular properties (e.g. the binding energies). One of the earliest and 
most popular GGA exchange functionals was proposed by A. D. Becke4 (B or B88) as a 
correction to the LSDA exchange energy (LDA for spin polarized systems): 
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The β parameter was determined by fitting to known data for the rare gas atoms using 
the dimensionless gradient variable x. It reduces the error in the exchange energy by almost 
two orders of magnitude relative to the LSDA results and thus represents a substantial 
improvement for a simple functional form containing only one adjustable parameter. There 
have similarly been various GGA functionals proposed for the correlation energy. One 
popular functional is due to Lee, Yang and Parr (LYP).5 The LYP correlation functional is 
often combined with the B88 exchange functional to produce the BLYP.  
 
The next generation of GGA methods is higher order gradient, or meta-GGA, 
methods which are characterized by the introduction of higher order derivatives of the 
electron density in the description of the exchange-correlation function. 
 
Models that include exact HF exchange are denoted by hybrid methods, the Becke 3 
parameter functional (B3) methods is example of such hybrid models, with the popular 
B3LYP method5,6 defined by: 
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The a, b and c parameters were determined by fitting to experimental data and depend on the 
chosen forms for GGAXE  and 
GGA
CE , with typical values being a ~ 0.2, b ~ 0.7 and c ~ 0.8. The 
usage of GGA and hybrid functionals yields to major improvement in terms of accuracy for 
chemical applications. At the moment the B3LYP functional proposed in 1993 is one of the 
most successful in terms of overall performance. Although the performance might be 
improved by fitting different combinations of exchange and correlation functionals to 
experimental data for a given property, such measures often result in the deterioration of the 
results for other properties.  
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II.2.3. Basis Set and Effective Core Potential Approximation 
 
The single particle wave functions used to derive the electron density in eq. 8 are 
expanded into a linear combination or atomic orbitals (LCAO) χm according to: 
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In principle any type of basis functions χm may be used for molecular calculations: 
exponential, Gaussian, polynomial, cubic functions, wavelets, plane waves, etc. A successful 
set of basis functions has two main characteristics: (i) the functions should have a physical 
reasonable behavior, and converge rapidly as more basis functions are added. For atomic and 
molecular systems, functions should go toward zero as the distance between the nucleus and 
electron becomes large. (ii) the functions should make it easy to calculate all the required 
integrals. The exponential functions are known to be the exact solution for the hydrogen 
atom. They are used to build the Slater type orbitals (STOs) (eq. 19), which decay 
exponentially from their origin. Despite the fact that STOs describe better the behavior of 
atomic wave functions, the Gaussian type orbitals (GTOs) (which have a Gaussian behavior, 
eq. 20) are much easier to handle numerically and they are preferred in the DFT calculations 
as much as in conventional ab initio techniques. 
 
 ),(),,( 1 ϕθϕθχ ς mlrnSTO YeNrr −−=  (19) 
 ),(),,( 222 ϕθϕθχ ς mlrlnGTO YeNrr −−−=  (20) 
 
Another aspect to take into account, when choosing the computational level to 
estimate the total energy of a molecular system, is the increase of the number of core 
electrons, unimportant in the chemical sense, with the rise of atomic number. In such cases 
the valence orbitals use a large number of basis functions to adequately account for electron-
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electron repulsion. Even more troubles arise in the lower half of periodic table where the 
relativistic effects further complicate the systems. The approach to solve these problems is to 
model the core electrons by a suitable function and to treat only the valence electrons 
explicitly. The usage of Effective Core Potential (ECP) became a common approach that 
gives good result at a fraction of the cost of a calculation involving all electrons, and part of 
the relativistic effects may also be accounted, without having to perform the full relativistic 
calculation. The potential have its parameters fitted such that the solutions of the Schrödinger 
equation produce pseudo-orbitals matching the all-electron valence orbitals.  
 
II.2.4. DFT Limitations  
 
In the treatment of the following systems the current DFT functionals are known to 
perform poorly1b: 
(i) The weak interactions due to dispersion forces, which arise from electron correlation 
in wave function methods, are poorly described by current DFT methods.7 However, the 
mainly electrostatic nature makes the hydrogen bonded systems well described by many DFT 
functionals.  
(ii) Loosely bound electrons, such as anions arising from systems with relatively low 
electron affinities, represent a problem for exchange–correlation functionals that do not 
include self-interaction corrections. Since these electrons have most of the associated density 
far from the nuclei, this may cause the self-interaction error to be larger than the actual 
binding energy, and thus lead erroneously to an unbound electron. Nevertheless, even a single 
set of diffuse functions added to a medium-sized basis set will give a reasonable estimate of 
the experimental electron affinity.8 The basis set limits the outer electron to be in the correct 
physical space, and the exchange–correlation functional gives a reasonable estimate of the 
energy of this density.  
(iii) Chemically bonded systems involving: two-centre two-electrons (e.g. normal covalent 
bonds), two-centre four-electrons (e.g. steric repulsion between closed shell systems), and 
three-centre three-electrons (e.g. radical abstraction) are reasonably described by gradient-
corrected methods. On the other hand systems involving: two-centre one-electron (e.g. radical 
cations), two-centre three-electrons (e.g. radical anions), and three-centre four electrons (e.g. 
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atom transfer transition structures) are predicted to be too stable.9 The dissociation of charged 
odd-electron systems is a problem for most DFT methods, with the dissociation energy 
profile displaying an artificial barrier and incorrect dissociation energy. Transition structures 
are similarly predicted to be too stable (barriers are underestimated) by functionals that do not 
include exact exchange. Since Hartree–Fock overestimates activation barriers, the hybrid 
methods involving exact exchange, often give reasonable barriers. 
(iv) The exchange–correlation functional is local, depending only on the density and 
possibly its derivatives at a given point, and this causes DFT methods to be unsuitable for 
describing charge transfer systems, where an electron is transferred over a large distance.  
(v) In HF theory the energy difference between states with different spin multiplicity 
with the same orbital occupancy is given by an exchange integral. In DFT, this must be 
described by the exchange–correlation functional, which only depends on the electron 
density. If the two spin states arise from the same electron configuration the two electron 
densities are very similar, and this makes the results sensitive to the details of the exchange–
correlation functional. In transition metal systems, where several low-energy spin states are 
often possible, HF favors high spin states (HS) while KS methods favor low spin states (LS). 
Hybrid methods perform differently depending on the studied system. For example, the 
authors of ref. 10 found the PBE011 functional (which includes ab initio estimate of the 
hybrid mixing of exact and GGA exchange) to perform best for computing the HS-LS energy 
difference in Fe(II) complexes with small ligands ([Fe(H2O)6]2+ and [Fe(NH3)6]2+). While the 
widely employed B3LYP (which uses without reoptimization the three semi-empirical 
coefficients fitted for experimental data together with PW9112 correlation) performs only 
acceptable. The authors in ref. 13 preferred the BP864,14 over B3LYP in the computations on 
zirconium(IV) complexes. The overestimation of the contribution of exchange energy by the 
B3LYP functional is well documented and the fitting of the mixing coefficients was proposed 
to overcome the problem.15 
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II.3. Electron Population Analysis 
 
Except the energy, another property derived after determining the electronic wave 
function is the atomic electron population which is often used for discussing and rationalizing 
structural and reactivity differences between molecules. There are three commonly used 
methods for assigning a charge to a given atom.1b  
 
II.3.1. Population Analysis Based on Basis Functions 
 
The Mulliken Population Analysis16 is an example of method using basis functions to 
derive the electron population. The scheme uses DS matrix17 for distributing the electrons 
into atomic contributions. The diagonal element DmmSmm is the number of electrons in the m 
atomic orbital (AO), and an off-diagonal element DmnSmn is (half) the number of electrons 
shared by AOs m and n (there is an equivalent DnmSnm element). The contributions from all 
AOs located on a given atom A may be summed up to give the number of electrons 
associated with atom A. In the Mulliken scheme the contribution involving basis functions on 
different atoms are equally divided between the two atoms: 
 
 ∑∑
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With the gross charge in atom A being the sum of the nuclear and electronic contributions:  
 
 AAA ZQ ρ−=  (22) 
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II.3.2. Population Analysis Based on the Electrostatic Potential 
 
A significant part of the non-bonded interaction between polar molecules is described 
in terms of electrostatic interactions between fragments with different electron distribution. 
The fundamental interaction is between the Electrostatic Potential18 (ESP) generated by one 
molecule (or fragment) and the charged fragments of another. The ESP at position r is given 
as a sum of contributions from the nuclei and the electronic wave function: 
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The potential is sampled by placing a suitable grid of points around each nucleus (typical 
sampling have a few hundred points for each atom) with distances from just outside the van 
der Waals radius to about twice that distance. The atomic charges are determined as those 
parameters that reproduce the electrostatic potential as closely as possible at these points, 
subject to the constraint that the sum is equal to the total molecular charge.  
 
II.3.3. Population Analysis Based on the Electron Density 
 
The electron density is the square of the wave function integrated over Nelec-1 
coordinates (eq. 5). If the total molecular volume could somehow be divided into subsections, 
each belonging to one specific nucleus, then the electron density could be integrated to give 
the number of electrons present in each of these atomic basins Ω, and the (net) atomic charge 
Q is then obtained by adding the nuclear charge Z: 
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The division into atomic basins requires a choice to be made as to whether a certain point in 
space belongs to one nucleus or another, and several different schemes have been proposed. 
 
The Atoms in Molecules (AIM)19 is the most rigorous way of dividing a molecular 
volume into atomic subspaces. In the large majority of cases it is found that the only maxima 
in the electron density occur at the nuclei (or very close to them), which is reasonable since 
they are the only sources of positive charge. The nuclei thus act as attractors of the electron 
density. At each point in space the gradient of the electron density points in the direction of 
the strongest (local) attractor. This forms a rigorous way of dividing the physical space into 
atomic subspaces: starting from a given point in space a series of infinitesimal steps may be 
taken in the gradient direction until an attractor is encountered. Once the molecular volume 
has been divided up, the electron density may be integrated within each of the atomic basins 
to give atomic charges and dipole, quadrupole, etc., moments.  
 
Hirshfeld20 charges are obtained by using atomic densities for partitioning the 
molecular electron density:  
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The initial (promolecular) density 0Molρ  is defined as the sum of atomic densities 0Atρ  placed 
at the nuclei in the molecule. The actual molecular electron density at each point in space 
)(rMolρ  is then partitioned by weighting factors according to the original contributions.  
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II.4. Bond Energy Analysis 
 
To characterize the bonding between the entities (fragments) of a molecular system I 
have analyzed the molecules in terms of interactions between two fragments using an energy 
decomposition scheme developed by Ziegler and Rauk21 as implemented in ADF.22 The 
overall bonding energy between two fragments, ∆E, is decomposed in: 
 
 orbPaulielstprepprep EEEEEEE ∆+∆+∆+∆=∆+∆=∆ int  (26) 
 
where ∆Eprep is the preparation energy required to deform the separated fragments from their 
equilibrium structure to the geometry in the molecule, including the excitation to their 
valence electronic configuration; ∆Eint is the interaction energy, and includes: repulsion 
between fragments due to Pauli principle ∆EPauli, electrostatic component ∆Eelst, and 
stabilizing orbital interactions ∆Eorb. The orbital interaction energy accounts for electron pair 
bonding, charge transfer and polarization. This can be further decomposed into the 
contributions from the irreducible representations Γ of the interacting system.22a  
 
II.5. Solvation Models 
 
In the previous parts I presented very briefly the theoretical and computational 
consideration to evaluate the total energy of a molecular system in gas phase. As the 
processes which I have been investigated during the thesis preparation take place mostly in 
solution, the following chapter contains the important aspects of computational environment 
modeling, in particular the consideration of solvent effects. The effects of solvation can be 
partitioned into two main groups: (i) non-specific (long-range) solvation and (ii) specific 
(short-range) solvation. The non-specific effects are mainly solvent polarization and 
orientation of the solvent electric multipole moments by the solute, where the dipole 
interaction is usually the most important. The specific (microscopic) interactions are 
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primarily located in the first solvation shell, at the solute-solvent boundary surface, although 
the second solvation shell may also be important for highly-charged ions. The microscopic 
interactions depend on the specific nature of the solvent molecule, such as the shape and the 
ability to form hydrogen bonds. Other short-range solvation effects to take into account are: 
van der Waals interactions solute-solvent, the charge transfer effects, hydrophobic or entropic 
effects, etc. The methods for solvation computation are mostly of two types: those describing 
explicitly the individual solvent molecules and those that treat the solvent as a continuous 
medium. A partial mixing of the models is also possible, for example by treating explicitly 
the first solvation shell and considering the rest of the solvent as a continuum model. The first 
class of methods involving an explicit use of the solvent molecules requires a sampling of the 
phase space. Since this is computationally expensive, there is a strong interest in developing 
methods where the solvent is modeled in a less rigorous fashion. 
 
II.5.1. Continuum Solvation Models 
 
In the continuum or implicit solvation models23 the solvent is considered as a uniform 
polarizable medium with a dielectric constant of ε, and the solute is placed in a suitably 
shaped cavity in the medium. The solvation free energy has three main terms (eq. 27): (i) the 
cavitation is a destabilization component, since the making of a hole in ordered medium costs 
energy; (ii) the stabilization component due to the dispersion interactions; and (iii) 
electrostatic stabilization that appears as consequence of medium polarization induced by the 
charge distribution in the solute. The dispersion term is sometimes denoted as 
dispersion/repulsion as the interaction between the solute and solvent might have a repulsive 
component as well.  
 
 elecdispersioncavitysolvation GGGG ∆+∆+∆=∆  (27) 
 
Beside the differences in the way to define the size and the shape of the cavity, the 
continuum models also differ in calculation methods of the cavity/dispersion contributions, 
the approach to describe the solute and its charge distribution, as well as in different 
description of the dielectric continuum. The solvent medium is normally taken to have a 
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constant value of ε, but may for some purposes also be taken to depend for example on the 
distance from solute. It should be noted that in continuum models solvents having the same ε 
value (such as acetone, ε=20.7, and 1-propanol, ε=20.1, or benzene, ε=2.28, and carbon 
tetrachloride, ε=2.24) are treated equally. The hydrogen bonding capability of 1-propanol 
compared with acetone will in reality most likely make a difference, and the solvent 
dynamics of an almost spherical CCl4 will be different from the planar benzene molecule.  
 
II.5.1.1. Cavity and Dispersion/Repulsion Contributions 
 
The big advantage of the simplest spherical or ellipsoidal cavity description is the 
analytical accessibility of the electrostatic interaction between solute and the dielectric 
medium. More realistic models employ molecular shaped holes, generated for example by 
interlocking spheres located on each nucleus. It is generally found that the shape of the hole 
is important, and that molecular shaped cavities are necessary to be able to obtain good 
agreement with experimental data. The energy required for cavity creation, and the 
stabilization due to van der Waals interactions between the solute and solvent is usually 
assumed to be proportional to the cavity surface area. In this sense the proper description and 
calculation of the surface boundary between solute and solvent is mandatory. The van der 
Waals surface is generated by multiplying the atomic van der Waals radius by a suitable 
factor (a typical value is 1.2). The disadvantage of such a surface generated for large 
molecules (for example proteins) is the presence of small inaccessible regions for solvent 
molecules. An alternative way to generate the solute-solvent boundary surface is by mapping 
it by a spherical particle of a given radius (a typical radius of 1.4 A models the water 
molecule) rolling on the van der Waals surface. This is denoted as the Solvent Accessible 
Surface (SAS). The corresponding cavity and dispersion energy terms may be taken simply 
as being proportional to the total SAS area (a single proportionality constant): 
 
 βγ +=∆+∆ SASGG dispersioncavity  (28) 
 
or parameterized by having a constant ξ specific for each atom type, with the ξ parameters 
being determined by fitting to experimental solvation data  
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The continuum models where the cavity/dispersion interaction is parameterized by 
fitting to experimental solvation energies are not recommended to use in combination with 
first shell explicit treatment of solvent molecules as the parameterization represents a best fit 
to experimental data without any explicit solvent present.1b 
 
II.5.1.2. Electrostatic Solvation Component 
 
The implicit solvation models differ also in the way of treating the electrostatic 
energy component in the eq. 27. 
 
- Poisson–Boltzmann method 
 
The Poisson equation describes the connection between the electrostatic potential 
Φ(r), the charge distribution ρ(r), and the dielectric constant ε: 
 
 ( ) )(4)()( rrr piρε −=Φ∇∇  (30) 
 
when the medium is a continuum dielectric with ε independent of the position, eq. 30 turns 
into:  
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If the charge distribution is a point charge, the solution of eq. 31 reduces to the Coulomb 
interaction. By taking into account the Boltzmann distribution of ions in the solvent the 
Poisson equation can be modified to the Poisson–Boltzmann Equation (PBE).24 
 
- Born/Onsager/Kirkwood methods 
 
In its simplest approach the reaction field model is a spherical cavity, where only the 
lowest order electric moment of the molecule is taken into account. The free energy of 
solvation in this case is equal to the work spent to transfer the net charge q in a cavity of 
radius a, from vacuum to a medium with a dielectric constant of ε, computed by using Born 
formula:25 
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Although, it is a simple and intuitive model it presents serious disadvantages. Firstly, this 
model does not distinguish between charge sign, and the solvation energies for positive and 
negative ions of the same size is the same. This is not the observed behavior in solvents such 
as water. Furthermore, the reciprocal dependence on the dielectric constant means that the 
calculated solvent effect is sensitive to the variation of ε in the low dielectric limit, but 
virtually unaffected by large differences in the high dielectric limit. Generalized Born model 
uses partial charges in eq. 32. 
 
The Onsager model26 refers to the methods that describe the solute as a dipole in a 
spherical cavity which, for a dipole moment of µ leads to an energy stabilization given by: 
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In contrast, the Kirkwood model27 refers to a general multipole expansion in a 
spherical cavity, while the Kirkwood–Westheimer model28 arises for an ellipsoidal cavity. 
Because the spherical or ellipsoidal cavities are realistic only for small and symmetric 
molecules the use of the Born/Onsager/Kirkwood models should therefore only be considered 
as a rough estimate of the solvent effects, and quantitative results can rarely be obtained.  
 
- Self-consistent reaction field models 
 
When a quantum description of the solute is employed, the calculated electric 
moments induce charges in the dielectric medium, which in turn acts back on the molecule, 
causing the wave function to respond and thereby changing the electric moments, etc. The 
methods that calculate the interaction of the solute with dielectric medium representing the 
solvent in an iterative procedure are Self-Consistent Reaction Field (SCRF) models. The 
interaction of a fixed dipole moment with a polarizable medium given by eq. 33 is not a 
SCRF model, as the dipole moment and stabilization are not calculated in a self-consistent 
way. The dipole moment changes when the back-polarization of the medium is taken into 
account depending on the molecular polarizability. In the SCRF model the full polarization is 
taking into account, i.e. the initial dipole moment generates a polarization of the medium, 
which changes the dipole moment, which in turn generates a slightly different polarization, 
etc. For spherical or ellipsoidal cavities the Poisson equation can be solved analytically, but 
for molecular shaped surfaces it must be done numerically. This is typically done by 
reformulating it in terms of a surface integral over surface charges, and solving this 
numerically by dividing the surface into smaller fractions each having an associated charge 
σ(rs). The surface charges are related to the electric field F(rs) (the derivative of the potential 
Φ) perpendicular to the surface by eq:  
 
 )()1()(4 ss rFr −= εpiεσ  (34) 
 
Once σ(rs) is determined the associated potential is added as an extra term to the Hamiltonian 
operator. The potential Φ(σ(rs)) from the surface charge is given by the molecular charge 
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distribution, but also enters the Hamiltonian and thus influences the molecular wave function, 
the procedure is therefore iterative.  
 
The Polarizable Continuum Model (PCM)29 employs a van der Waals cavity formed 
by interlocking atomic van der Waals radii scaled by an empirical factor, the 
cavity/dispersion contributions are parameterized based on the surface area, and a detailed 
description of the electrostatic potential is used. 
 
The Conductor-like Screening Model (COSMO)30 also employs molecular shaped 
cavities, and represents the electrostatic potential by partial atomic charges. In fact it may be 
considered as a limiting case of the PCM model, where the dielectric constant is set to 
infinity.  
The Solvation Models31 (SMx, where x =1–5) are generalized Born type models used 
in connection with the semi-empirical AM1 and PM3 methods. The partial atomic charges 
are calculated from the wavefunction, and the dispersion/cavity terms in eq. 27 are 
parameterized based on the SAS, eq. 29. The different version numbers indicate increasingly 
sophisticated parameterizations.  
 
The accuracy of the solvation models is difficult to evaluate by default. The fact that 
all of them were parameterized for specific environmental interactions and specific molecular 
systems suggests the necessity of their benchmarking before starting a new computational 
project. 
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II.6. Optimization Techniques 
 
This last introductory part I dedicate to the technical approaches employed to find the 
stationary points on the Potential Energy Surface (PES). Current progresses in the techniques 
for exploring PESs are reviewed in ref. 32.  
 
II.6.1. Finding Minima 
 
The simplest approach to reach a minimum of a function is to step one variable at a 
time until the function has reached a minimum, and then switch to another variable. This 
requires only the ability to calculate the function value for a given set of variables. The 
complexity of molecular systems makes this approach impractical. All commonly used 
methods use the analytical computed gradient of the function with respect to all variables to 
find a minimum. Some methods went further and use the second derivative matrix, the 
Hessian, for this purpose. It should be noted that the target function and its derivative(s) are 
calculated with a finite precision, which depends on the computational implementation. A 
stationary point can therefore not be located exactly as the gradient can only be reduced to a 
certain value. In computational chemistry molecular geometry optimization is considered 
converged when the energy, energy gradient or nuclear displacement between consecutive 
steps are reduced below the user defined threshold. These criteria may in some cases lead to 
problems, as a function with a very flat surface in a certain region may satisfy the contiditions 
without containing a stationary point. 
 
II.6.1.1. Steepest Descent 
 
In the Steepest Descent (SD) method the first order functional derivative is computed 
and the function value is lowered by stepping in the opposite direction. A series of such is 
performed in the negative gradient direction, until the energy starts to increase. Then an 
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approximate function minimum is determined by interpolation between the calculated points. 
At this interpolated point, a new gradient is calculated and used for the next search. The 
disadvantages of this method are: (i) two successive steps are necessarily perpendicular to 
each other; if there was a gradient component along the previous search direction, the 
function could be further lowered in this direction, consequently spoiling the previous search; 
(ii) the SD path oscillates around the minimum path, and as the minimum is approached, the 
rate of convergence slows down; (iii) the steepest descent will actually never reach the 
minimum; it will crawl towards it at an ever decreasing speed. The optimization program 
should therefore have implemented an algorithm to stop it a point. The advantages are: (i) the 
algorithm is very simple, and requires only storage of a gradient vector; (ii) the method will 
always lower the energy value.  
 
II.6.1.2. Conjugate Gradient Methods 
 
The Conjugate Gradient (CG) methods compensates the lack of information about 
the previous searches in the SD methods by performing each optimization step not only along 
the current gradient, but along a line that is constructed such that it is “conjugate” to the 
previous search direction(s). The first step is equivalent to a steepest descent step, but 
subsequent searches are performed along a line formed as a mixture of the current negative 
gradient and the previous search direction:  
 
 1−+−= iiii dgd β  (35) 
 
where d is the direction of search and g is the gradient. Conjugate gradient methods have 
much better convergence characteristics than the steepest descent, but they are again only 
able to locate minima. They do require slightly more storage than the SD, since two (current 
gradient and previous search direction) vectors must be stored. 
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II.6.1.3. Newton–Raphson methods 
 
The Newton–Raphson (NR) algorithm calculates the second order derivative of the 
function around the current point. The optimization step is produced by moving in the 
direction of the second order gradient neutralization. Near a minimum, all the Hessian 
eigenvalues are positive (by definition), and the step direction is opposite to the gradient 
direction. If, however, one of the Hessian eigenvalues is negative, the step in this direction 
will be along the gradient component, and thus increase the function value. In this case, the 
optimization may end up at a stationary point with one negative Hessian eigenvalue, a first-
order saddle point. In general, the NR method will attempt to converge on the “nearest” 
stationary point, regardless of whether this is a minimum, saddle point or maximum. The 
disadvantage of the method is the necessity to calculate the full second derivative matrix, 
which must be stored and inverted (diagonalized). This is the reason why, when using this 
method, the initial geometry of computed molecule is very important, and the chemical 
intuition helps to choose the right geometry, especially in transition structure searches. Since 
analytic Hessians are rather expensive, especially for larger systems, it is advantageous to 
avoid computing second derivatives. In the quasi-Newton (QN) approach, instead of using an 
analytic Hessian at each step, an approximate Hessian is computed at the start of the 
calculation (i.e. an empirically estimated Hessian or a Hessian computed at a lower level of 
theory) and use Hessian updating at the subsequent steps in the optimization. Hessian 
updating approximates the Hessian using the change in position and gradient from the 
previous step. 
 
II.6.1.4. GDIIS methods 
 
Newton–Raphson methods can be combined with extrapolation procedures, and the 
best known of these is the Geometry Direct Inversion in the Iterative Subspace (GDIIS).33 In 
the GDIIS method, the NR step is not taken from the last geometry but from an interpolated 
point with a corresponding interpolated gradient based on the previously calculated points on 
the surface. The method is useful when the geometry is near a sharp minimum, and is 
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counterproductive in the cases when a flat PES region is scanned, because the DIIS 
procedure will attempt to pull the structure back to the flat energy region, since this is where 
the gradient is small. 
 
II.6.2. Finding First Order Saddle Points 
 
To locate a minimum on the PES is fairly easy: if everything else fails, the steepest 
descent method is guaranteed to lower the energy value. On the other hand finding the first-
order saddle points, transition structures (TS), is much more difficult. The proposed strategies 
can be divided into two general categories: (i) those based on interpolation between two 
minima, and (ii) those using only local information. Interpolation methods assume that the 
reactant and product geometries are known, and that TS is located somewhere in “between”. 
Local methods use only information about the function and its first and possibly also second 
derivatives at the current point, i.e. they require no knowledge of the reactant and/or product 
geometries. Local methods require a good starting estimate of the TS in order to converge. 
Once the TS has been found, the whole reaction path may be located by tracing the intrinsic 
reaction coordinate (IRC)34 which corresponds to a steepest descent path from the TS to the 
reactant and product. 
 
II.6.2.1. Interpolation Methods 
 
The one structure interpolation methods start by selection of one or a few internal 
“reaction” coordinate that connects reactant and product. The selected coordinate(s) is (are) 
fixed at certain values, while the remaining variables are optimized, thereby adiabatically 
mapping the energy as a function of the reaction variable(s). The TS is located as maximum 
on the obtained energy profile. The success of these methods depends on the ability to choose 
a good set of reaction variables. The methods work well if only one or two variables change 
significantly between reactant and product, and the obtained geometry is a good 
approximation to the TS.  
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In the Linear Synchronous Transit (LST) method all coordinates are varied linearly 
between the reactant and product, and no optimization is performed. The assumption is that 
all variables change at the same rate along the reaction path, and the TS estimate is simply the 
highest energy structure along the interpolation line. There are not many cases when LST 
lead to a reasonable estimate of the TS.  
 
The Quadratic Synchronous Transit (QST) approximates the reaction path by a 
parabola instead of a straight line. After the LST is performed, the QST is generated by 
minimizing the energy in the directions perpendicular to the LST path, and the QST path 
may then be searched for an energy maximum. A more recent variation of QST, called 
Synchronous Transit-guided Quasi-Newton (STQN), uses a circle arc instead of a parabola 
for the interpolation, and uses the tangent to the circle for guiding the search towards the TS 
region. Once the TS region is located, the optimization is switched to a quasi–Newton. 
 
Other interpolation techniques use two or more structures to find the TS. The 
characteristics of interpolation methods are: (i) the methods estimate an intermediate 
geometry on the reaction path that may or may not be the true transition structure; (ii) the TS 
found is not necessarily one that connects the two minima used in the interpolation, and an 
IRC calculation must be performed to check the reactants and products connected by the TS 
found; (iii) the reaction path formed by a sequence of points generated by constrained 
optimizations may be discontinuous; (iv) the existence of many TSs connecting two minima 
impose the guidance from the user at the initial search steps (for example by adding various 
intermediate structures) to find more than one TS and to compare the obtained results; (v) the 
advantage of the methods is that the constrained optimization can usually be carried out using 
only the first derivative of the energy, this avoids an explicit, and computationally expensive, 
calculation of the Hess matrix. 
 
II.6.2.2. Local Methods 
 
In the Gradient Norm Minimization methods transition structures are located as zero 
gradient points on the PES, by minimizing the gradient norm. The obvious disadvantages are: 
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(i) there are typically many points where the gradient norm has a minimum without being 
zero; and (ii) any stationary point has a gradient norm of zero, thus all types of saddle points 
and minima/maxima may be found, not just TSs.  
 
At a point sufficiently close to the TS, the standard Newton-Raphson formula will 
locate the TS rapidly. The Hessian at this point should have exactly one negative eigenvalue, 
and the eigenvector should be in the correct direction, along the “reaction coordinate”. Near 
such a point the NR step maximizes the energy in one direction (along the Hessian TS 
eigenvector) and minimizes the energy along all other directions. Based on this scheme were 
developed algorithms to help the program to find the true first order saddle points (e.g. 
Partitioned Rational Function Optimization (P-RFO),35 Quadratic Approximation (QA)36 
Trust Radius Image Minimization (TRIM)37). All NR methods assume that a reasonable 
guess of the TS geometry is available. Except chemical intuition the interpolation schemes 
may be useful to find an initial geometry for the TS search, as well.  
 
The local methods are characterized by: (i) the necessity of good initial geometry 
guess; (ii) the methods use the Hessian, which is quite expensive in terms of computer time 
for electronic structure methods; (iii) systems with many soft vibrational modes are often 
problematic, as the resulting low Hessian eigenvalues interfere with the negative curvature 
along the reaction vector; (iv) the availability of a good starting geometry and Hessian assure 
a rapid convergence, that often requires only a few tens of gradient calculations. 
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III. Computational Electrochemistry of Ruthenium 
Anticancer Agents. Unprecedented Benchmarking of 
Implicit Solvation Methods 
 
III.1. Abstract 
 
Two ruthenium(III) complexes, (HIm)[trans-RuCl4(DMSO)(Im)] (NAMI-A) and 
(HInd)[trans-RuCl4(Ind)2] (KP1019); DMSO = dimethyl sulfoxide, Im = imidazole, Ind = 
indazole, have been tested in phase I clinical trials as potential anticancer drugs. Ru(III) 
anticancer agents are likely activated in vivo upon reduction to their Ru(II) analogs. Aiming 
at benchmarking implicit solvation methods in DFT studies of ruthenium pharmaceuticals at 
the B3LYP level, we have calculated the standard redox potentials (SRPs) of Ru(III/II) pairs 
that were electrochemically characterized in the literature. 80 SRP values in four solvents 
were calculated using three implicit solvation methods and five solute cavities of molecular 
shape. Comparison with experimental data revealed substantial errors in some of the 
combinations of solvation method and solute cavity. For example, the overall mean unsigned 
error (MUE) with the PCM/UA0 combination, which is the popular default in Gaussian 03, 
amounts to 0.23 V (5.4 kcal/mol). The MUE with the CPCM/UAKS combination, which was 
employed by others for recent computational studies on the hydrolysis of NAMI-A and trans-
[RuCl4(Im)2]–, amounts to 0.30 V (7.0 kcal/mol) for all compounds and to 0.60 V (13.9 
kcal/mol) for a subset of compounds of the medicinally relevant type, trans-[RuCl4(L)(L’)]–. 
The SRPs calculated with the PCM or CPCM methods in Gaussian 03 can be significantly 
improved by a more compact solute cavity constructed with Bondi’s set of atomic radii. 
Earlier findings that CPCM performs better than PCM cannot be confirmed, as the overall 
MUE amounts to 0.19 V (4.3−4.4 kcal/mol) for both methods in combination with Bondi’s 
set of radii. The Poisson-Boltzmann finite element method (PBF) implemented in Jaguar 7 
together with the default cavity performs slightly better, with the overall MUE being 0.16 V 
(3.7 kcal/mol). Because the redox pairs considered in this study bear molecular charges from 
+3/+2 to −1/−2 and the prediction of solvation free energies is most challenging for highly 
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charged species, the present work can serve as a general benchmarking of the implicit 
solvation methods.  
 
III.2. Objective 
 
Due to the success of cisplatin as an anticancer drug,1 the search for new 
metallopharmaceuticals has continued and extended to non-platinum complexes,2 most 
notably ruthenium3 and rhodium.4 Two Ru(III) complexes, NAMI-A5 and KP1019,6 with the 
common lead structure, trans-[RuCl4(L)(L’)]– (Figure 1), successfully completed phase I 
clinical trials.7 Recent developments of organometallic Ru(II) anticancer complexes are 
promising as well.8,9 Ru(III) complexes are believed to be activated in vivo upon reduction to 
their Ru(II) analogs.10 A selective reduction in cancer cells occurs likely due to the reducing 
environment caused by deficiency of molecular oxygen in tumors (hypoxia),11 as the blood 
flow to the rapidly growing tumor is insufficient. The standard redox potential (SRP) of a 
Ru(III) complex is believed to be crucial to its anticancer activity.12 If it is too low, the 
complex is not reduced and remains inactive. If it is too high, the complex is reduced too 
easily and the selectivity to cancer cells is lost.  
 
Figure 1. NAMI-A and KP1019, two Ru(III) anticancer complexes in clinical trials. 
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The prediction of SRPs can rationalize and accelerate the search for new drugs, 
because an in silico screening can be performed before relevant compounds are selected, 
synthesized, and tested in vitro and in vivo. So far, SRPs were often predicted using an 
empirical increment system13 derived from experimentally measured SRPs. This empirical 
approach is successful if strongly related compounds are compared to each other; for 
example, it does not distinguish between geometric isomers. A more general approach for the 
prediction of SRPs is based on modern quantum chemical calculations.14 The objective of the 
present work is benchmarking various implicit solvation methods15 and molecule-shaped 
solute cavities employed for DFT studies at the B3LYP16,17 level.  
 
Recent computational studies of other groups are highly complementary to the present 
work. First, benchmarking studies were carried out to assess the performance of different 
implicit solvation protocols for organic and main group element compounds.18,19 Second, 
computation of SRPs of group 8 metal complexes mostly in organic solvents demonstrated 
that the approach is valid for a wide range of SRPs.20 Third, the SRP of the aqueous 
Ru3+aq/Ru2+aq pair was calculated using a variety of quantum chemical methods, ECP’s, and 
basis sets, implicit solvent models, and cavities. The influence of the first and second 
solvation shells on the SRP of the Ru3+aq/Ru2+aq pair was investigated as well.21 DFT studies 
on Ru(III) anticancer agents were recently reported, but validation of the method by 
predicting their SRPs was not taken into account.22,23 In the present work, we consider 80 
SRPs of 61 ruthenium complexes in four solvents.24,25 While various types of ruthenium 
complexes are included, an emphasis is placed on anticancer complexes in aqueous solution, 
the SRPs of which were measured recently25,26,27 and fall into a fine biologically relevant 
window (from −0.4 to +0.8 V vs NHE).28 We believe that the results of this work provide a 
general benchmarking of the implicit solvation approaches and will improve the accuracy and 
credibility of future computational studies of ruthenium pharmaceuticals and other metal 
complexes.  
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III.3. Methods  
 
The geometries of the molecules were optimized at the gradient-corrected DFT level 
using the 3-parameter fit of exchange and correlation functionals of Becke16 (B3LYP), 
which includes the correlation functional of Lee, Yang, and Parr (LYP),17 as implemented in 
Gaussian 03.29 The Stutgart-Dresden scalar-relativistic energy-consistent small-core effective 
core potential (ECP) and the corresponding valence-basis sets were used for the Ru 
(MWB28)30 and I atoms (MWB46),31 and the 6-31G(d,p) basis sets were used for the other 
atoms.32 This basis-set combination is denoted M. Vibrational frequencies were also 
calculated at B3LYP/M; all structures reported herein are minima on the potential energy 
surfaces. Improved total energies were calculated at the B3LYP level using the same ECP 
and valence-basis set at Ru and I, but totally uncontracted and augmented with two sets of f 
functions and one set of g functions,33 together with the 6-311+G(d,p) basis sets at the other 
atoms, and the 6-311+G(3d) on S, Cl and Br atoms. This basis-set combination is denoted 
XL. Free energies in vacuo (G1) were calculated by adding corrections from unscaled zero-
point energy (ZPE), thermal energy, work, and entropy evaluated at the B3LYP/M level at 
298.15 K, 1 atm to the energies calculated at the B3LYP/XL//M level.  
 
Solvation free energies (∆Gsolv) of the structures optimized in vacuo at the B3LYP/M 
level were calculated using three implicit solvation methods:15 The Polarizable Continuum 
model (PCM)34 in its integral equation formalism (IEF)35 as implemented in Gaussian 03 and 
the Conductor-like36 Polarizable Continuum Model (CPCM)37 in Gaussian 03,29 and the 
Poisson-Boltzmann finite element method (PBF)38 in Jaguar 7.39 These methods belong to the 
class of self-consistent reaction field (SCRF) methods. The solute is embedded in a 
continuum dielectric with a dielectric constant ε representing the solvent.40 The solute charge 
distribution polarizes the continuum dielectric, and the potential arising from the solvent 
polarization in turn modifies the solute Hamiltonian. The calculation of the solute wave 
function is carried out iteratively until self-consistency. The PCM method describes the 
solvent reaction potential in terms of apparent surface charges localized on tesserae at the 
continuum boundary. The CPCM method uses apparent surface charges as well, but describes 
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the solvent first as a conductor (ε = ∞) and then rescales the charges for a finite value of the 
dielectric constant. The PBF method uses finite elements for numerical solution of the 
Poisson-Boltzmann differential equation. The PCM and CPCM calculations were done at the 
B3LYP/M level, while the PBF calculations were done at the B3LYP/LACVP** level, which 
includes a scalar-relativistic energy-consistent small-core ECP41 and basis set at the metal and 
the 6-31G(d,p) basis sets at the other atoms.  
 
The three solvation methods were used together with solute cavities of molecular 
shape; the PCM and CPCM methods together with the cavities based on the UA0, UAHF, 
UAKS, and Bondi radii and the PBF method in Jaguar 7 together with the default set of radii. 
In the United Atom (UA) topological models,42 the cavity is obtained from spheres centered 
on non-hydrogen atoms. The radius of each sphere depends on the atom type, its connectivity 
and the number of hydrogen atoms attached; typical values are listed in Table 1. The UA0 
radii are based on the Universal Force Field (UFF).43 Variants of these radii were optimized 
at the Hartree-Fock level (UAHF)44 and Perdew-Burke-Ernzerhof (PBE)45 Kohn-Sham DFT 
level (UAKS).29 In contrast, Bondi’s46 set of radii consider hydrogen atoms explicitly, and the 
values depend on atom identity rather than on its connectivities or hybridization. The radii are 
used in several ways for the construction of cavity in the calculations of the solvation free 
energies ∆Gsolv, which is decomposed into solute-cavity-formation47 (∆Gcav), electrostatic 
(∆Gelst), and dispersion and repulsion (∆Gdis-rep) contributions (∆Gsolv = ∆Gelst + ∆Gdis-rep + 
∆Gcav). In the PCM and CPCM implementations, the non-electrostatic contributions ∆Gdis-rep 
and ∆Gcav are calculated using a solvent accessible surface (SAS),48 whereas ∆Gelst is 
calculated using a similar surface constructed by the radii scaled by a factor49 and additional 
spheres to smoothen the surface. In the PBF method, ∆Gelst is calculated using an SAS 
constructed by a set of standard radii including explicit hydrogen atoms (Table 1). An 
empirical formula depending linearly on the SAS area is employed for the remaining terms, 
∆Gdis-rep + ∆Gcav. Our attempts to further refine this set of radii or change the basis sets 
indicated that the PBF protocol had been reasonably optimized.  
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Table 1. Radii (Å) used for constructing the solute cavities considered in this work.  
 UA0 UAHF UAKS Bondi PBF 
H    1.200 1.150 
C    1.700 1.900 
Ce 1.925 1.725 1.725   
CHe 2.125 1.905 1.905   
CH2e 2.325 2.193 2.193   
CH3e 2.525 1.950 1.950   
N    1.550 1.600 
Na 1.830 1.551 1.461   
NHa 1.930 1.641 1.551   
NH2c 2.030 1.680 1.680   
NH3b 2.130 1.770 1.770   
O    1.520 1.600 
Oa 1.750 1.569 1.479   
OHd 1.780 1.590 1.590   
OH2b 1.950 1.569 1.569   
S 2.017a 1.959a 1.959a 1.800 1.900 
Cl 1.973a 1.959a 1.959a 1.750 1.974 
Br 2.094c 2.080c 2.080c 1.850 2.095 
Ru 1.482 1.482 1.482 1.482 1.481 
I 2.250f 2.350f 2.350f 1.980 2.250 
a In trans-[RuCl4(DMSO)(Im)]–. b In cis-[Ru(NH3)4(OH2)2]3+. c In trans-
[Ru(NH3)4Br(isn)]2+ d In [Ru(NH3)5(OH)]2+ e In mer,trans-[RuCl3(Et2S)(Ind)2]. f In cis-
[Ru(NH3)4I(py)]2+.  
 
Standard redox potentials (SRPs) were calculated on the basis of the thermodynamic 
cycle shown in Figure 2,14,50 which is similar to that proposed for the prediction of acidity 
constants.51 The SRP is related to the reaction free energy in solution (∆Gε):  
 
SRP = (∆Gε/zF) - ∆SRPNHE  
with ∆Gε = - ∆Gsolv(Ox) + ∆G1 + ∆Gsolv(Red)  
 
according to Figure 2. ∆G1 is the reaction free energy in vacuo, ∆Gsolv(Ox) and ∆Gsolv(Red) 
are the solvation free energies in of the oxidized and reduced form, F = 96,485 C/mol = 
23.061 kcal/(Vmol) is the Faraday constant, and z = 1 for one-electron reductions. The SRPs 
are shifted by ∆SRPNHE = 4.28 V to align the results to the scale of the Normal Hydrogen 
Electrode (NHE).52  
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Figure 2. Thermodynamic cycle for calculating redox potentials.  
 
 
III.4. Results and Discussion  
 
We start with the default solvation protocol in Gaussian 03, which consists of the 
Polarizable Continuum Model (PCM)34 together with the default definition of the solute 
cavity on the basis of the united atom topological model UA0.42 This approach is denoted as 
Protocol I. Figure 3a shows the calculated (PCM/UA0) vs experimental SRPs. The results are 
displayed as follows: (i) The solvent (ACN, DMF, DMSO, water) is indicated by the color of 
symbol. (ii) The molecular charge of the redox pairs ranging from +3/+2 to −1/−2 is indicated 
by the shape of symbol. (iii) The medicinal relevance is indicated by the filling of symbol, as 
the aqueous SRPs for the complexes of the type trans-[RuCl4(L)(L’)]– are displayed as filled 
symbols. The two drug candidates in the clinics, KP1019 and NAMI-A, belong to this 
category (Figure 1). To analyze the results in a quantitative manner, mean unsigned errors 
(MUE) are listed in Table 2, sorted by solvent, molecular charge, and medicinal relevance. 
The overall MUE of Protocol I for the complete set of data (all compounds in all solvents) is 
0.23 V (5.4 kcal/mol). Similar MUE values are obtained for subsets of complexes in water 
and medicinally relevant complexes, 0.26 V (6.0 kcal/mol) and 0.29 V (6.8 kcal/mol), 
respectively. 
 
 52 
Figure 3. Calculated vs experimental SRPs. (a) Protocol I, PCM/UA0, (b) Protocol II, 
PCM/UAHF, (c) Protocol IV, PCM/Bondi, (d) Protocol VII, PB. The data are sorted by 
solvent (color of symbol) and charge (shape of symbol). Aqueous SRPs of the medicinally 
relevant complexes with the lead structure, trans-[RuCl4(L)(L’)]–, are displayed as filled 
symbols.  
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Protocol II combines the PCM method with the UAHF cavity, as implemented in 
Gaussian 03. This approach has been frequently used, as it is recommended for the prediction 
of solvation free energies by comparing solution and gas phase free energies.29 Figure 3b 
displays the calc. vs exp. SRPs and Table 2 includes the MUEs. The calculations reveal that 
this protocol performs worse than protocol I: The MUE for the complete set of data (all 
compounds in all four solvents) is 0.32 V (7.4 kcal/mol). Considering the molecular charges 
of the redox couples, the most unsatisfactory results are obtained for the highly charged 
complexes, as the +3/+2 pairs and −1/−2 redox pairs have MUEs of 0.30 V (7.0 kcal/mol) 
and 0.59 V (13.5 kcal/mol), respectively. A rather high MUE of 0.63 V (14.6 kcal/mol) is 
obtained for the medicinally relevant subset. Protocol III uses the same PCM method together 
with the UAKS radii, as implemented in Gaussian 03; this definition of the solute cavity is 
recommended for DFT calculations.29 The calculations show only a very minor improvement 
in comparison with the UAHF approach, as the MUEs are similar to those of Protocol II 
(Table 2).  
 
Table 2. Mean unsigned errors (MUE) in the calculation of SRPs using Protocols I-VII. All 
values in Volt (V). 
  I II III IV V VI VII 
  PCM PCM PCM PCM CPCM CPCM PBF 
compounds number UA0 UAHF UAKS Bondi UAKS Bondi  
all 80 0.23 0.32 0.31 0.19 0.30 0.19 0.16 
solvent         
ACN 4 0.10 0.64 0.65 0.02 0.64 0.03 0.02 
DMF 16 0.10 0.16 0.16 0.25 0.15 0.26 0.16 
DMSO 14 0.34 0.38 0.36 0.21 0.35 0.22 0.17 
water 46 0.26 0.33 0.31 0.18 0.31 0.17 0.17 
charge         
+3/+2 8 0.45 0.30 0.27 0.27 0.27 0.27 0.23 
+2/+1 18 0.19 0.18 0.16 0.15 0.16 0.15 0.13 
+1/0 10 0.10 0.15 0.13 0.19 0.13 0.19 0.19 
0/-1 21 0.26 0.24 0.24 0.18 0.23 0.19 0.11 
-1/-2 23 0.23 0.59 0.57 0.20 0.57 0.20 0.19 
         
Leada 14 0.29 0.63 0.61 0.14 0.60 0.14 0.16 
a Aqueous SRPs of the compounds with the lead structure trans-[RuCl4(L)(L’)]– 
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To analyze the performance of the methods further and to identify systematic errors, 
we have also calculated the mean signed errors (MSE, see Table 3). For protocols I-III, the 
MSEs are positive for cationic redox pairs charge (+3/+2), but they are negative for anionic 
redox pairs (−1/−2). The relatively large errors for these highly charged complexes remained 
undiscovered in the past, because typical benchmarking studies uses pKa values and SRPs 
involving only species that have a molecular charge between +1 and −1. Because SRPs are 
derived from the differential free energies of the reduced forms (Figure 2), the MSEs 
translate to an underestimation of solvation free energies that is strongest for the species 
bearing the highest (positive or negative) molecular charge q. Bearing the simple Born 
model53 for ions in spherical cavities (∆Gsolv proportional -q2r-1) in mind, one would expect 
that a more compact molecular cavity improves the results, because of the reciprocal 
dependence of the solvation free energy ∆Gsolv on the sphere radius r. While our attempts to 
manually adjust the cavity within the united atom approach did not improve the results, we 
have also considered the PCM model combined with a more compact cavity based on Bondi 
radii (Table 1); this combination is denoted as Protocol IV. SRPs are plotted in Figure 3c and 
the MUE and MSE are listed in Table 2 and 3. The calculations reveal that Protocol IV 
significantly improves the agreement with the experimental values. The overall MUE for the 
complete set of data (all compounds in all solvents) is 0.19 V (4.3 kcal/mol). Remarkably, the 
MUEs are now relatively similar for all charges of redox pairs from +3/+2 to −1/−2 (Table 2). 
The MSEs indicate that the systematic errors have been largely eliminated (Table 3). The 
performance of this protocol is convincing, as is indicated by MUEs of 0.18 V (4.0 kcal/mol) 
for the complexes in aqueous solution and 0.14 V (3.3 kcal/mol) for the medicinally relevant 
set (Table 2).  
 55 
 
Table 3. Mean signed errors (MSE) in the calculation of SRPs using protocols I-VII. All 
values in Volt (V). 
  I II III IV V VI VII 
  PCM PCM PCM PCM CPCM CPCM PBF 
compounds number UA0 UAHF UAKS Bondi UAKS Bondi  
all 80 0.01 -0.17 -0.17 0.08 -0.17 0.08 0.03 
solvent         
ACN 4 -0.10 -0.64 -0.65 -0.01 -0.64 0.00 0.00 
DMF 16 0.06 -0.11 -0.11 0.23 -0.10 0.24 0.11 
DMSO 14 -0.18 -0.33 -0.33 0.21 -0.33 0.22 0.15 
water 46 0.06 -0.09 -0.10 -0.01 -0.10 -0.01 -0.03 
charge         
+3/+2 8 0.45 0.29 0.25 0.20 0.25 0.20 0.20 
+2/+1 18 0.14 0.14 0.12 -0.07 0.11 -0.07 -0.05 
+1/0 10 0.03 -0.01 -0.02 0.10 -0.02 0.10 -0.02 
0/-1 21 -0.11 -0.22 -0.20 0.18 -0.19 0.19 0.09 
-1/-2 23 -0.15 -0.59 -0.57 0.04 -0.57 0.05 -0.01 
         
Leada 14 -0.29 -0.63 -0.61 -0.12 -0.60 -0.11 -0.16 
a Aqueous SRPs of the compounds with the lead structure trans-[RuCl4(L)(L’)]– 
 
On the basis of pKa predictions for neutral and monocationic organic molecules, it 
was convincingly shown18 that the conductor-like screening approach (CPCM) performs 
better than the polarizable continuum model (PCM). Without further benchmarking 
calculations for metal complexes, the CPCM method together with the UAKS cavity was 
recently employed for a computational studies on the hydrolysis of NAMI-A and trans-
[RuCl4(Im)2]–.23 Hence, we have included the CPCM/UAKS approach in our benchmarking 
(Protocol V). The calculations reveal that Protocol V performs as disappointingly as does 
Protocol II (PCM/UAKS). For example, the MUE for the set of medicinally relevant 
compounds of the trans-[RuCl4(L)(L’)]– type amounts to 0.60 V (13.9 kcal/mol). To compare 
the PCM and CPCM performance further, we have also considered the CPCM method and 
the Bondi radii (Protocol VI); these results are very similar to those of Protocol III 
(PCM/Bondi). In summary, there is a striking agreement between the PCM and CPCM 
approaches, which is consistent with a benchmarking study of the SRPs of nitrogen oxides.19 
An appropriate definition of the solute cavity appears to be at least as important as the choice 
of the solvent model.  
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Finally, we have employed a finite element method for the numerical solution of the 
Poisson-Boltzmann equation (PBF) as implemented in Jaguar 7, together with the default set 
of radii for setting up the solute cavity (Protocol VII). This approach has been used in our 
series Quantum chemical studies of metals in medicine54 and in other studies55 of medicinally 
relevant metal complexes. Figure 3d visualizes the SRPs and Table 2 and 3 list the errors. 
The overall MUE for the complete set of data (all compounds in all solvents) is 0.16 V (3.7 
kcal/mol), which is the best value among all solvation protocols considered in this work. The 
approach performs well for all four solvents and all molecular charges of redox pairs from 
+3/+2 to −1/−2. The MUE is 0.17 V (4.0 kcal/mol) for the complexes in water and 0.16 V 
(3.7 kcal/mol) for the medicinally relevant set. The performance of Protocol VII (PB) is very 
similar to the PCM and CPCM methods with the Bondi radii.  
 
Despite the overall success of the PBF method, we have identified a few cases where 
this approach predicts unsatisfactory results, as compared to the experimental values. The 
aqueous SRP of the hydrated Ru ion redox couple, [Ru(OH2)6]3+/2+ is computationally 
overestimated by +0.83 V (Figure 3d).56 In contrast, the SRP of [Ru(NH3)5(OH)]2+/+ and cis-
[Ru(NH3)4Cl2]+/0 are computationally underestimated by -0.52 V and -0.60 V, respectively 
(Figure 3d). The other protocols perform better for the latter compound (see Figure 3 and 
Table S3), but all protocols using the Bondi and UA0 cavities overestimate the SRP of 
[Ru(OH2)6]3+/2+ by +0.91-0.93 V. The fact that the aqueous Ru(III/II) redox couple poses a 
challenge to computational chemistry was also pointed out in a recent article that focuses 
entirely on this redox pair.21 These authors make extensive use of their computationally 
efficient solvation model termed SM657 and predict at B3LYP a SRP that is +0.77 V higher 
than the experimental value. As the [Ru(OH2)6]3+ is highly charged and contains six aqua 
ligands, the predicted SRP depends strongly on the radius employed for the oxygen and 
hydrogen atoms. We find that shrinking the H atom radius or H and O atom radii in the PBF 
method to 1.02 Å or 1.02 and 1.52 Å, respectively, reduces the error in the calculated SRP to 
+0.46 V or +0.39 V, but increases the errors for the other two problem cases. The surface 
charge density of [Ru(OH2)6]3+ can be lowered by the second hydration shell, which was 
represented in the recent study21 by a symmetric arrangement of 12 additional water 
molecules. Remarkably, this approach led at B3LYP to a SRP that is –0.23 V lower than the 
experimental value.  
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Finally, we would like to emphasize that there is some arbitrariness in the prediction 
of absolute SRPs because of the choice of ∆SRPNHE. ∆SRPNHE may be calculated using a 
thermodynamic cycle for the reaction, 1/2 H2 → H+ + e-, analogue to that in Figure 2. 
∆SRPNHE is the sum of the gas phase free energy ∆G1NHE of this reaction and the solvation 
free energy of H+. The authors of ref. 52 chose ∆G1NHE = 362.59 kcal/mol58 obtained from 
thermochemical data and ∆Gsolv(H+) = –263.98 kcal/mol59 obtained from extrapolating 
thermochemical data for ion-pair clusters with up to 6 water molecules to bulk solvent to 
arrive at ∆SRPNHE = 4.28 V,52 which is the same value employed for the present work. 
Considering ∆G1NHE = 362.59 kcal/mol58 together with ∆Gsolv(H+) = –264.61 kcal/mol60 
obtained from a thermodynamic cycle of acetic acid dissociation results in the alternative 
value of ∆SRPNHE = 4.25 V, thus shifting the predicted SRPs of our Ru(III/II) redox couples 
by +0.03 V. Considering ∆G1NHE = 362.5 kcal/mol61 together with ∆Gsolv(H+) = –259.5 
kcal/mol62 obtained from electrochemical data leads to the popular value of ∆SRPNHE = 4.44 
V.63 Considering ∆G1NHE = 364.27 kcal/mol, calculated at the B3LYP/XL//M level, and the 
same ∆Gsolv(H+) = –263.98 kcal/mol59 results in ∆SRPNHE = 4.35 V. By estimating the 
absolute half cell potential using the method64 which shifts the surface dipole layer problem 
away from the electrolyte-air interface and focuses it on the solid the widely used value of 
4.43 V was obtained. Because of this arbitrariness in the choice of ∆G1NHE and ∆Gsolv(H+), 
one may simply treat ∆SRPNHE as a free parameter to be obtained in a fitting procedure. 
Given that the mean signed error (MSE) of the PBF method (Protocol VII) amounts to only 
0.03 V (Table 3), however, we believe that ∆SRPNHE = 4.28 V suggested in ref. 52 is an 
excellent choice.  
 
In conclusion, we recommend the Poisson-Boltzmann finite element solver (PBF) 
implemented in Jaguar (Protocol VII) and the PCM or CPCM method together with the 
Bondi radii implemented in Gaussian (Protocols IV and VI) for future DFT/CDM studies. 
However, caution is advised if the solute is highly charged and contains many hydrogen bond 
donors in the first shell. Our recommendation is not limited to ruthenium complexes, as the 
metal center in the compounds considered in this work is surrounded by an octahedral ligand 
environment and not directly exposed to solvent. In addition, the wide range of the molecular 
charges of the redox pairs from +3/+2 to −1/−2 has made the calculation of solvation free 
energies very challenging. Consideration of highly charged species has led to the 
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identification of systematic errors in the solvation free energies that were difficult to find in 
previous benchmarking studies involving compounds with molecular charges from +1 to –1. 
Hence, the results of the present work may serve as an unprecedented benchmarking of 
implicit solvation methods for density functional studies of the reactions of metal complexes 
involved in catalysis, biology, and medicine.  
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III.6. Supporting Information  
 
Table S1. Mean unsigned errors (MUE) in the calculation of SRPs using protocols I-VII. All 
values in kcal/mol.  
  I II III IV V VI VII 
  PCM PCM PCM PCM CPCM CPCM PBF 
compounds number UA0 UAHF UAKS Bondi UAKS Bondi  
all 80 5.4 7.4 7.1 4.3 7.0 4.4 3.7 
solvent         
ACN 4 2.3 14.8 14.9 0.6 14.8 0.7 0.5 
DMF 16 2.3 3.7 3.6 5.7 3.5 6.0 3.6 
DMSO 14 7.8 8.7 8.2 4.8 8.1 5.0 3.9 
water 46 6.0 7.6 7.2 4.0 7.1 4.0 4.0 
charge         
+3/+2 8 10.4 7.0 6.2 6.2 6.1 6.1 5.3 
+2/+1 18 4.3 4.0 3.7 3.4 3.6 3.4 3.1 
+1/0 10 2.4 3.4 3.0 4.3 3.0 4.3 4.3 
0/-1 21 6.0 5.6 5.4 4.2 5.3 4.4 2.5 
-1/-2 23 5.2 13.5 13.2 4.6 13.0 4.6 4.4 
         
Leada 14 6.8 14.6 14.0 3.3 13.9 3.1 3.7 
a
 Aqueous SRPs of the compounds with the lead structure trans-[RuCl4(L)(L’)]– 
Table S2. Mean signed errors (MSE) in the calculation of SRPs using protocols I-VII. All 
values in kcal/mol.  
  I II III IV V VI VII 
  PCM PCM PCM PCM CPCM CPCM PBF 
compounds number UA0 UAHF UAKS Bondi UAKS Bondi  
all 80 0.2 -3.8 -3.9 1.7 -3.8 1.9 0.7 
solvent         
ACN 4 -2.3 -14.8 -14.9 -0.2 -14.8 0.1 0.1 
DMF 16 1.3 -2.6 -2.5 5.3 -2.4 5.6 2.6 
DMSO 14 -4.1 -7.7 -7.7 4.8 -7.5 5.0 3.4 
water 46 1.3 -2.2 -2.2 -0.3 -2.2 -0.2 -0.8 
charge         
+3/+2 8 10.4 6.7 5.8 4.6 5.7 4.5 4.7 
+2/+1 18 3.2 3.2 2.7 -1.6 2.6 -1.6 -1.1 
+1/0 10 0.8 -0.1 -0.5 2.3 -0.5 2.4 -0.4 
0/-1 21 -2.7 -5.1 -4.6 4.0 -4.5 4.3 2.2 
-1/-2 23 -3.5 -13.5 -13.2 1.0 -13.0 1.2 -0.1 
         
Leada 14 -6.8 -14.6 -14.0 -2.7 -13.9 -2.6 -3.7 
a
 Aqueous SRPs of the compounds with the lead structure trans-[RuCl4(L)(L’)]– 
 60 
 
Table S3. Calculated vs experimental SRPs. Protocol I: PCM/UA0; II: PCM/UAHF; III: 
PCM/UAKS; IV: PCM/Bondi; V: CPCM/UAKS; VI: CPCM/Bondi; VII: PBF. The results 
are sorted by molecular charge, solvent, and chemical similarity.  
  I II III IV V VI VII   
  PCM PCM PCM PCM CPCM CPCM PBF   
Complexa (oxidized form) solvent UA0 UAHF UAKS Bondi UAKS Bondi PBF exp Ref 
[Ru(Im)6]3+ water 0.51 0.66 0.56 0.24 0.56 0.24 0.42 0.30 24g 
[Ru(MeIm)6]3+ water 0.40 0.46 0.36 0.06 0.36 0.06 0.16 0.28 24g 
[Ru(en)3]3+ water 0.46 0.29 0.27 0.23 0.27 0.23 0.23 0.18 24b 
[Ru(OH2)6]3+ water 1.16 0.16 0.16 1.14 0.15 1.14 1.06 0.23 56 
[Ru(NH3)5(OH2)]3+ water 0.68 0.53 0.53 0.34 0.53 0.34 0.25 0.08 24b 
cis-[Ru(NH3)4(Im)2]3+ water 0.52 0.57 0.56 0.23 0.56 0.22 0.27 0.15 24g 
trans-[Ru(NH3)4(Im)2]3+ water 0.53 0.59 0.54 0.27 0.54 0.27 0.26 0.12 24g 
cis-[Ru(NH3)4(OH2)2]3+ water 0.79 0.48 0.47 0.51 0.46 0.51 0.40 0.11 24b 
[RuCl(OH2)5]2+ water 0.56 0.66 0.62 0.61 0.62 0.61 0.52 0.08 24b 
[Ru(NH3)5Br]2+ water 0.16 0.13 0.13 -0.07 0.13 -0.07 -0.11 -0.02 24a 
[Ru(NH3)5Cl]2+ water 0.08 0.01 0.01 -0.15 0.01 -0.15 -0.20 -0.06 24b 
[Ru(NH3)5(OH)]2+ water -0.75 -0.75 -0.75 -0.86 -0.75 -0.86 -0.93 -0.41 24b 
cis-[Ru(NH3)4Cl(py)]2+ water 0.28 0.25 0.25 0.06 0.25 0.06 0.09 0.17 24a 
trans-[Ru(NH3)4Cl(py)]2+ water 0.28 0.26 0.26 0.08 0.26 0.08 -0.05 0.20 24a 
cis-[Ru(NH3)4Cl(isn)]2+ water 0.47 0.41 0.45 0.26 0.42 0.26 0.25 0.23 24a 
trans-[Ru(NH3)4Cl(isn)]2+ water 0.36 0.36 0.34 0.17 0.34 0.17 0.14 0.29 24a 
cis-[Ru(NH3)4(CH3CN)Cl]2+ water 0.45 0.38 0.36 0.21 0.36 0.21 0.21 0.31 24a 
trans-[Ru(NH3)4(CH3CN)Cl]2+ water 0.52 0.47 0.47 0.28 0.46 0.28 0.23 0.32 24a 
cis-[Ru(NH3)4Br(py)]2+ water 0.36 0.32 0.32 0.11 0.32 0.11 0.14 0.19 24a 
trans-[Ru(NH3)4Br(py)]2+ water 0.33 0.32 0.32 0.12 0.32 0.12 0.11 0.19 24a 
cis-[Ru(NH3)4Br(isn)]2+ water 0.47 0.41 0.46 0.29 0.46 0.29 0.27 0.24 24a 
trans-[Ru(NH3)4Br(isn)]2+ water 0.33 0.39 0.32 0.09 0.32 0.09 0.19 0.30 24a 
cis-[Ru(NH3)4I(py)]2+ water 0.41 0.39 0.40 0.19 0.39 0.19 0.25 0.23 24a 
trans-[Ru(NH3)4I(py)]2+ water 0.10 0.45 0.13 -0.25 0.13 -0.26 0.26 0.18 24a 
cis-[Ru(NH3)4I(isn)]2+ water 0.53 0.48 0.49 0.34 0.49 0.34 0.37 0.26 24a 
trans-[Ru(NH3)4I(isn)]2+ water 0.55 0.54 0.53 0.30 0.52 0.30 0.35 0.29 24a 
cis-[Ru(NH3)4Cl2]+ water -0.25 -0.41 -0.41 -0.31 -0.41 -0.30 -0.71 -0.11 24b 
trans-[Ru(NH3)4Cl2]+ water -0.14 -0.34 -0.34 -0.24 -0.34 -0.23 -0.23 -0.16 24a 
cis-[RuCl2(OH2)4]+ water 0.05 0.06 0.06 0.27 0.06 0.27 0.25 0.03 24b 
trans-[RuCl2(Im)4]+ DMF -0.20 -0.17 -0.19 0.13 -0.19 0.14 -0.24 -0.15 25c 
trans-[Ru(bim)4Cl2]+ DMF 0.28 0.28 0.24 0.43 0.25 0.44 0.25 -0.03 25c 
trans-[RuCl2(trz)4]+ DMF 0.31 0.30 0.31 0.42 0.31 0.42 0.18 0.24 25c 
trans-[RuCl2(pz)4]+ DMF 0.23 0.18 0.21 0.22 0.21 0.22 0.22 0.35 25c 
trans-[RuCl2(Im)4]+ DMSO -0.23 -0.27 -0.29 -0.17 -0.29 -0.17 -0.24 -0.18 25c 
trans-[Ru(bim)4Cl2]+ DMSO 0.20 0.19 0.10 0.23 0.10 0.24 0.31 -0.03 25c 
trans-[RuCl2(trz)4]+ DMSO 0.22 0.28 0.23 0.18 0.23 0.18 0.17 0.20 25c 
Ru (bpy)(4,4’-bpy)Cl3 ACN 0.06 -0.36 -0.33 0.12 -0.32 0.13 0.14 0.18 24i 
Ru (bpy)(CH3CN)Cl3 ACN 0.14 -0.42 -0.42 0.23 -0.41 0.24 0.23 0.21 24i 
mer,trans-RuCl3(Me2S)(Ind)2 DMF 0.11 0.04 0.11 0.25 0.06 0.24 0.21 0.16 25b 
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mer,trans-RuCl3(Et2S)(Ind)2 DMF 0.13 0.00 0.02 0.19 0.08 0.23 0.11 0.17 25b 
mer-Ru (buim)3Cl3 DMF -0.57 -0.76 -0.80 -0.31 -0.79 -0.29 -0.39 -0.50 25c 
mer -Ru(bim)3Cl3 DMF -0.32 -0.54 -0.50 -0.12 -0.49 -0.09 -0.29 -0.41 25c 
mer -RuCl3(Metrz)3 DMF -0.11 -0.23 -0.22 0.02 -0.22 0.03 -0.06 -0.18 25c 
mer-RuCl3(Mepz)3 DMF 0.01 -0.15 -0.13 0.06 -0.13 0.08 -0.05 -0.13 25c 
mer-RuCl3(pz)3 DMF -0.01 -0.09 -0.06 0.17 -0.06 0.18 0.09 -0.10 25c 
mer-RuCl3(Ind)3 DMF 0.08 0.02 0.03 0.28 0.03 0.29 0.22 0.10 25c 
mer,trans-RuCl3(Me2S)(Ind)2 DMSO 0.15 -0.21 -0.20 0.26 -0.20 0.27 0.22 0.18 25b 
mer,trans-RuCl3(Et2S)(Ind)2 DMSO 0.11 -0.24 -0.24 0.21 -0.23 0.22 0.13 0.19 25b 
mer-Ru (buim)3Cl3 DMSO -0.50 -1.03 -1.04 -0.33 -1.03 -0.32 -0.37 -0.46 25c 
mer-Ru(bim)3Cl3 DMSO -0.29 -0.81 -0.76 -0.12 -0.75 -0.10 -0.27 -0.38 25c 
mer-RuCl3(Metrz)3 DMSO -0.11 -0.56 -0.55 -0.03 -0.55 -0.02 -0.05 -0.20 25c 
mer-RuCl3(Mepz)3 DMSO 0.03 -0.42 -0.39 0.10 -0.39 0.11 -0.03 -0.13 25c 
mer-RuCl3(pz)3 DMSO 0.03 -0.32 -0.30 0.17 -0.29 0.18 0.10 -0.11 25c 
mer-RuCl3(Ind)3 DMSO -3.33 -0.07 -0.08 0.41 -0.07 0.42 0.24 0.09 25c 
mer-RuCl3(DMSO)2(OH2) water 0.68 0.53 0.56 0.76 0.56 0.77 0.60 0.43 24d 
mer-Ru(NH3)Cl3(DMSO)2 water 0.69 0.50 0.52 0.69 0.52 0.69 0.62 0.36 24d 
mer -RuCl3(DMSO)2(Im) water 0.42 0.33 0.36 0.47 0.37 0.48 0.38 0.34 24d 
[Ru(bpy)Cl4]– ACN -0.19 -0.84 -0.90 -0.07 -0.89 -0.06 -0.07 -0.08 24i 
[Ru(dcbpy)Cl4]– ACN -0.01 -0.56 -0.55 0.09 -0.54 0.09 0.10 0.08 24i 
trans-[RuCl4(DMSO)(Im)]– DMF -0.16 -0.38 -0.38 0.01 -0.37 0.03 -0.10 -0.22 25a 
trans-[RuCl4(Im)2]– DMF -0.58 -0.85 -0.90 -0.31 -0.88 -0.29 -0.40 -0.72 25c 
trans-[RuCl4(trz)2]– DMF -0.36 -1.33 -1.34 -0.15 -1.33 -0.13 -0.16 -0.48 25c 
trans-[RuCl4(Ind)2]– DMF -0.27 -0.48 -0.47 0.06 -0.46 0.07 -0.11 -0.43 25c 
trans-[RuCl4(Im)2]– DMSO -0.59 -1.46 -1.46 -0.35 -1.45 -0.33 -0.35 -0.74 25c 
trans-[RuCl4(trz)2]– DMSO -0.37 -1.22 -1.20 -0.18 -1.20 -0.18 -0.12 -0.44 25c 
trans-[RuCl4(Ind)2]– DMSO -0.23 -0.92 -0.90 0.09 -0.90 0.10 -0.09 -0.41 25c 
trans-[RuCl4(Im)2]– water -0.47 -0.92 -0.83 -0.20 -0.83 -0.19 -0.30 -0.15 24f 
trans-[RuCl4(tz)2]– water -0.28 -0.62 -0.63 -0.09 -0.63 -0.08 -0.12 -0.01 24h 
trans-[RuCl4(Ind)2]– water -0.12 -0.45 -0.45 0.19 -0.44 0.20 0.03 0.03 25a 
trans-[RuCl4(DMSO)2]– water 0.18 -0.15 -0.11 0.31 -0.11 0.32 0.28 0.47 24c 
trans-[RuCl4(DMSO)(OH2)]– water 0.06 -0.19 -0.17 0.21 -0.17 0.21 0.25 0.35 24c 
trans-[Ru (NH3)Cl4(DMSO)]– water -0.05 -0.35 -0.33 0.08 -0.33 0.09 0.05 0.27 24d 
trans-[RuCl4(DMSO)(Im)]– water -0.06 -0.47 -0.38 0.12 -0.37 0.13 0.07 0.24 24d 
trans-[RuCl4(DMSO)(MeIm)]– water -0.11 -0.42 -0.40 0.07 -0.39 0.08 0.04 0.25 24d 
trans-[RuCl4(DMSO)(pz)]– water 0.03 -0.33 -0.31 0.16 -0.31 0.17 0.11 0.31 24d 
trans-[RuCl4(DMSO)(Ind)]– water 0.06 -0.28 -0.27 0.18 -0.27 0.19 0.16 0.33 24d 
trans-[RuCl4(DMSO)(py)]– water -0.01 -0.33 -0.31 0.15 -0.31 0.16 0.15 0.31 24d 
trans-[RuCl4(py)(TMSO)]– water -0.03 -0.37 -0.37 0.15 -0.36 0.16 0.12 0.30 24d 
a
 bim: benzimidazole, bpy: 2,2’-bipyridine, 4,4’-bpy: 4,4´-bipyridine, buim: 1-
butylimidazole, dcbpy: 4,4’-dicarboxylic acid-2,2’-bipyridine, Et2S: diethyl sulfide, Me2S: 
dimethyl sulfide, DMSO: dimethyl sulfoxide, en: ethylenediamine, Im: imidazole, Ind: 
indazole, isn: isonicotinamid, Meim: 4-methylimidazole, Mepz: 4-methylpyrazole, Metrz: 1-
methyl-1,2,4-triazole, py: pyridine, pz: pyrazole, trz: 1,2,4-triazole, Metrz: 1-methyl-1,2,4-
triazole, TMSO: tetramethylene sulfoxide, tz: thiazole.  
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Figure S1. Calculated vs experimental SRPs. (a) Protocol III, PCM/UAKS, (b) Protocol V, 
CPCM/UAKS, (c) Protocol VI, CPCM/Bondi. The data are sorted by solvent (color of 
symbol) and charge (shape of symbol). Aqueous SRPs of the medicinally relevant complexes 
with the lead structure, trans-[RuCl4(L)(L’)]–, are displayed as filled symbols.  
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IV. Density Functional Study of Ruthenium(III) Anticancer 
Complexes 
 
IV.1. Abstract 
 
The chemical behavior of four potential anticancer ruthenium(III) species: trans-
tetrachloridobis(1H-imidazole)ruthenate(III) (ICR), trans-tetrachloridobis(1H-
pyrazole)ruthenate(III), trans-tetrachlorido(dimethylsulfoxide)imidazoleruthenate(III) 
(NAMI-A) and trans-tetrachloridobis(1H-indazole)ruthenate(III) (KP1019) and their reduced 
analogs has been explored by high level quantum calculation. The electronic aspects 
governing their electrochemistry have been investigated by using the bond energy 
decomposition analysis revealing the role of π-electron acceptor character of DMSO and 
indazole ligands in stabilization of Ru(II) species. Influence of the electron donor properties 
of the protein and DNA models directly bound to the metal, the medium pH and dielectric 
constant on the standard redox potentials have been examined. Furthermore, the mechanistic 
aspects of the aquation process have been studied in detail. In agreement with experimental 
data available and contrary to part of the previous computational works we have found the 
preference for the interchange mechanism of dissociative character (Id) for aquation of 
Ru(III) species. Moreover, for the first time we have studied the limiting dissociative 
mechanism (D) of the aquation of Ru(II) analogs and have found it to be prefered over the 
interchange mechanism. The importance of aquation products, mono- and cis-di-aqua 
complexes, as precursors for the biological actions is analyzed. The kinetics and 
thermodynamics of reactions towards biomodels have been computed and no clear preference 
for either nitrogen or sulfur protein binding sites was found. In the binding to isolated purinic 
nucleobases, to model the reaction with DNA, the kinetic preference for binding guanine over 
adenine is found for the reduced cis-di-aqua complexes; the characteristic transition 
structures being stabilized by a hydrogen bonding pattern similar to cisplatin reactions. The 
hydrogen bond between guanine O6 and cis-aqua ligand stabilizes the reaction products in 
both oxidation states. The possible involvement of Ru(III) complexes in the redox cycling 
inside the cancer cell that can catalyze generation of reactive hydroxyl radicals is discussed as 
well.  
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IV.2. Introduction  
 
Globally one half of all tumor therapies are based on three platinum complexes: 
cisplatin, carboplatin, and oxaliplatin.1 Since the discovery of the antineoplastic properties of 
cisplatin2 a continuous search for platinum and other transition metal complexes with similar 
properties has been pursued. High toxicity of cisplatin along with wide range of side effects, 
and its inactivity against a number of carcinomas are the reasons of increasing interests in 
other metallopharmaceuticalls. Studies on the promising complexes of gallium,3 rhodium4 
and ruthenium5 which show a remarkable anticancer potential are ongoing and attract more 
and more scientists worldwide. Two Ru(III) complexes NAMI-A6 (imidazolium [trans-
tetrachlorido(dimethylsulfoxide)imidazoleruthenate(III)]) and KP10197 (indazolium [trans-
tetrachloridobis(1H-indazole)ruthenate(III)]) (Chart 1) successfully completed phase I 
clinical trials8 and have started (NAMI-A) a phase II study.9 Recent developments of 
organometalic Ru(II) anticancer complexes are promising as well.10 
 
The cisplatin mode of action1 is well established and described by the binding of the 
products of cisplatin aquation at two adjacent guanine DNA sites, and subsequent cell 
apoptosis after the recognition of structurally modified DNA. Relatively little is known about 
the mode of action of other transition metal potential anticancer drugs, but their different 
coordination chemistry, reactivity, the capacity of replacement of essential metals, and the 
redox behavior most likely induce a biologically different mode of action. Due to their 
reduced general toxicity, as compared to platinum compounds, and their high activity against 
platinum-based drugs resistant tumors, Ru(III) complexes appear to be the most promising 
alternatives as anticancer metallopharmaceuticals.5 Due to the similarity of their coordination 
chemistry, ruthenium resembles iron in the binding to albumin and transferrin.11 This could 
partially explain the lower toxicity of the ruthenium compounds in comparison to platinum-
based drugs. The delivery of the octahedral ruthenium compounds to the cell is mediated by 
transferrin receptor endocytosis which is less likely to operate in the case of square planar 
platinum(II) compounds. Although they are capable of binding to these proteins as well, 
contrary to the ruthenium complexes, this process is supposed to contribute to the drug 
administration side effects.12  
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Ru(III) complexes are believed to be activated in vivo upon reduction to their more 
reactive Ru(II) analogs.13 A selective reduction in cancer cells occurs likely due to the 
reducing environment caused by deficiency of molecular oxygen in tumors (hypoxia),14 as the 
blood flow to the rapidly growing tumor is insufficient. However, the prodrugs could be 
reduced prior reaching the reducing milieu in tumors, e.g. as a result of aquation, the resulting 
products of which have different redox properties than the initial prodrug. In particular, the 
first step aquation product of KP1019 ([RuIIICl3(H2O)(Hind)2]; Hind = 1H-indazole) (E1/2 = –
0.16 V vs. NHE in DMF) is significantly easier to reduce than the administered non-aquated 
prodrug (Ep/2 = –0.43 V vs. NHE in DMF).15 
 
A major contribution to the understanding of the mode of action of metallo-drugs is 
attained by modern quantum chemistry. The transition structures and reaction intermediates, 
which are difficult to detect experimentally, are accessible in silico, and the elementary 
reaction steps can be precisely explored. Experimentally proposed and theoretically possible 
competing mechanisms can be rigorously investigated by computation chemists shedding 
light into the biological mystery of the metal complexes anticancer potency. Many quantum 
chemical studies focused on the cisplatin aquation16 and the subsequent binding of the 
aquation products to DNA bases.17 On the other hand, considerably less computational work 
was dedicated to other anticancer metal complexes. In particular, for the promising anticancer 
Ru(III) compounds, at the moment of writing, only aquation mechanisms of NAMI-A,18 
ICR18b,19 (imidazolium [trans-tetrachloridobis(imidazole)ruthenate(III)]), TzICR (thiazolium 
[trans-tetrachloridobis(thiazole)ruthenate(III)]) and (2-NH2)TzICR ((2-aminothiazolium 
[trans-tetrachloridobis(2-amminothiazole)ruthenate(III)])18d were investigated. The 
thermodynamics of the binding of Ru(II) and Ru(III) complexes to DNA by investigating 
monofunctional ruthenium complexes of the formula [Ru(NH3)5B]Z+ (Z = 2,3), where B is a 
nucleobase or a protein model was studied as well,20 revealing the preference for guanine 
over adenine binding for both Ru(II) and Ru(III) complexes.  
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Chart 1. NAMI-A and KP1019, successful Ru(III) anticancer complexes in clinical trials 
 
 
In order to understand the mechanism of action of octahedral Ru(III) anticancer 
agents we have systematically investigated: (i) the aquation of the Ru(III) compounds; (ii) the 
effect of the axial ligands, pH, environment and the protein binding on their redox behavior; 
and (iii) the kinetic and thermodynamic aspects of the binding towards proteins and DNA 
models. For this purpose an in silico four-species-evolution approach (Chart 2, 1–4) (similar 
to the one used previously21) which includes trans-tetrachloridobis(1H-
imidazole)ruthenate(III) (ICR, 2–Cl) and trans-tetrachloridobis(1H-pyrazole)ruthenate(III) 
(3–Cl) to rationally connect two successful Ru(III) anticancer drugs NAMI-A (1–Cl) and 
KP1019 (4–Cl) were investigated. (For the sake of clarity from this point down we will refer 
to the tetrachlorido complexes without specifying explicitly the functional group in the 
designator, i.e. by 1 we refer to NAMI-A and by 5 to its reduced form, respectively, instead 
of using 1–Cl and 5–Cl). Experimental observation that only aged aqueous solution of ICR 
(2) reacts with DNA,22 supports the assumption that, similarly to cisplatin, the aquation 
products of Ru(III) complexes being more reactive than their parent chlorido complexes once 
formed are the subject of substitution. The reactivity of aquated species towards relevant 
nitrogen and sulfur nucleophiles has been studied by using a collection of functional groups 
employed in similar computations on cisplatin16e,23 and organometalic Ru(II) complexes.16e 
The library (Chart 2) contains small nitrogen NH3 and sulfur H2S nucleophiles and protein 
models: methylamine representing terminal amino group; imidazole representing histidine; 
dimethylsulfide representing methionine; methylthiolate and methylthiol representing 
glutathione and cysteine in their deprotonated and protonated forms respectively. Guanine 
and adenine were used as DNA models. The standard redox potentials (SRPs) of chlorido 
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complexes and their monosubstituted derivatives have been computed and the factors 
influencing the SRPs rationalized. Because the “activation-by-reduction” hypothesis suggests 
that Ru(II) species are responsible for anticancer activity of ruthenium drugs, the aquation of 
reduced species and their binding to biological models have been investigated as well.  
 
Chart 2. Metal complexes and biological relevant substituent models 
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IV.3. Aquation mechanism of ruthenium anticancer agents 
 
The aquation is the replacement process of a ligand in an inorganic complex by a 
water molecule. The abundance of water molecules at physiological conditions makes 
metallo-drugs susceptible to aquation. The process, being the crucial step of the in vivo 
transformations of cisplatin, determines its ultimate success as anticancer drug. Experimental 
evidence that only aged aqueous solution of ICR reacts with DNA,22 suggests that similarly 
to cisplatin, the aquation products of ruthenium drugs, being more reactive than their parent 
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chlorido complexes are the active forms of the drug. Moreover, the high lability of the aqua 
ligand in mono-aqua derivative of KP1019 suggests that this complex is the potential active 
species responsible for the antitumor activity of KP1019.24 The common “activation by 
reduction” hypothesis13 does not exclude the aquation as being an important step in the 
ruthenium anticancer activity. Therefore, it is not surprising that the aquation has been the 
subject of many experimental and, since recently, of computational studies.18,19 
 
Although the importance of detailed understanding of aquation process is essential, 
the lack of experimentally relevant data and the variety of possible pathways make the 
assessment of the aquation mechanism of Ru(III) compounds a real challenge for chemists. 
Figure 1 represents the mechanism types in a water exchange process. The associative (A) 
and dissociative (D) substitution reaction mechanisms proceed in two steps and involve 
intermediates with an increased or a decreased coordination number, respectively. The 
experimental evidences for these limiting mechanisms are restricted by the fact that the 
intermediates are not always detectable, because of their short lifetime. If the experimental 
detection of intermediates is not possible, by default, an interchange mechanism is assumed, 
in which formation of the metal bond with the entering ligand is concerted with weakening of 
the metal bond with the leaving group. The transition state is characterized by weak bonding 
of both the leaving, and the entering ligands. If bond formation is more pronounced than the 
bond breaking, the mechanism is called associative interchange (Ia); otherwise (if bond 
breaking dominates) the dissociative interchange (Id) mechanism operates. For the 
interchange (I) mechanism the same extent of the bond formation and breaking is 
characteristic. In addition to the investigation of the presence or absence of reaction 
intermediates, the information about the intrinsic mechanism of the substitution process is 
obtained by experimentally measuring the activation parameters entropy (∆S#) and volume 
(∆V#), as well. A positive value of the activation volume or activation entropy is 
characteristic for Id or D mechanisms. In contrast, the negative sign of the activation volume 
and activation entropy is characteristic for Ia or A mechanisms. One should note that the 
activation entropy alone is not a measure of the experimental assessment of the reaction 
mechanism, as it depends not only on the bond strength at the transition states, but also on 
other factors25 described for the phosphate monoester hydrolysis (e.g.: steric factors that 
determine the configurational volumes available to the reactants during the reaction, solvation 
and desolvation effects that may be associated with charge redistribution upon approaching 
the transition state, entropy changes associated with intramolecular degrees of freedom as the 
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transition state is approached, etc). To assess theoretically the reaction mechanism, the 
investigation of all the species involved (reactants, transition states, intermediates and 
products) is mandatory. The subsequent investigation of the computed reaction profiles 
determines the most plausible reaction pathway and implicitly mechanism for the given 
process. The decisive assignment of the mechanism is done by combining both experimental 
and theoretical studies.26 
 
Figure 1. Schematic representation of the substitution mechanism types in a water exchange 
process. The colored circles define the positions of entering and leaving ligands relative to 
the central metal atom in transition structures. Heptacoordinate and pentacoordinate 
intermediates are generated during the substitution reactions proceeding via limiting A or D 
mechanisms respectively. 
 
Theoretical studies available in the literature on platinum anticancer complexes 
suggest the aquation process to follow an interchange mechanism of associative character 
(Table 1). Recently, the influence of the electronic interaction of the metal orbitals with the 
ligands in trans position to aqua on the water exchange mechanism was systematically 
investigated for the square-planar Pt(II) compounds,27 and the correlation between the 
electron donor abilities of the trans ligand on the substitution mechanism was revealed. 
Supported by the decomposition and natural orbital analyses, two cases where the most 
favorable mechanism was found to be different form the commonly accepted Ia for the water 
exchange process at Pt(II) centers were found. The substitution proceeds via an Id 
mechanism if the trans ligand is a strong σ donor (e.g. CH3–), and via a limiting A 
mechanism in the case of compounds bearing ligands such as C2H4 and CO in trans position 
which can lower considerably the electron density at the metal, due to π-back donation. 
Because there is a smaller number of the computation studies on ruthenium compounds, 
discrepant in some cases (Table 1) the dispute on their aquation mechanism is still not 
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finished. By performing calculations at carefully tested theoretical level28 the most viable 
mechanism can be found. 
 
Table 1. Aquation mechanisms of different anticancer metallo-drugs. ΣTS–ΣRA: difference 
between the lengths sum of the bonds formed and broken during the aquation in TS and 
reactants adduct (RA). 
   Exp. activation parameters  
ΣTS–ΣRA Meca ref ∆H ∆S Mec ref compound 
Å   kJ/mol J/mol×K   
–0.85 Ia 16a 19.7 –15 Ia 29 
–0.83 Iab 16a     
–0.42 Ia 30     
Cisplatin 
–0.96 Iab 16d     
trans-[Pt(NH3)2LT(H2O)]n+   27     
LT = H2O  Iac -     
LT = Cl–  Iac -     
LT = CH3–  Idc -     
LT = C2H4  Ac -     
Carboplatin  
 
 88.4 –15 Ia 31 
–0.68 Ia 32     Oxaliplatin 
–0.54 Iab 32     
Rhodium tetracarboxylate  
 
 49.0 ± 1.0 –60 Ia 33 
 Ia 21 79.5 ± 3.4 –30.8 ± 11.5 Ia 34 
–0.88 Ia 35     
[(η6-benzene)RuII(en)Cl]+ 
–0.58 Iab 35     
–0.49 Ia 18c     
0.26 Idb,c 18c     
–1.20 Ia 18a     
 Idc 18b     
NAMI-A 
1.58 Id this work     
 Idc 18b     RuII analog of NAMI-A 
 D this work     
–0.69 Ia 19 117.0 ± 7.0 55.0 ± 23.0 Id 36 
 Idc 18b     
ICR 
1.33 Id this work     
 Idc 18b     RuII analog of ICR 
 D this work     
TzICR 0.01 I 18d     
(2-NH2)TzICR –0.09 Ia 18d     
KP1019  Id this work     
RuII analog of KP1019  D this work     
trans-[RuIIICl4(Hpz)2]–  Id this work     
trans-[RuIICl4(Hpz)2]2–  D this work     
a mechanism 
b
 optimizations in solution. 
c
 mechanism assignment is made by the authors. All other mechanism types are our 
estimations either from ΣTS–ΣRA parameter value or from the activation entropy. 
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Similarly to the ∆Σd(M–O) criterion37 used to ascribe the mechanism of water 
exchange reaction of transition metal complexes, we use the sum of the lengths change of the 
two bonds involved in the aquation (metal–entering (E) and metal–leaving (L) ligands) to 
evaluate the mechanism of the potent anticancer agents, available in the literature (Table S1 
in Supporting Info). The only usage of the bonds directly involved in the substitution reaction 
is imposed by the fact that they are generally provided in the literature, at the same time the 
spectator metal–ligand bonds (which do not participate in the aquation) do not change 
dramatically, and consequently do not influence the activation volume at the same extent as 
the bonds broken and formed during the process. For this purpose, in contrast to the rest of 
the work, we considered the optimization of the reactant complexes involved in the aquation 
process as well. A good correlation between the mechanisms predicted by the ΣTS–ΣRA38 
parameter and the experimental mechanisms (deduced from the activation entropy value) is 
found for aquation of platinum, rhodium and piano-stool type Ru(II) arene complexes. This is 
not true for NAMI-A, aquation mechanism of which is described by two different 
mechanisms in the literature. While the authors of the references 18c and 18a were able to 
reproduce quantitatively the experimentally measured aquation rate constants, their predicted 
activation mechanisms are different. By optimizing all the species involved in the chlorido 
aquation, up to the second step (molecules, intermediates and transition states), and by 
drawing the free energy profiles, we aim to reveal the aquation mechanism, as well as to 
reproduce experimentally available kinetic and thermodynamic data. However, one should 
note that partial substitution of DMSO ligand in NAMI-A by water molecule was observed 
experimentally at physiological pH as well.39  
 
IV.3.1. Aquation of Ru(III) complexes 
 
Figure 2 displays the energy profile corresponding to the interchange aquation 
mechanism (Scheme 1) of Ru(III) complexes 1–4 up to the second aquation step. The 
activation free energies of the first aquation step are comparable (∆Ga = 24.9–28.6 kcal/mol, 
Table 2), with the lowest activation barrier computed for 3. This may be due to strong 
hydrogen bonding stabilization of the transition structure, that has, additionally to the 
hydrogen bonding between water’s hydrogen and leaving Cl (dH···Cl = 2.07–3.17 Å) found in 
all TS, strong hydrogen bonding interactions (Figure 3) between the entering water molecule 
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and the N–H site of the axial pyrazole (dO···H = 1.62 Å) and between leaving Cl ligand and the 
N–H of the second pyrazole (dCl···H = 2.01 Å). The indazole ligand, which like pyrazole has 
the N–H site available for hydrogen bonding in transition states, stabilizes only the leaving Cl 
ligand (dCl···H = 1.96 Å). The corresponding stabilization of water molecule by hydrogen 
bonding to N–H of the second indazole ligand was not possible to reproduce. The reactions 
are endergonic (Table 2), the exception is ∆Gr = –0.8 kcal/mol of the first aquation step of 
NAMI-A. The computed rate constants are in good agreement with experimental data (Table 
2). The formation of the cis di-aqua isomers in the second aquation step is both kinetically 
and thermodynamically preferred over the trans isomers (Table 2, Figure 2) in agreement 
with previously computed data.18b At physiological conditions, the deprotonation of aqua 
ligand of the mono-aqua complexes readily occurs (computed pKa values are quoted in Table 
3 and Table S4) and the most abundant aquation products are mono-hydroxido derivatives of 
the initial complexes. 
 
Figure 2. Free energy profile of the aquation of Ru(III) complexes up to the second step. Free 
energies (kcal/mol) are calculated with respect to the separated reactants. 
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Scheme 1. Interchange mechanism of the first aquation step of Ru(III) complexes 
 
 
Table 2. Free energies relative to separated reactants of the species involved in the aquation 
process of 1–4 up to the second step (kcal/mol). Reaction rates for the first aquation step (s–1) 
 R TS1a P1 cis-TS2 cis-P2 trans-TS2 trans-P2 k (calc) k (exp)40 
1 0 28.6 –0.8 31.3 4.3 38.4 5.9 3.6×10-7 1.4×10–7–
3.1×10–6 
2 0 27.8 2.3 28.1 4.8 39.3 4.9 1.4×10–6 1.1×10–5 
3 0 24.9 3.0 27.1 7.6 39.3 7.8 1.9×10–4  
4 0 27.8 2.3 28.0 9.0 38.9 10.3 1.4×10–6 0.4×10–5 
 
a
 the digits represents the aquation step; R, TS and P stand for reactants, transition states and 
products respectively 
 
Figure 3. Hydrogen bonding pattern in computed transition state of the first aquation step of 3 
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Table 3. Absolute pKa values of aqua and thiol complexes 
 OH2 MeSH 
1–Y 3.4 –0.9 
2–Y 4.3 –1.4 
3–Y 3.1 –2.6 
4–Y 2.3 –3.1 
5–Y 18.6 10.9 
6–Y 16.4 11.3 
7–Y 16.0 11.3 
8–Y 12.7 10.5 
 
By taking into account the solvent effects by means of implicit solvation models 
during optimizations, the authors in ref. 18c found the transition structure characteristic for an 
interchange mechanism with dissociative character (Id) of aquation of 1 (positive (ΣTS–ΣRA) 
parameter in Table 1) contrary to the associative character (Ia) found when the optimization 
is carried out in vacuo.18c One should note that in these calculations additional three explicit 
water molecules were employed to simulate the first shell solvation interactions. Our model 
predicts even stronger dissociative character of the interchange mechanism:41 (ΣTS–ΣRA) = 
1.58 vs 0.26 (Table 1). Moreover, we found geometrical differences in the transition 
structures optimized by us, as compared to the TSs described in the ref. 19, mostly related to 
the length of the metal-ligand bonds involved in aquation. For ICR (2) aquation, our model 
predicts a strong dissociative character of the interchange mechanism in contrast to the Ia 
mechanism described previously19 (ΣTS–ΣRA = 1.33 vs –0.69), but in agreement with more 
recent computations.18b The experimental positive value of the activation entropy supports 
our findings that the aquation of ICR occurs via an Id mechanism and the reliability of our 
model. Moreover, we tried to investigate the Ia mechanism, by optimizing a more compact 
transition state (similar to the one obtained by the authors of the ref 19) and obtained a higher 
kinetic preference for the Id mechanistic path characterized by an activation barrier of 
aquation lower by 6 kcal/mol. 
 
IV.3.2. Aquation of Ru(II) complexes 
 
In transition metals series the mechanism of water exchange at the metal center 
changes as function of occupancy of d orbitals, the coordination number and the ionic radius 
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of the central metal. In extreme case of Ga(III) complexes with electronic configuration d10 
substitution proceeds via a limiting D mechanism.26 In contrast, the water exchange at Sc(III) 
center, with electronic configuration d0, proceeds via limiting A mechanism which is clearly 
more favorable than the D mechanism, for which characteristic transititon structures were 
optimized as well.37b Square-planar Pt(II) and Pd(II) complexes, (electronic configuration d8) 
are more likely to react via associative pathways because of coordination sphere is less 
congested to start with. The reactions with these complexes proceed via an Ia mechanism. 
The dissociative character of the water exchange mechanism for such complexes was 
assigned only in the cases when a strong σ-donor is present in trans position (CH3–).27 The 
differences between the substitution mechanisms at Ru(II) as compared to Ru(III) are mainly 
due to the change of the occupancy of d orbitals, from d5 to d6. The gradual filling of the non-
bonding t2g orbitals, spread out between ligands disfavors electrostatically the approach of a 
seventh molecule towards a face of the octahedron emphasizing the dissociative character of 
the mechanism. The increase of the ionic radius enhances the dissociative character, as the 
leaving ligands are less strongly attached to the metal center, therefore easier dissociate.  
 
Because the aquation of Ru(III) complexes proceeds only via an interchange 
mechanism with strong dissociative character, in the case of Ru(II) complexes a limiting D 
mechanism should be expected. Although the experiments do not exclude the possibility of 
an interchange mechanism, the computational attempts to find typical transition states for 
water exchange at Ru(II) in hexaaqua complexes failed in the previous studies.42 In our 
attempts to find TS characteristic for an interchange mechanism only strongly stabilized by 
hydrogen bonding TSs involved in 7 and 8 aquation were optimized. The 
H(N1(1’):Hpz,Hind)–Cl contacts are 2.02 Å. Even in these cases the dissociative mechanism 
is preferred path of aquation showing a ∆Ga lower by ~4 kcal/mol (Table S5, Table S6 and 
Figure 4). This is the reason why we investigated only the D mechanism (Scheme 2) of the 
substitution at the metal center in Ru(II) complexes for all subsequent reactions. Figure 4 
shows the energy profiles of Ru(II) aquation. The loss of chlorido ligand proceeds fast, the 
first step has low activation barriers of 9.5–12.9 kcal/mol. The resulting intermediates bind 
one water molecule in the second step of D mechanism, which is not the rate determining, the 
reactions being exergonic. Because aqua ligand has a week trans effect, higher activation 
barriers are expected for the first step of dissociative mechanism, therefore the formation of 
the trans-di-aqua isomer is kinetically less feasible. In contrast to Ru(III) species the 
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deprotonation of the aqua ligand is a thermodynamically less favorable process (Table S6, 
Figure 4). 
 
Scheme 2. The dissociative (D) mechanism of Ru(II) aquation 
 
 
Figure 4. Free energy profile of the aquation of Ru(II) complexes. The solid lines represent D 
mechanism, while dotted lines are used for less favorable interchange mechanism of 
associative character. Free energies (kcal/mol) are calculated with respect to separated 
reactants. The digit following the transition states designator (TS) denotes the aquation step. 
The first and second steps of D mechanism are symbolized by D1 and D2 respectively. 
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IV.4. Factors controlling the SRPs 
 
The “activation by reduction” hypothesis ascribes to the reduction potential of the 
Ru(III) anticancer drugs a central role in their pharmacological activity. The SRPs of the 
chlorido prodrugs fall into the biological accessible range of –0.4 to 0.8 V.43 The aquation 
and subsequent binding to a protein residue or a purine base change the redox potential, and 
implicitly influence the activity. The ultimate success of the Ru(III) anticancer drugs implies 
the possibility to rationalize the control of the redox potentials. So far, SRPs of the metal 
complexes were predicted using an empirical increment system44 derived from 
experimentally measured SRPs. In this study we use a computational approach which was 
recently checked and validated28 by predicting the SRPs of 61 ruthenium complexes. By 
performing computational prediction of the redox potentials we are interested in revealing the 
effect of the axial ligands, pH; substituted ligands, and environment on the redox behavior of 
Ru(III) compounds. 
 
IV.4.1. Effect of axial ligands 
 
To characterize the metal-axial ligands interaction in 1–8, we have analyzed the 
molecules in terms of interactions between the two fragments: (i) the common for all four 
low spin d5(d6) complexes fragment [RuCl4]–/2–, f1, and (ii) the fragment containing axial 
ligands, f2, using an energy decomposition scheme developed by Ziegler and Rauk45 at the 
B3LYP level as implemented in ADF. The metal orbital interactions with axial ligands in 
trans-[RuCl4(Hpz)2]–/2– are displayed in Figure 5 and their energy contributions are collected 
in Table S7 in Supporting Info. The low symmetries of studied compounds (C2h for bis-azole 
compounds (2–4) and Cs symmetry of NAMI-A (1)) do not allow the full analysis of metal 
orbital interaction with the axial ligands orbitals. To overcome this problem we studied the 
rotamers of the 2–4 compounds in the C2v symmetry as well. To reveal the interaction of the 
metal with DMSO ligand we adopted a different approach: we have studied trans-
[RuCl4(DMSO)2]–/2– complexes which have higher symmetry (9 and 10 in Chart 2). The 
replacement of imidazole by DMSO increases the symmetry of the system, and the rotamers 
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of C2h and C2v symmetry become accessible. Either C2h or C2v symmetry itself is not enough 
to fully characterize the metal-ligand interactions, but their combination enables full 
description of the interaction systems with following approximations: there are negligible 
interactions between symmetry adapted axial ligands orbitals with 4d(x2–y2) and 5px metal 
orbitals. Figure 6 displays an example of how to use the rotamers’ approach to compute the 
stabilizing orbital energy component due to back-donation from the 4dxz orbital to DMSO 
ligand. Table S7 in Supporting Info includes the formula used to calculate and the values of 
the interaction energies of the metal orbitals with the axial ligands. The results of the bonding 
analysis for 4, 9 and their reduced species 8 and 10 are presented in Table 4 (Table S8 for 2,3 
and 6,7), which reports all contributions to the f1–f2 interaction energy, and includes: 
repulsion between fragments due to Pauli principle ∆EPauli, electrostatics ∆Eelst, and 
stabilizing orbital interactions ∆Eorb (∆Eint = ∆Eelst + ∆EPauli + ∆Eorb). The orbital energy 
component is further decomposed in contributions from irreducible representations of 
particular point group. Figure 7 displays the contribution from metal orbitals to the stabilizing 
orbital interactions in compounds 6–8, and 10. The orbital interaction is governed by a strong 
σ-donation from the ligands to the empty dz2 or 5s orbitals46 of the ruthenium and π-back 
donation from dyz (including dxz in the case of DMSO) to the axial ligands. The interactions 
of metal 4dxy, 5pz, 5py and 5dxz (in the case of bis-azole complexes) orbitals with the axial 
ligands are not accompanied by a charge transfer and have only a polarization character. 
Interestingly, the involvement of the empty metal p orbitals in the bonding at the transition 
metals, being controversially disputed in the literature,47 is found to be strongly basis set 
dependent. Despite the quantitative improvements, in the terms of energy components, arisen 
by improving the quality of basis set from triple to quadruple zeta are negligible, the orbital 
interactions description is altered. The usage of triple zeta quality basis set predicts the 
participation to bonding of the metal pz orbital by computing significant charge transfers to 
this orbital. However these interactions have only a polarization character when the enhanced 
basis of quadruple zeta quality is used (Table S9 and Table S10).  
 
The large energy value of π-back donation from the dyz in the case of 8 as compared 
to 7 is induced by the large negative charge of the complexes which is compensated by 
solvation (Figure 8). Computations on the neutral model complexes show similar stabilization 
due to π-back donation from dyz (Table S11). Figure 8 displays the gas-phase change in the 
interaction energy between f1 [RuCl4]–/2– and axial ligands in 1–4 and 5–8, together with their 
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difference in the gas-phase and in solution. The gas-phase differences predict a larger 
stabilization of 4 upon reduction in comparison to 1. The measured SRPs sequence in 
solution is reproduced after the inclusion of solvation, which seems to be an important factor 
in stabilization of the reduced forms. 
 
Figure 5. Interactions of metal orbitals with axial ligands in [RuCl4(Hpz)2]–/2– 
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Figure 6. Usage of the rotamer’s approach to evaluate the 4dxz contribution to orbital 
interaction energy 
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Table 4. Decomposition of the interaction energy between [RuCl4]–/2– and the axial ligands in 
9, 4 and in their reduced forms 10 and 8 (kcal/mol) 
 C2h C2v 
 9 10 4 8 9 10 4 8 
Eint –70.7 –75.8 –89.3 –91.6 –70.8 –75.2 –88.7 –90.5 
Esolv –61.5 –185.1 –59.5 –178.1 –62.3 –186.5 –60.0 –179.2 
Eint+solv –132.2 –260.8 –148.8 –269.7 –133.1 –261.7 –148.7 –269.7 
∆EPauli 182.5 213.4 183.0 214.2 182.5 213.2 182.9 214.0 
∆Eelst –148.0 –175.9 –172.9 –188.7 –147.7 –175.4 –173.0 –188.6 
∆Eorb –105.2 –113.3 –99.4 –117.1 –105.5 –112.9 –98.6 –115.9 
∆EΓi C2h (C2v)         
ag (a1) –90.2  –93.2 –78.1 –76.0  –69.8 –61.4  –64.5 –58.2 
bg (a2) –27.0 –38.2 –26.1 –55.3  –23.1 –35.5 –20.9 –54.0 
au (b1) –3.3 –5.1 –3.2 –5.8 –36.5 –48.6 –32.9 –37.1 
bu (b2) –16.5 –17.4 –20.1 –20.4 –7.8 –8.1 –8.5 –7.3 
 
Figure 7. Contribution from metal orbitals to the stabilizing orbital interactions in compounds 
6–8 and 10 
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Figure 8. Total interaction energies ∆Eint between RuCl42–/– and the axial ligands in 1–4 and 
5–8, along with their interaction energy differences which determines the SRPs; in vacuo and 
in aqueous solution. 
 
Figure 9 displays the change of the calculated SRPs as function of the substituted 
ligand at the metal center in the substituted complexes (1–4) (Chart 2). The first “evolution” 
step involves the exchange of the DMSO ligand in NAMI-A type compounds by an 
imidazole. The replacement is accompanied by a drastic decrease of the SRPs in the studied 
series by 355 mV in average. Strong π-backdonation found by the decomposition analysis 
from ruthenium 4dxz and 4dyz to DMSO ligand reveals its good π-electron acceptor character 
(Table 4) which stabilizes the reduced forms. The replacement of the axial imidazoles by 
pyrazoles increases the SRPs by 190 mV in average. The subsequent expanding of electron 
delocalization at axial ligands by fussion of benzo ring to each pyrazole is accompanied by a 
137 mV average increase of the redox potentials of the KP1019 derivatives. This last step 
partially compensates the effect of DMSO removal, as the SRPs grow to be comparable to the 
SRPs of NAMI-A derivatives (Figure 9, Table S12). These changes are consistent with the 
variation of the donating properties of the free ligand series: imidazole (pKa = 7.11) > 
pyrazole (pKa = 2.64) > indazole (pKa = 1.25),48 i.e. the weaker donor character of the axial 
ligands is (lower pKa value), the reduction is easier, stronger stabilization of the reduced 
forms is observed, and higher SRPs are expected (Figure 10). 
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Figure 9. Redox potential change upon substitution in 1–Y:4–Y series. The red scale 
represents the biologically inaccessible redox-potentials 
 
 
Figure 10.The easier reduction occurs at an electronically less crowded metal center 
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IV.4.2. Ligand effect 
 
To investigate the effect of biologically relevant substituents at the metal center on the 
redox behavior of 1–4 in aqueous solution, we have calculated the SRPs at B3LYP level by 
including the effects of solvation by employing a continuous dielectric model with a 
dielectric constant ε = 80 for water (Figure 9). The derivatives of 1–4 are ordered by the 
experimental pKa values of the substituted ligands in their free forms. A large change, 330 
mV in average, of the reduction potential of the lead structures is observed when one chlorido 
is substituted by sulfur ligands. The binding to nitrogen sites of proteins and purine bases 
increases the SRPs by 180 and 140 mV in average. The largest positive effect on the SRPs in 
the nitrogen series is found for the adenine substituted complexes consistently with its lowest 
pKa value in the nitrogen series: AdeH+ (pKa < –2) < GuaH+ (pKa = 3.3)49 < ImH+ (pKa = 7.1) 
< NH4+ (pKa = 9.25) < MeNH3+ (pKa = 10.6). The coordination of anionic hydroxido (OH–) 
and thiolato (MeS–) ligands is accompanied by a SRP drop of 330 mV in average. 
Remarkably, the most successful drugs KP1019 (4, blue values) and NAMI-A (1, red values) 
are predicted to show generally the same redox behavior upon substitution (Figure 9). The 
donating properties of the free ligands influence the redox potentials of metal complexes. As 
mentioned in the previous section, the pKa value is a good measure of these properties. The 
oxidized Ru(III) species are more strongly stabilized by the ligands whose conjugate acids 
have higher pKa values making reduction more difficult to occur.  
 
 
IV.4.3. pH effect 
 
In vivo the control of the protonation state of a molecule is realized by medium acidity 
and the environment (dielectric constant of microenvironment, hydrophobicity, 
hydrophilicity, hydrogen bonding, etc.). Depending on the acidity constant of acidic sites of 
the molecule, the medium pH directly controls its protonation state and implicitly its SRP. 
We were interested at which extent an eventual deprotonation of the ligands influences the 
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SRPs of the studied compounds. For this reason one should evaluate the imminent shift of the 
pKas of the free ligands upon coordination to the metal. The coordination to a positively 
charged metal ion results in an acidification of the acidic sites of the molecule. The extent of 
acidification depends on (i) the electronic effects exerted by the metal ion, which occur 
through bonds, as well as (ii) the long-range electrostatic repulsion between the proton under 
consideration and the positively charged metal ion.49 The effect is strongest on the directly 
coordinated atoms and diminishes with distance increasing between acidic site and the metal. 
We calculated the pKa values of the aquation products and thiol substitution products. The 
pKa calculation method involves a thermodynamic cycle (see Computational details) which 
presents a maximum error of ~0.7 pKa units when applied to free azoles (Table S13) and was 
found to be very accurate in the prediction of relative pKa trend16e of metal complexes, with 
the absolute error of up to 4 kcal/mol. Table 3 summarizes calculated pKa values of Ru(III/II) 
aqua and thiol complexes. Once coordinated, the pKa of water molecule drops dramatically 
from 15.75 in its free state to 2–4 pKa units in mono-aqua Ru(III) compounds. The formation 
of hydroxido complexes was observed experimentally by measuring the pH drop during 
aquation studies.50 The coordination of methylthiol (pKa = 10.4) to Ru(III) is accompanied by 
strong acidification of sulfhydryl group (–SH) reflected by negative computed pKa values 
(Table 3).51 The aquation promotes reduction as the aqua complexes slightly increase the 
redox potentials of the parent chlorido prodrugs making the reduction easier, on the other 
hand the formation of hydroxido species impedes the reduction, as the redox potentials of all 
4 hydroxido-complexes fall outside the biological relevant window (Figure 9, Table S12). 
The same is true for the coordinated thiols whose SRPs drop significantly upon deprotonation 
by 740 mV in average. The pKa values of water and thiols coordinated to Ru(II) species are 
all calculated to be > 10 suggesting a strong stabilization of protonated species upon 
reduction.  
 
IV.4.4. Environmental effect 
 
To consider the effect of the environment on the redox properties of the studied 
compounds, we have computed SRP values at a lower dielectric constant characteristic for 
protein environment. Depending on whether the site of interest is located on the protein 
surface, solvent-exposed, or deeply buried into protein, medium ε might be as low as 3, and 
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typically lower than 10,52 while ε of DNA in aqueous solution was estimated to be 24.53 We 
have chosen the value of ε = 10, to reveal the influence of low dielectric constant on the 
redox potential. The computed SRPs of complexes 1–4 and their monosubstituted derivatives 
drop significantly with 270 mV in average. The most affected are highly charged compounds 
(the prodrugs (tetrachlorido complexes), thiolato and hydroxido complexes), the SRPs of 
which fall by 550 mV in average (Table S14 in Supporting Info). The same behavior was 
observed experimentally by measuring the SRP of ruthenium anticancer agents in different 
solvents.54 The influence of dielectric constant on the solvation energy is explained by 
considering a simple Born model55 of solvation, that states that the free energy of solvation is 
equal to the work spent to transfer the ion in a spherical cavity from vacuum (ε = 1) to a 
medium with a dielectric constant of ε (∆Gsolv proportional to –(1 – ε–1)q2r–1). The decrease of 
ε from 80 to 10 is accompanied by decrease of solvation energy. The strongest effect being 
supported by highly charged species, i.e. by Ru(II) species, that results in lower SRP values. 
 
IV.5. Reactivity towards biomolecules 
 
The binding towards relevant biomolecules in aqueous solution was investigated by 
computing characteristic activation and reaction free energies of the reactions of mono-aqua 
ruthenium species with a choice of nucleophiles (Chart 2). In this sense the optimization of 
all involved species, i.e. transition states and reaction products, was performed. Similarly to 
the computations on cisplatin, the reactivity of Ru(III) complexes was investigated in terms 
of the exchange of the aqua ligand with all model ligands (Y) presented in Chart 2, by 
exploring the free energy profiles of the substitution mechanism of interchange character: 
 
RuCl3LL’(H2O) + Y → [H2O···RuCl3LL’···Y]‡ → RuCl3LL’(Y) + H2O 
 
Figure 11 displays at a glance the predicted activation and free energies of these 
reactions.The mechanism of binding to Ru(II) analogs of anticancer complexes was 
investigated in the terms of D mechanism as was found that Cl dissociation proceeds very 
fast after reduction, and is the rate limiting step for the aquation. The available in vivo 
biological targets compete with water molecule to bind the intermediate formed after the first 
step of the D mechanism. Therefore only the free energy profiles of the second step of D 
mechanism were computed: 
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[RuCl3LL’]– + Y → [RuCl3LL’···Y]‡– → [RuCl3LL’(Y)]– 
 
Figure 12 displays the activation and reaction free energies of substitution process of protein 
and DNA models at Ru(II) centers. The transition states correspond to the second step of the 
dissociative mechanism with reference to mono-aqua species of 5–8.  
Figure 11. Predicted activation ∆Ga (top) and reaction free energies ∆Gr (bottom) of the aqua 
substitution in 1–OH2:4–OH2 by Y (Chart 2). Gua* - guanine substitution at cis-di-aqua 
complexes of 1–4. 
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Figure 12. Predicted activation ∆Ga (top) and reaction free energies ∆Gr (bottom) of the 
binding of Ru(II) (5–OH2:8–OH2) complexes to biological models Y (Chart 2). Gua* - 
guanine substitution in cis position of di-aqua complexes. 
 
 
IV.5.1. Reactions with proteins 
 
Kinetically the Ru(III) species do not have a clear kinetic preference for either 
nitrogen or sulfur ligands (Figure 11, Table S15). Although the reaction with imidazole (Im), 
representing histidine, is slightly preferred (∆Ga is lower by 1–2 kcal/mol than corresponding 
∆Ga of the reactions with MeSH and Me2S) the activation energy of the Ru(III) complexes 
binding to MeNH2 is higher by 3–4 kcal/mol than the activation energies of the reaction with 
all sulfur containing models. The highest activation energies were found for the aqua ligand 
substitution at 1–OH2. This may be due to steric repulsions between bulky DMSO moiety 
and the entering ligands. The substitution proceeds via an interchange mechanism with strong 
dissociative character (Table S17). The Ru(II) species do not show either a clear preference 
for sulfur or nitrogen containing protein models. (Figure 12, Table S16). Generally, the loss 
of Cl ligand in the first step of the D mechanism is the rate determinant for the aquation; 
further binding to proteins or water molecules having similar activation energies. 
Thermodynamically the nitrogen containing protein sites are more favorable for the 
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substitution at ruthenium center in both oxidation states. The exception is the enhanced 
preference of Ru(III) centers for the deprotonated thiol ligand (MeS–) reflected in the largest 
negative reaction free energies with thiolates. In the case of reduced species a clear 
stabilization of substitution products of protein binding as compared to the aquation products 
is observed.  
 
IV.5.2. Reactions with DNA 
 
The interaction with DNA was modeled as binding of the metal to free N7 sites of 
purine bases: adenine (Ade) and guanine (Gua). While Ru(III) compounds kinetically 
slightly prefer the guanine over adenine for binding (∆Ga is up to 2.9 kcal/mol lower in the 
case of 1 (Table S15)), their reduced forms prefer adenine (∆Ga is up to 2.2 kcal/mol lower 
in the case of reduced ICR (6)); the exception is the similar activation energies of 5 binding 
to both purine bases. Thermodynamically the interaction with Ade and Gua is less favorable 
than interaction with proteins.  
 
The intriguing finding is that, contrary to cisplatin, the ruthenium anticancer drugs 
virtually do not have any clear preference for either purine bases. The presence of a hydrogen 
bond between the O6 of Gua and the aqua or ammine ligand determines mainly the 
preference for Gua binding of cisplatin.17 In the case of ruthenium anticancer compounds 
such stabilization can occur only if the active species is considered to be the cis product of 
second aquation step. To verify the influence of the hydrogen bonding on the energy profile 
we optimized the TSs and the products for the reaction of investigated cis-di-aqua ruthenium 
compounds with Gua paying particular attention to the presence of the hydrogen bonding 
between O6 of Gua and the aqua ligand bound to the metal. The kinetics of the interaction 
between Ru(III) complexes with DNA does not change (Figure 11); contrary to the 
substitution kinetics of reduced species (Figure 12). In this case the transition states are 
stabilized by up to 7 kcal/mol (Table S16). The Gua becomes the preferred binding site for 
Ru(II) species (Figure 12), and more favorable than sulfur protein sites for Ru(III) species, 
except thiolates. Figure 13 shows characteristic geometries of the transition structures for 
Gua substitution at Ru(II) centers. The presence of hydrogen bonding between guanine N7 
and N1 of pyrazole stabilizes the entering ligand in an orientation that is energetically 
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disfavored for complexation (with the N7 lone pair perpendicular to Ru–N bond in 
formation). This arrangement requires additional energy to reorient the molecule in a position 
suitable for binding to the metal. This barrier is canceled in the binding to di-aqua complexes, 
as the N7 lone pair shows appropriate orientation towards the metal. In addition, the 
stabilization due to the hydrogen bonding between guanine O6 and the aqua ligand in cis 
position (Figure 13) contributes as well to lowering the activation energies. Although the 
similar geometric changes in the transition structures are observed in the case of substitution 
at Ru(III) centers, the activation barriers are predicted to be higher.  
 
Figure 13. Typical hydrogen bonding pattern in Gua substitution at 7 and 7–OH2 in cis 
position 
 
 
IV.6. Mode of action  
 
Based on our computed data and experimental findings, the mode of action of Ru(III) 
anticancer drugs may be divided into two steps. The first step describes the chemical 
behavior of the drugs prior and post administration, before reaching the cancer cells; the 
second step includes the chemical transformations of the complexes in the tumors. The 
aquation is an important process in both steps, firstly because it influences directly the pre-
administration storage of the chlorido complexes, and secondly because water molecules are 
most abundant binding partners in vivo and are essential for the metallo-drug activity, as aqua 
species are orders of magnitude more labile than the corresponding chlorido species. 
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Although the aquation process of ICR and KP1019 is slow at 25° C,40b and complexes remain 
in their inert form, under physiological conditions (37°C, pH 7.4) one chlorido ligand is 
displaced by a water molecule, as has been confirmed in X-ray diffraction studies of a number of 
aqua complexes.24,56 The parent Ru(III) complexes enter the blood stream where they are the 
subject of aquation. The process is slow characterized by high activation barriers (Table 2); 
the experimental rate constants are comparable with those of cisplatin.57 The aquation of the 
second chlorido ligand is both kinetically and thermodynamically less feasible process and 
cis-di-aquated products can be formed only in trace quantities. The water molecule in mono-
aqua species is replaced by available biological partners. Experimentally was found that KP1019 
binds to transferrin within minutes,58 and the highest affinity sites are the iron specific binding 
sites (His253) in human apo-lactoferrin, which is structurally similar to human transferrin and 
shares 60–80% of sequence identity.59 Despite the fact that there is not a clear kinetic preference 
for the binding to nitrogen or sulfur protein sites (the substitution at histidine protein residues 
being only slightly favorable) the thermodynamics favors relatively strong binding to the nitrogen 
protein sites, at the same time the binding to sulfur groups being reversible process. Similarly to 
cisplatin, the cysteine binding, followed by the deprotonation of –SH group of the substituted 
complex, contributes to the deactivation pathway, as the thiolates bind irreversibly. Once 
bound to transferrin the drug is selectively delivered to and accumulated in the tumor cells, 
which have a large number of transferrin receptors on their surface due to high iron 
requirement.60 The release of the bound drug can be achieved due to the lower pH 
characteristic of endosomes.12 After the release, the Ru(III) complexes can bind to the cellular 
proteins and DNA, inducing apoptosis. The second step aquation products are more likely to 
be formed inside the cells due to low concentration of the Cl– ions. The rate of binding to 
cellular components is enhanced by reduction. The calculations show that all parent 
complexes have biologically accessible reduction potentials; moreover the aquation facilitates 
the process. Low extracellular pH and large amounts of cellular reducing agents (e.g. 
glutathione, E0’ = –0.25 V;61 ascorbic acid, E0’ = 0.06 V62) in cancer cells form the reductive 
environment in the tumor compared to the normal tissue, thus determining the selective 
reduction in cancer cells. In contrast to the slow substitutions at Ru(III) centers, the reduced 
species are characterized by the fast ligand substitution reactions. Significantly lower 
computed activation barriers for the substitution at Ru(II) mean these compounds are much 
more reactive, than their oxidized forms, the fact observed experimentally.5 In parallel to 
substitution reactions at Ru(II) centers the back auto-oxidation process can occur as well, the 
phenomenon revealed experimentally during the study of NAMI-A chemical behavior in 
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aqueous solution,6b when in the presence of catalytic amount of reducing agents, the rate of 
aquation of Ru(III) complex significantly increased. The aquation is fast,63 and goes up to the 
second step, the kinetically favorable cis-di-aqua products are the most abundant species. The 
fast release of one ligand, characteristic for D mechanism in the first step, offers a free 
coordination site available for the substitution, and ruthenium compounds bind reversibly to 
biological targets without clear preference. We computed the reaction energy profiles for the 
first ligand substitution with the biological models, and believe that the substitution at di-aqua 
species should present similar barriers. One exception is the binding of guanine model, which 
may show a distinct hydrogen bonding pattern in both transition state and in products. As a 
result, the calculations reveal a clear kinetic and thermodynamic preference for guanine over 
adenine in the binding to DNA. In contrast to cisplatin, the formation of interstrand cross-
links was assumed.64 Although not excluded, the binding to DNA alone as the main reason 
for the anticancer effect of ruthenium drugs is still widely doubted.3,8c Figure 14 shows the 
energetic profile of the chemical transformations for KP1019. 
 
Figure 14.Free energy profiles for chemical transformations of KP1019 in aqueous solution at 
physiological conditions 
 
 98 
 
The reduced ruthenium compounds can be oxidized back by cellular oxidants such as 
superoxide radical (eq. 1, E = 0.94 V)65 or by hydrogen peroxide (eq. 2, E = 0.38 V),65 which 
are normal metabolites in the aerobic cells: 
 222 2 OHeHO →++
+−
 (1) 
 
−• +→+ OHOHeOH 22  (2) 
 
Superoxide anion is produced in vivo as a byproduct of mitochondrial respiration, as well as 
by several other enzymes, for example xanthine oxidase or NADPH oxidase. Its cell 
concentration is maintained at 10–12 – 10–11 M by superoxide dismutase.66 Mitochondria, 
microsomes, peroxisomes, and cytosolic enzymes have all been recognized as effective H2O2 
generators, the level of H2O2 inside the cell is up to 3 – 4 orders of magnitude greater than of 
O2–, 10–9 – 10–7 M. Experimentally findings that in vitro overproduction of hydrogen 
peroxide is a constitutive characteristic of cancer cells (the concentration of H2O2 reaches 
millimolar range)67 suggest that H2O2 might play an important role in the reoxidation of 
Ru(II) complexes in hypoxic conditions in tumors. High concentration of hydrogen peroxide 
is cytotoxic. It is therefore widely thought that H2O2 is very toxic in vivo and must be rapidly 
eliminated by enzymes such as catalases, peroxidases and thioredoxin-linked systems. 
However, H2O2 is poorly reactive: it can act as a mild oxidizing or as a mild reducing agent, 
but it does not oxidize most biological molecules readily, including lipids, DNA and 
proteins.68 The danger of H2O2 largely comes from its ready conversion to the 
indiscriminately reactive hydroxyl radical, either by exposure to ultraviolet light or by 
interaction with a range of transition metal ions. Living organisms have evolved mechanisms 
to sequester transition metal ions into protein-bound forms that cannot catalyze hydroxyl 
radical formation and other free radical reactions in vivo. These mechanisms are especially 
important in such extracellular fluids as the blood plasma. The hydroxyl radicals formed can 
damage proteins, cell walls, and DNA, inducing apoptosis.  
 
The transition metal oxidation by hydrogen peroxide is the long time studied process 
that makes the subject of so called Fenton’s chemistry.69 Two factors should be considered 
for a metal complex to act as a Fenton reagent:70 i) the availability of a free coordination site 
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or the possibility of replacement of one ligand by H2O2, through which the peroxide is 
activated; and ii) the suitable reduction potential for the redox couple. Ru(II) complexes 
generated inside the cells fulfill these requirements and might operate as catalyst in Fenton 
type reactions. The intermediates produced during reversible processes of aquation or 
substitution at the metal center have a free coordination site available for binding of one 
hydrogen peroxide molecule, in this way generating the activation complex (eq. 3):  
 
 
[ ] [ ] [ ] •−+++ ++→−→+ OHOHRuOHRuOHRu 3222222  (3) 
 
Additionally, the accessible redox potentials of free and bound ruthenium make the redox 
cycling possible and likely to occur. We believe that the redox cycling of ruthenium species 
inside the cells, that generates continuously reactive hydroxyl radicals, can contribute to the 
ruthenium drugs cytotoxic effects. Indeed, the lower cytotoxic effect of ICR as comparing to 
KP1019 or NAMI-A,71 can be in part attributed to lower redox potential of ICR that makes 
the reduction, and implicitly the redox cycling, more difficult to occur.  
 
Recently, the catalytic behavior of organometalic Ru(II) “piano-stool” complexes 
([(η6-arene)Ru(azpy)I]+, arene = p-cymene or biphenyl, azpy = N,N-dimethylphenyl or 
hydroxyphenyl-azopyridine) in the oxidation of the major intracellular reducing agent 
glutathione to glutathione disulfide was reported.72 In this case, a ligand centered redox 
cycling was assumed to be responsible for the generation and accumulation of reactive 
oxygen species. Because the free azopyridine ligands are not readily reduced in vivo, the 
complexation is needed to raise the redox potential to become biologically accessible. A 
similar fine tuning of SRP of redox innocent ligands by metalation is described in chapter V 
of this thesis. 
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Figure 15. Mode of action of ruthenium anticancer agents 
 
 
IV.7. Conclusions 
 
In this work, by using high level quantum chemical calculations, we have investigated 
chemical aspects of the anticancer activity of four potent Ru(III) anticancer complexes: 
NAMI-A, ICR, trans-tetrachloridobis(pyrazole)ruthenate(III) and KP1019 (1–4, Chart 2). 
The computational setup was tested in advance and gives the best performance in 
computation of reduction potentials of Ru(III) complexes. The experimental aquation rates 
are predicted within one order of magnitude accuracy. Because of the biologically accessible 
reduction potential of these complexes, the description of their mode of action is more 
challenging than the computational investigation of the most known anticancer compound 
cisplatin. Moreover, since the first time the “activation by reduction” hypothesis was 
formulated some 30 years ago,13 the reduction is supposed to be the major factor determining 
the anticancer behavior of Ru(III) complexes. The reduction, as important aspect of the 
activity, is taken into account, in addition, the electronic aspects governing the 
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electrochemical behavior of the Ru(III) complexes were revealed. The analysis of computed 
data shows interesting features of Ru(III) anticancer activity and can be summarized as 
follows: 
 
1. Under normal conditions a slow aquation of one chlorido ligand takes place leading 
to mono-aqua species of Ru(III) complexes. The second step aquation is possible, but the di-
aqua complexes are computed to be thermodynamically unstable, combined with high 
activation barriers of second aquation step, these species are less likely to form. The 
reduction promotes aquation which, following a dissociative mechanism, proceeds much 
faster than the aquation at more inert Ru(III) centers, and the process is exergonic except for 
6 (reduced ICR). The few orders of magnitude faster kinetics favors the formation of the cis 
over trans isomer of di-aqua complexes, therefore the most abundant Ru(II) metabolites are 
likely to be mono-aqua and the cis-di-aqua complexes. At this point, the calculations reveal 
the relevance of the oxidation state for the aquation, and implicitly for the reactivity of 
Ru(III) anticancer agents. 
 
2. We have investigated four major factors influencing the redox potential of the 
Ru(III) complexes: (i) the nature of the axial ligands at octahedral metal centers of initial 
prodrugs; (ii) the binding to biological targets; (iii) the influence of the medium pH; and (iv) 
the influence of the environment dielectric constant. The energy decomposition analysis 
clearly reveals the decisive role of π-electron acceptor character of DMSO land indazole 
igands in stabilization of Ru(II) species, promoting NAMI-A and KP1019 reduction. The 
successive change of the electron acceptor character from DMSO to imidazole through 
indazole and pyrazole correlates well with the reduction potential order of the original Ru(III) 
compounds. The solvation is an important factor determining the redox potential, as it 
compensates the effect of large negative charges on the π-back donation from the metal to 
bulky ligands such as indazole (Figure 8). The change of reduction potential after the binding 
to biologically relevant targets is directly related to the pKa values of the free protonated 
ligands. A higher pKa correlates with a more difficult reduction. The milieu acidity influences 
the protonation state of the ligands and consequently the reduction potential. The low 
dielectric constant of the medium impedes the reduction, as the SRPs fall dramatically with 
the decrease of ε. A smart tuning of the reduction potential by changing the axial ligands is a 
necessary condition in the rational design of the future Ru(III) anticancer complexes. The 
reduced ruthenium complexes may enter the redox cycling being oxidizing back by hydrogen 
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peroxide. The cycling may act as a continuous generator of reactive hydroxyl radicals, which 
damage the cells. 
 
3. The interaction with biological targets was investigated by computing the activation 
barriers and reaction free energies of the aqua ligand substitution with a set of biological 
models representing N- and S- sites of proteins, along with adenine and guanine as purine 
DNA bases models. The aquation takes place prior to binding to biomodels and determines 
the rate of substitution. Similarly to cisplatin the substitution occurs at the more labile aqua 
ligands of the Ru(III) species. Despite the prediction that there is not a clear kinetic preference 
for the binding to nitrogen or sulfur protein sites (the substitution at histidine protein residues 
being only slightly favorable) the thermodynamics favors relatively strong binding to the nitrogen 
protein sites, which are computed to be ~10 kcal/mol more stable than the sulfur containing 
ligands. The exception being the thiolates which stabilize the Ru(III) compounds by up to 25 
kcal/mol. NAMI-A is found to be overall less disposed to the substitution in both the kinetic 
and thermodynamic sense. After reduction, the Ru(II) species become much more reactive 
showing low activation barriers and large reaction free energies characteristic for all binding 
sites. However, a slight thermodynamic preference for N-containing ligands is revealed. The 
fact that the ruthenium species are not selective towards the purine bases of DNA suggests 
the mechanism of action other than that of cisplatin, which binds preferentially to the guanine 
sites of DNA. The exception is the cis-di-aqua species which prefer to bind guanine N7 site. 
Similarly to cisplatin the hydrogen bond from one aqua ligand in the mono-aqua substituted 
species to O6 of guanine stabilizes the transition states and the reaction products. This 
preference could play a significant role for the reactivity of the reduced species. 
 
IV.8. Computational details 
 
The structure optimizations were carried out using the 3-parameter fit of exchange 
and correlation functionals of Becke73 (B3LYP), which includes the correlation functional of 
Lee, Yang, and Parr (LYP),74 as implemented in Gaussian 03.75 The Stuttgart-Dresden 
(MWB28) effective core potentials (ECPs)76 and the corresponding valence-basis sets were 
used on ruthenium and the 6–31G(d,p) basis sets on the other atoms.77 Vibrational 
frequencies calculated at this level confirm that all structures are either minima (NIMAG = 0) 
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or first order saddle points (NIMAG = 1) on the potential energy surfaces. Improved energies 
were calculated at B3LYP level by augmenting the metal basis set with two sets of f and one 
set of g functions78 together with the same ECPs, the 6–311+G(3d) basis set on the S and Cl 
atoms, and the 6–311+G(d,p) basis sets on the other atoms. Free energies in vacuo were 
calculated by adding corrections from unscaled zero-point energy (ZPE), thermal energy, 
work, and entropy evaluated at the B3LYP level at 298.15 K, 1 atm to the improved energies.  
 
Solvation free energies of the optimized structures were computed by means of 
Poisson-Boltzmann finite element method79 as implemented in Jaguar 780 with the dielectric 
constant being 80.37 representing water as the solvent. This solvation model, in combination 
with above described gas-phase optimization protocol, gives the best performance in the 
SRPs computations, as shown in our previous benchmarking work.28 We found an overall 
error of 0.03 V in the computations of 80 SRPs of 61 ruthenium (III) complexes bearing a 
wide range of molecular charges (from –1 to +3) in four different solvents. We have shown 
that the solute cavity choice is crucial in these computations; the performance of the model 
being strongly related to the solute cavity size in the solvent continuum. Because the metal is 
well buried into the octahedral surrounding of ligands, its radius does not influence the cavity 
size and implicitly the solvation energies. On the other hand the metal becomes exposed to 
the solvent as the nucleophilic substitution advances, and its radius might influence directly 
the activation free energies. The solvation energies of the penta-coordinated intermediates of 
the dissociative mechanism suffer mostly from the inaccuracy of the metal radius used. We 
adjusted the Ru(II) van der Waals radii used to build the solute cavity in Jaguar to fit best the 
experimentally available activation energies of water exchange in [Ru(H2O)6]2+ and in 
[Ru(NH3)5(H2O)]2+ by pyridine and acetonitrile (details are available in Supporting Info 
Table S19). For consistency, the fitted value (2.08 Å) for Ru(II) atoms was used in solvation 
calculations. All free energies in solution were modified by an entropic term that is half of the 
entropy in vacuo, with the opposite sign, because the continuum dielectric models do not 
consider properly the changes of solvation entropy in bimolecular reactions. According to 
Wertz and others,81 various molecules lose a constant fraction (approximately 0.5) of their 
entropy, when they are dissolved in water. 
 
Because the aquation reaction is bimolecular the rate constant k computed by the use 
of Eyring equation (eq. 4) employing the predicted activation free energies contains the factor 
arisen from water concentration in the medium (55.5M). 
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where kB is the Boltzmann constant, T is the absolute temperature, and h is the Planck 
constant. ∆Ga is the activation free energy. 
 
pKa predictions were carried out using the thermodynamic cycle82 displayed in Figure 
16. 
 
Figure 16. Thermodynamic cycle to predict acidity constants 
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where ∆G1 is the reaction free energy of AH deprotonation in gas-phase; ∆Gaq is the reaction 
free energy in water; ∆Gsolv are solvation energies of each species involved in the process. R 
is the ideal gas constant, and T is the temperature (298.15 K). We have used the values 
Gvac(H+) = –6.28 kcal/mol83 and ∆Gsolv(H+) = –263.98 kcal/mol extrapolated from cluster ion 
solvation data.84  
 
Standard redox potentials were calculated on the basis of the thermodynamic cycle 
similar to the one used for the prediction of acidity constants. The SRP is related to the 
reaction free energy of electron attachment process: Ox +e– → Red in water (∆Gaq) by:  
 
SRP = – (∆Gaq/zF) – ∆SRPNHE 
with ∆Gaq = – ∆Gsolv(Ox) + ∆G1 + ∆Gsolv(Red) 
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∆G1 is the reaction free energy in vacuo, ∆Gsolv(Ox) and ∆Gsolv(Red) are the solvation free 
energies of the oxidized and reduced form, F = 96,485 C/mol = 23.061 kcal/(Vmol) is the 
Faraday constant, and z = 1 for one-electron reductions. The SRPs are shifted by ∆SRPNHE = 
4.28 V to align the results to the scale of the Normal Hydrogen Electrode (NHE).85  
 
The chemical intuitive energy decomposition analysis as implemented in the 
Amsterdam Density Functional 2007 programs package (ADF)86 was successfully applied in 
the similar computations on the nature of bonding in ruthenium complexes of the formula 
[Ru(NH3)5B]Z+ (Z = 2,3), where B is a nucleobase or a protein model.20 We performed the 
single point calculations on 1–10 at the B3LYP/ZORA87 level using the large QZV4P basis 
set at ruthenium and the other atoms.  
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Table S1. Geometrical parameters used for the hydrolysis mechanism assessment  
 
* optimization in solution, ** data in this work ΣRA – the sum of the metal-leaving ligand bond RA(L) and the metal entering ligand RA(E) in 
the reactant complex; ΣTS – the sum of the metal-ligands bonds of the transition state involved in substitution. 
 
M–Cl(O)   M–OH2    
Experimental activation 
parameters  
R RA (L) RA (E) TS ∆(R) ΣRA P PA(E) PA(L) TS ∆(P) ΣTS ΣTS–ΣRA ref ∆H ∆S ref  
Å Å Å Å Å  Å Å Å Å Å Å  Å Å  kJ/mol J/mol×K  
2.370 2.383 3.610 2.742 0.37 5.99 2.087 2.03 3.953 2.401 0.31 5.14 –0.85 16a 19.67 –15 29 
2.390 2.399 3.667 2.819 0.43 6.07  2.042 4.135 2.42 5.24 –0.83 16a*    
 2.277 3.183 2.693 5.46  2.027 3.885 2.344 5.04 –0.42 30    
Cisplatin 
 2.361 3.862 2.798  6.22  2.082 4.083 2.467 
 
5.27 –0.96 16d*    
trans-[Pt(NH3)2LT(H2O)]n+              27    
LT = H2O 2.066   2.408   2.066   2.426        
LT = NH3 2.109   2.470   2.109   2.476        
LT = OH– 2.190   2.689   2.190   2.688        
LT = F– 2.140   2.561   2.140   2.562        
LT = Cl– 2.180   2.566   2.180   2.566        
LT = Br– 2.203   2.581   2.203   2.581        
LT = H2S 2.136   2.446   2.136   2.450        
LT = CH3S– 2.281   2.826   2.281   2.880        
LT = SCN– 2.179   2.570   2.179   2.583        
LT = CN– 2.224   2.581   2.224   2.581        
LT = PH3 2.189   2.483   2.189   2.484        
LT = CO 2.125   2.396   2.125   2.396        
LT = NO2– 2.219   2.564   2.219   2.564        
LT = CH3– 2.335   3.684   2.335   3.785        
LT = H– 2.319   3.075   2.319   3.294        
LT = C2H4 2.197   2.268   2.197   2.734        
Carboplatin    2.42      2.38    88 88.4 –15 31 
 2.00 3.47 2.45 5.47  2.01 3.19 2.34 4.79 –0.68 32    Oxaliplatin 
 2.00 3.46 2.48  5.46  2.08 3.28 2.44  4.92 –0.54 32*    
2.07   2.93 0.86  2.07   2.64 0.57   89 49.0±1.0 –60 33 Rhodium 
Tetracarboxylate                  
2.418   3.090 0.67  2.244   2.620 0.38   21 79.5±3.4 –30.8±11.5 34 
 2.424 4.138 3.099 6.56  2.142 3.898 2.586 5.69 –0.88 35    
[(η6-benzene)RuII(en)Cl]+ 
 2.479 4.221 3.238  6.70  2.168 4.271 2.884  6.12 –0.58 35*    
NAMI-A 2.42 2.44 4.86 3.679 1.26 7.30 2.23 2.125 4.642 3.127 0.90 6.81 –0.49 18c    
 2.42 2.387 4.506 3.92 1.50 6.89 2.23 2.141 4.608 3.23 1.00 7.15 0.26 18c*    
 2.43 2.45 4.30 2.99 0.56 6.75 2.21 2.14 4.69 2.56 0.35 5.55 –1.20 18a    
 2.44 2.45 4.12 4.26 1.82 6.57 2.20 2.15 4.68 3.89 1.69 8.15 1.58 **    
2.44 2.48 4.16 3.21 0.77 6.64 2.24 2.16 4.62 2.74 0.50 5.95 –0.69 19 117.0±7.0 55.0±23.0 36 ICR 
2.43 2.43 4.07 4.12 1.69 6.50 2.23 2.14 4.60 3.71 1.48 7.83 1.33 **    
TzICR 2.434 2.455 4.078 3.520 1.09 6.53  2.156 4.537 3.020  6.54 0.01 18d    
(2-NH2)TzICR 2.450 2.462 4.084 3.044 0.59 6.55 2.227 2.252 4.765 2.606 0.38 5.65 –0.09 18d    
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Table S2. Geometrical parameters of Ru(III) species formed during aquation of 1–4 
  1st step 2nd step (cis) 2nd step (trans) 
  R RA TS PA P Pb R RA TS PA P Pa Pb R RA TS PA P Pa Pb 
1 Ru–Cl 2.44 2.45 4.26 4.68   2.35 2.37 2.88 4.01    2.33 2.35 2.85 4.17    
 
Ru–Ow  4.12 3.89 2.15 2.20   4.03 2.65 2.16 2.16/2.21 2.20   4.03 2.40 2.06 2.07/2.16 2.24  
 
Ru–Oh      1.96      1.96 1.98/1.99      1.93 1.99/2.04 
2 Ru–Cl 2.43 2.43 4.12 4.60   2.38 2.39 3.60 4.00    2.31 2.32 2.84     
 
Ru–Ow  4.07 3.71 2.14 2.23   4.20 3.51 2.17 2.19/2.18 2.23   4.20 2.38  2.11/2.11 2.26  
 
Ru–Oh      1.99      1.96 1.99/2.00      1.92 2.01/2.02 
3 Ru–Cl 2.45  4.26    2.39  3.60     2.30  2.85     
 
Ru–Ow   3.50  2.23    3.34  2.18/2.19 2.22    2.40  2.11/2.11 2.25  
 
Ru–Oh      1.96      1.97 1.97/1.97      1.93 2.00/2.00 
4 Ru–Cl 2.44  3.79    2.38  3.59     2.32  2.84     
 Ru–Ow   3.41  2.22    3.38  2.18/2.19 2.22    2.39  2.12/2.12 2.25  
 Ru–Oh      1.96      1.97 1.97/1.97      1.91 2.05/2.05 
R reactants, RA reactants adducts TS-transition stratures, PA products adducts P products. Ru–Cl bond broken during aquation, Ru–Ow 
ruthenium aqua ligand bond formed during aquation. Ru–Oh rutheniium hydroxido ligand bond, formed by deprotonation of aqua ligand. 
a
 hydroxido complexes  b di-hydroxido complexes 
 
Table S3. Geometrical parameters of Ru(II) species formed during aquation of 5–8 
  
1st step 2nd step (cis) 2nd step (trans) 
  R TS1 TS2 P Pb R TS1 TS2 P Pa Pb R TS1 TS2 P Pa Pb 
5 Ru–Cl 2.55 4.17    2.52 3.75     2.44 4.70     
 
Ru–Ow   3.36 2.27     2.20/2.23 2.24    3.32 2.15/2.18 2.32  
 
Ru–Oh     2.07     2.07 2.07/2.09     2.06 2.11/2.19 
6 Ru–Cl 2.54 3.61    2.57 3.49     2.43 4.54     
 
Ru–Ow   3.82 2.27     2.23/2.24 2.27    4.17 2.17/2.17 2.37  
 
Ru–Oh     2.08     2.08 2.10/2.10     2.06 2.15/2.16 
7 Ru–Cl 2.57 3.53    2.58 3.32     2.46      
 
Ru–Ow   3.96 2.23     2.22/2.22     3.80 2.16/2.17   
 
Ru–Oh     2.08             
8 Ru–Cl 2.55 3.89    2.50 3.71     2.45 4.84     
 Ru–Ow   3.82 2.23    4.30 2.22/2.22 2.23    3.53 2.16/2.16 2.33  
 Ru–Oh     2.19     2.04 2.05/2.05     2.02 2.09/2.09 
R reactants, TS-transition states (TS1/TS2 first/second step of D mechanism), P products.  Ru–Cl bond broken during aquation, Ru–Ow 
ruthenium aqua ligand bond formed during aquation. Ru–Oh rutheniium hydroxido ligand bond, formed by deprotonation of aqua ligand. 
a
 mono-hydroxido complexes  b di-hydroxido complexes 
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Table S4. Computed pKa of mono and di-aqua species 
 mono-aqua cis-di-aqua trans-di-aqua 
 pKa pKa1 pKa2 pKa1 pKa2 
1 3.4 –0.4 6.5 –1.8 10.0 
2 4.3 2.0 8.7 1.0 10.8 
3 3.1 –0.6 6.6 0.5 11.5 
4 2.3 –2.4 6.1 –3.4 8.0 
5 18.6 13.7 19.5 14.6 20.9 
6 16.4 17.1 19.0 19.0 20.0 
7 16.0 16.1 17.8   
8 12.7 15.0 16.7 16.9 18.0 
 
Table S5. Free energies relative to separated reactants of the species involved in the aquation process up to the second step (kcal/mol) of Ru(II) 
compounds. Dissociative mechanism 
* The digit following the transition states designator (TS) denotes the aquation step. The first and second steps of D mechanism are symbolized 
by D1 and D2 respectively. 
 R TS1D1* I1 TS1D2 P1 cis-TS2D1 cis-I2 cis-TS2D2 cis-P2 trans-TS2D1 trans-I2 trans-TS2D2 trans-P2 
5 0 12.9 2.4 11.7 –5.6 10.0 3.1  –5.9 16.0 2.2 15.9 –6.0 
6 0 11.8 4.6 10.5 0.1 7.6 3.5  –2.3 16.8 5.3 11.0 –4.2 
7 0 9.5 4.0 10.3 –1.8 7.7 4.1  –3.8  4.7 9.2 –5.8 
8 0 12.1 5.2 11.3 –1.7 10.7 5.6 12.1 –2.5 18.9 6.7 11.4 –4.5 
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Table S6. Free energies relative to separated reactants of the species involved in the aquation process up to the second step (kcal/mol) of 
ruthenium(II) compounds. Interchange mechanism 
 R TS1  P1 cis-TS2 cis-P2 trans-TS2 trans-P2 
5 0  –5.6 14.2 –5.9 21.9 –6.0 
6 0  0.1 13.6 –2.3 23.6 –4.2 
7 0 13.6 –1.8 13.2 –3.8 22.6 –5.8 
8 0 16.1 –1.7 16.8 –2.5 24.8 –4.5 
 
Table S7. Interaction energies of the metal orbitals with the axial ligands orbitals in 2–4 and 6–10 (kcal/mol) 
 
 
 
 
 
 
 
 
 
 
 
a
 assumption 
Orbital Representation Formula 9 10 2 6 3 7 4 8 
 C2h C2v          
dz2,5s ag a1 a1 –69.8 –61.4 –65.5 –57.0 –65.0 –56.6 –64.5 –58.2 
5pz bu b1 bu –16.5 –17.4 –17.7 –17.2 –21.1 –20.5 –20.1 –20.4 
4dyz bg a2 a2 –23.1 –35.5 –15.6 –31.3 –15.8 –33.1 –20.9 –54.0 
4dxz ag b1 b1–bu –20.0 –31.3 –9.4 –13.2 –12.7 –16.4 –12.9 –16.6 
4dxy bg b2 bg–a2 –3.9 –2.7 –7.4 –5.3 –6.0 –3.6 –5.2 –1.3 
4dx2–y2 ag a1 0         
5px bu a1  0a         
5py au b2 au –3.3 –5.1 –2.8 –3.3 –3.0 –3.9 –3.2 –5.8 
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Table S8. Decomposition of interaction energy between [RuCl4]–/2– and the axial ligands in 2, 3 and in their reduced forms 6 and 7 (kcal/mol) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S9. Basis set dependence of the charge transfer between metal orbitals and axial ligands orbitals in 2–4 and 6–10 (C2h) 
 
 
 
 
 
 
Values are computed at B3LYP/ZORA level using QZV4P basis at ruthenium and other atoms. Values in paranthesis are computed by using 
TZV2P quality basis. 
  C2h C2v 
 2 6 3 7 2 6 3 7 
Eint –75.7 –55.1 –87.9 –79.1 –75.6 –55.2 –86.8 –77.7 
Esolv –79.9 –214.3 –63.6 –191.0 –80.0 –214.3 –63.1 –192.3 
Eint+solv –155.6 –269.4 –151.5 –270.1 –155.6 –269.5 –149.9 –270.0 
∆EPauli 183.6 197.5 183.6 197.9 183.5 197.4 183.3 197.5 
∆Eelst –165.6 –158.5 –172.6 –176.0 –165.5 –158.5 –172.5 –175.7 
∆Eorb –93.7 –94.1 –98.9 –101.0 –93.7 –94.1 –97.6 –99.4 
∆EΓi : C2h (C2v)         
ag (a1) –75.0 –70.2 –79.1 –74.3 –65.5 –57.0 –65.0 –56.6 
bg (a2) –23.0 –36.5 –21.8 –36.7 –15.6 –31.3 –15.8 –33.1 
au (b1) –2.8 –3.3 –3.0 –3.9 –27.1 –30.4 –33.8 –36.9 
bu (b2) –17.7 –17.2 –21.1 –20.5 –10.3 –8.6 –9.2 –7.5 
Representation 9 10 2 6 3 7 4 8 
C2h         
ag 0.43(0.46) 0.39(0.39) 0.32(0.36) 0.28(0.31) 0.33(0.36) 0.29(0.31) 0.33(0.35) 0.31(0.32) 
au 0.05(0.07) 0.07(0.12) 0.05(0.06) 0.11(0.13) 0.06(0.06) 0.15(0.17) 0.08(0.09) 0.29(0.32) 
bg 0.00(0.00) 0.00(0.00) 0.00(0.00) 0.00(0.00) 0.00(0.00) 0.00(0.00) 0.00(0.00) 0.00(0.00) 
bu 0.00(0.20) 0.00(0.18) 0.00(0.12) 0.00(0.03) 0.00(0.11) 0.00(0.10) 0.00(0.10) 0.00(0.02) 
 113 
 
Table S10. Basis set dependence of the charge transfer between metal orbitals and axial ligands orbitals in 2–4 and 6–10 (C2v)  
 
 
 
The values are computed at B3LYP/ZORA level using QZV4P basis at ruthenium and other atoms. Values in paranthesis are computed by using 
TZV2P quality basis. 
 
Table S11. Decomposition of interaction energy in trans,trans -[RuCl2(OH2)(Hpz)2] (trans-di-aqua-7) and trans,trans -[RuCl2(OH2)(Hind)2] 
(trans-di-aqua-8) (kcal/mol) 
  C2h C2v  
 trans-di-aqua-7 trans-di-aqua-8 trans-di-aqua-7 trans-di-aqua-8 
Eint –98.0 –95.7 –96.7 –94.7 
Esolv –26.7 –26.5 –27.8 –27.2 
Eint+solv –124.7 –122.1 –124.5 –121.9 
∆EPauli 192.3 208.6 191.9 208.5 
∆Eelst –187.8 –196.3 –187.6 –196.3 
∆Eorb –102.5 –108.0 –101.1 –106.9 
∆EΓi : C2h (C2v)     
ag (a1) –78.5 –80.7 –62.2 –64.3 
bg (a2) –24.9 –30.8 –19.2 –25.9 
au (b1) –3.4 –3.7 –33.9 –34.4 
bu (b2) –18.9 –19.0 –9.0 –8.5 
 
Representation 9 10 2 6 3 7 4 8 
C2v         
a1 0.43(0.46) 0.39(0.39) 0.32(0.36) 0.28(0.31) 0.33(0.35) 0.29(0.30) 0.33(0.35) 0.31(0.32) 
a2 0.04(0.04) 0.07(0.12) 0.05(0.06) 0.11(0.13) 0.06(0.06) 0.15(0.17) 0.08(0.09) 0.29(0.32) 
b1 0.00(0.20) 0.12(0.16) 0.00(0.11) 0.00(0.11) 0.00(0.10) 0.00(0.10) 0.00(0.10) 0.00(0.03) 
b2 0.00(0.00) 0.00(0.03) 0.00(0.00) 0.00(0.00) 0.00(0.00) 0.00(0.00) 0.00(0.00) 0.00(0.00) 
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Table S12. Computed standard redox potentials in eV vs NHE 
Y 
 Cl SH2 MeSH Me2S Ade OH2 Gua Im NH3 MeNH2 MeS– OH– 
1–Y 0.07 0.42 0.32 0.29 0.31 0.27 0.12 0.14 0.14 0.11 –0.34 –0.65 
2–Y –0.25 0.12 0.03 –0.01 –0.10 –0.18 –0.27 –0.25 –0.29 –0.29 –0.68 –0.89 
3–Y –0.19 0.31 0.25 0.18 0.10 0.02 –0.04 –0.03 –0.03 –0.07 –0.56 –0.72 
4–Y 0.02 0.40 0.36 0.29 0.22 0.16 0.11 0.10 0.09 0.04 –0.42 –0.50 
pKa (exp) –8.00    < –2.049 –1.70 ~349 7.1148 9.25 10.64 10.40 15.75 
 
 
 
Table S13. Experimental and computed pKa’s values of free azoles 
 calc exp48 
H–Ind 1.1 1.25 
H–Pz 3.1 2.64 
H–Im 7.8 7.11 
 
 
 
Table S14. Computed standard redox potentials in eV vs NHE, at ε = 10 
Y 
 Cl SH2 MeSH Me2S Ade OH2 Gua Im NH3 MeNH2 MeS– OH– 
1–Y –0.53 0.20 0.14 0.04 0.02 –0.05 –0.15 –0.12 –0.10 –0.13 –0.93 –0.95 
2–Y –0.70 0.10 0.02 –0.04 –0.10 –0.19 –0.30 –0.26 –0.27 –0.30 –1.08 –1.28 
3–Y –0.88 –0.15 –0.24 –0.27 –0.35 –0.45 –0.57 –0.54 –0.56 –0.56 –1.29 –1.51 
4–Y –0.48 0.19 0.12 0.06 0.09 0.04 –0.14 –0.11 –0.09 –0.11 –0.89 –1.18 
pKa (exp) –8.00    < –2.049 –1.70 ~349 7.1148 9.25 10.64 10.40 15.75 
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Table S15. Predicted activation (∆Ga) and reaction free energies (∆Gr) in kcal/mol of the aqua substitution in mono–aqua complexes of 1–4 by 
Y (Chart 2) 
 ∆Ga  
 SH2 MeSH Me2S Ade Gua Gua* Im NH3 MeNH2 MeS– 
1–OH2 21.7 22.8 24.0 26.5 23.7 27.6 23.2 24.5 24.2 28.9 
2–OH2 19.8 20.0 20.9 20.8 20.1 22.3 18.9 23.7 22.6 23.3 
3–OH2 20.8 21.5 21.7 21.5 20.1 19.7 20.3 21.2 24.5 20.6 
4–OH2 21.3 22.2 21.7 21.7 20.6 23.7 20.0 20.3 24.1 20.6 
 ∆Gr  
1–OH2 –2.6 –5.2 –5.3 –2.7 –1.9 –9.1 –13.3 –14.0 –15.0 –20.7 
2–OH2 –4.1 –6.6 –6.4 –6.8 –3.8 –15.9 –14.2 –14.4 –14.7 –22.9 
3–OH2 –3.8 –6.7 –7.3 –5.3 –4.7 –14.3 –14.6 –14.2 –15.5 –24.6 
4–OH2 –3.5 –6.3 –6.9 –5.5 –5.4 –10.4 –14.5 –14.3 –15.5 –24.9 
 
 
Table S16. Predicted activation ∆Ga and reaction free energies ∆Gr in kcal/mol of the biological models Y (Chart 2) binding to 5–OH2 : 8–OH2. 
Second step of D mechanism 
 ∆Ga  
 SH2 MeSH Me2S Ade Gua Gua* Im NH3 MeNH2 MeS– 
5–OH2 13.4 13.5 16.8 19.1 19.1 14.8 17.9 13.5 15.9 17.9 
6–OH2 9.7 10.0 11.4 11.2 13.4 6.5 11.9 9.0 8.9 11.4 
7–OH2 10.6 12.3 11.9 12.3 13.4 6.4 9.9 10.4 10.4 8.8 
8–OH2 11.8 11.8 12.7 12.3 14.1 10.1 10.4 11.9 11.8 11.1 
 ∆Gr  
5–OH2 –6.1 –7.1 –5.9 –3.7 1.7 –12.8 –10.1 –11.0 –11.5 –6.3 
6–OH2 –11.0 –11.6 –10.8 –8.7 –2.0 –17.5 –12.5 –11.9 –12.0 –10.4 
7–OH2 –10.6 –11.9 –11.3 –7.3 –3.1 –16.2 –13.4 –12.9 –13.2 –10.7 
8–OH2 –9.5 –11.1 –9.9 –7.1 –4.4 –16.3 –13.1 –12.7 –13.0 –10.9 
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Table S17. Characteristic metal-ligand bonds involved in the substitution process at Ru(III) centers in mono-aqua complexes of 1–4. 
 
 Reactants Transition Structures Products 
 
 R R* SH2 MeSH Me2S Ade Gua Gua* Im NH3 MeNH2 MeS– SH2 MeSH Me2S Ade Gua Gua* Im NH3 MeNH2 MeS– 
1–OH2 Ru–Cla 2.33 2.30 2.29 2.29 2.29 2.29 2.34 2.34 2.28 2.30 2.30 2.39 2.35 2.36 2.37 2.37 2.36 2.32 2.38 2.36 2.37 2.43 
 
Ru–Cl                       
 
Ru–Ob 2.20 2.21 3.93 3.89 3.94 3.64 3.57 2.59 3.81 4.02 3.92 2.57           
 
Ru–O*  2.16      2.21          2.10     
 
Ru–Sc   4.03 4.00 4.29       3.11 2.51 2.5 2.48       2.33 
 
Ru–Nd      3.50 3.98 2.58 3.67 3.56 3.73     2.18 2.17 2.24 2.13 2.17 2.18  
2–OH2 Ru–Cla 2.31 2.31 2.28 2.28 2.28 2.28 2.28 2.31 2.28 2.28 2.29 2.33 2.33 2.34 2.34 2.34 2.34 2.34 2.35 2.34 2.35 2.46 
 
Ru–Cl                       
 
Ru–Ob 2.23 2.21 3.95 3.88 3.72 3.53 3.68 3.67 3.54 3.86 3.79 3.42           
 
Ru–O*  2.19                2.16     
 
Ru–Sc    3.54 3.75 3.90       4.31 2.51 2.48 2.50       2.32 
 
Ru–Nd        3.35 4.21 3.49 3.48 3.48 3.46     2.19 2.19 2.18 2.16 2.17 2.18  
3–OH2 Ru–Cla 2.30 2.32 2.27 2.27 2.27 2.27 2.28 2.27 2.27 2.27 2.29 2.32 2.32 2.33 2.33 2.34 2.33 2.33 2.34 2.33 2.33 2.46 
 
Ru–Cl                       
 
Ru–Ob 2.22 2.19 3.89 3.75 3.64 3.71 3.70 3.60 3.37 3.43 3.60 3.22           
 
Ru–O*  2.18      2.11          2.10     
 
Ru–Sc   3.61 3.76 3.79       3.96 2.51 2.48 2.50       2.31 
 
Ru–Nd      3.65 3.73 3.47 3.28 3.17 3.71     2.19 2.19 2.16 2.15 2.18 2.19  
4–OH2 Ru–Cla 2.32 2.32 2.28 2.27 2.27 2.27 2.27 2.31 2.29 2.27 2.29 2.32 2.31 2.32 2.33 2.35 2.32 2.33 2.34 2.33 2.33 2.45 
 
Ru–Cl                       
 
Ru–Ob 2.22 2.19 3.84 3.69 3.61 3.67 3.95 3.66 3.89 3.81 3.64 3.20           
 
Ru–O*  2.18      2.10          2.16     
 
Ru–Sc   4.09 3.77 3.78       3.97 2.52 2.49 2.50       2.31 
 
Ru–Nd      3.57 3.63 3.34 3.60 3.18 3.69     2.17 2.25 2.17 2.16 2.18 2.19  
a
 trans bonded Cl ligand to the leaving/entering ligand 
b
 Ru–O(leaving water) 
c
 Ru–S(entering sulfur containing ligands) 
d
 Ru–N(entering nitrogen containing ligands) 
* Substitution at cis-di-aqua species 
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Table S18. Characteristic metal-ligand bonds involved in the substitution process at Ru(II) centers in 5–OH2 : 8–OH2. Second step of D 
mechanism 
  Reactants Transtition Structures Products 
  R R* SH2 MeSH Me2S Ade Gua Gua* Im NH3 MeNH2 MeS– SH2 MeSH Me2S Ade Gua Gua* Im NH3 MeNH2 MeS– 
5–OH2 Ru–Cla 2.44 2.44 2.39 2.39 2.39 2.38 2.42 2.37 2.38 2.39 2.38 2.39 2.50 2.48 2.48 2.48 2.48 2.43 2.49 2.49 2.49 2.52 
 
Ru–Cl                       
 
Ru–Ob 2.24 2.27                     
 
Ru–O  2.24      2.18          2.18     
 
Ru–Sc   4.02 4.31 3.95       4.49 2.40 2.37 2.39       2.48 
 
Ru–Nd      3.88 2.78 4.02 3.28 3.64 3.73     2.16 2.11 2.21 2.15 2.15 2.16  
6–OH2 Ru–Cla 2.43 2.44 2.38 2.38 2.39 2.38 2.39 2.39 2.39 2.38 2.38 2.44 2.46 2.47 2.47 2.47 2.47 2.45 2.48 2.48 2.48 2.54 
 
Ru–Cl                       
 
Ru–Ob 2.27 2.27                     
 
Ru–O  2.27      2.21          2.19     
 
Ru–Sc   3.96 3.67 4.09       3.90 2.34 2.34 2.36       2.45 
 
Ru–Nd      4.61 3.25 4.15 3.01 3.27 3.69     2.14 2.10 2.08 2.11 2.14 2.16  
7–OH2 Ru–Cla 2.46 2.45 2.37 2.37 2.38 2.40 2.38 2.37 2.39 2.37 2.37 2.42 2.44 2.45 2.45 2.47 2.45 2.46 2.50 2.46 2.46 2.50 
 
Ru–Cl                       
 
Ru–Ob 2.23 2.23                     
 
Ru–O  2.23      2.20          2.18     
 
Ru–Sc   4.68 3.94 4.18       3.94 2.36 2.36 2.37       2.48 
 
Ru–Nd      4.73 3.26 3.95 2.93 3.36 4.01     2.15 2.11 2.10 2.11 2.15 2.17  
8–OH2 Ru–Cla 2.45 2.45 2.36 2.37 2.36 2.37 2.40 2.37 2.38 2.36 2.36 2.40 2.43 2.44 2.44 2.48 2.43 2.45 2.47 2.45 2.45 2.49 
 
Ru–Cl                       
 
Ru–Ob 2.23 2.23                     
 Ru–O  2.23      2.18          2.18     
 Ru–Sc   4.15 3.89 4.38       4.16 2.37 2.37 2.38       2.47 
 Ru–Nd      4.40 3.27 3.92 3.05 3.36 4.32     2.15 2.18 2.10 2.12 2.15 2.17  
a
 trans bonded Cl ligand to the entering ligand 
b
 Ru–O(leaving water) 
c
 Ru–S(entering sulfur containing ligands) 
d
 Ru–N(entering nitrogen containing ligands) 
* Substitution at cis-di-aqua species 
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Table S19. Ru(II) radii calibration to experimental data on energetics (kcal/mol) of the substitution process: RuIIL5OH2 +Y → RuIIL5Y + H2O 
Y     OH2 py ACN 
 r (Ru) Å R TSD1 I TSD2 P TSD2 P TSD2 P 
exp     19.990a 16.290b 16.790b 
[RuII(OH2)6]2+ 1.48 0 12.29 5.98 12.29 0     
 1.58 0 14.01 8.33 14.01 0     
 1.68 0 15.23 10.30 15.23 0     
 1.78 0 16.05 11.87 16.05 0     
 1.88 0 16.71 13.17 16.71 0     
 1.98 0 17.26 13.98 17.26 0     
 2.08 0 17.67 14.68 17.67 0     
 2.18 0 17.84 15.26 17.84 0     
[RuII(NH3)5(OH2)]2+ 1.48 0 12.51 1.89   15.40 –10.97 5.22 –18.77 
 1.58 0 12.46 3.55   15.36 –10.98 5.86 –18.81 
 1.68 0 12.53 4.61   15.31 –11.01 8.02 –18.72 
 1.78 0 12.97 5.55   15.20 –11.05 7.98 –18.86 
 1.88 0 13.29 6.25   15.23 –11.02 8.61 –18.81 
 1.98 0 13.44 6.72   15.23 –11.03 8.88 –18.80 
 2.08 0 13.53 7.07   15.05 –11.05 9.24 –18.81 
 2.18 0 13.65 7.38   15.21 –11.06 9.42 –18.83 
R-reactants, TS-transition states, I-intermediates, and P products in the limiting D mechanism with D1-first, and D2-second step.The calibration 
was started from default radius for ruthenium atoms as defined in Jaguar 7.080 (1.48 Å) with the step size of 0.1 Å. We have chosen the value of 
2.08 Å for computations since the consideration of larger radii (2.18 Å) does not improve the activation energies of processes (∆E ~ 0.2 kcal/mol 
by changing Ru radii from 2.08 Å to 2.18 Å) and the value of 2.18 Å already exceed the Ru–N(azole) bond distances. The calibration does not 
change the preference for the D over Id mechanism of aquation process of studied reduced species (Table S20). 
 
Table S20. Influence of Ru(II) radii calibration on the ∆Ga (kcal/mol) of aquation of 7 and 8 
r (RuII) 1.48 2.08 
Mechanism Id D Id D 
7 14.8 9.4 13.6 10.3 
8 17.9 17.7 16.1 12.1 
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V. Electrochemistry of Antineoplastic Gallium, Iron and 
Ruthenium Complexes with Redox Non-Innocent α-N-
Heterocyclic Chalcogensemicarbazones.  
 
This chapter constitutes a collaboration between experiment and theory. Only sections 
V.4, V.5 and the theoretical parts of sections V.6, V.7 are being submitted as part of the 
thesis. 
 
V.1. Abstract 
 
The electrochemical properties of a series of α-N-heterocyclic 
chalcogensemicarbazones (HL), namely thiosemicarbazones, selenosemicarbazones and 
semicarbazones and their gallium(III), iron(III) and ruthenium(III) metal complexes with the 
general formula [ML2][Y] (M = Ga, Fe or Ru; Y = PF6− or NO3−) were studied in detail by 
cyclic voltammetry. All complexes show several, mostly reversible, redox waves attributable 
to the reduction of the non-innocent chalcogensemicarbazone ligand(s) at lower potentials (< 
–0.4 V vs. NHE) than the metal-centered iron or ruthenium redox waves (> 0 V vs. NHE) in 
organic electrolyte solutions. The cyclic voltammograms of the gallium complexes display at 
least two consecutive reversible one-electron reduction waves. These reductions are strongly 
shifted by ~0.6 V to lower potentials in the corresponding iron and ruthenium complexes. 
The ligand-centered reduction is supposed to take place at the CH3C=N double bond by 
comparing electrochemical, chemical and spectroscopic data. Quantum chemical calculations 
on the geometric and electronic structure of a thiosemicarbazone HL, the corresponding 
metal complexes [Ga(L)2]+ and [FeII(L)2], and the one-electron reduction product for each of 
these species support this assignment of the reduction site and elucidate the observed order of 
the ligand-centered redox potentials; E1/2([FeII(L)2]) < E1/2(HL) < E1/2([Ga(L)2]+).  
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V.2. Introduction 
 
Metal-based anticancer prodrugs may be activated selectively in the hypoxic tumor 
tissue upon reduction by biological reducing agents.1,2 Electron-transfer can occur either to 
the metal-center, or, if in the biologically accessible range, to non-innocent ligands, resulting 
in reactive species capable of attacking biologically relevant target molecules either by ligand 
displacement at the low valent metal center or by radicals formed at the ligand entity, 
respectively. An “activation-by-reduction” step is thought to be important for platinum(IV) 
complexes which have been evaluated in clinical development, e.g. tetraplatin ([PtCl4(1,2-
(NH2)2C6H4)], abandoned), satraplatin ([PtCl2(OAc)2(NH3)(NH2C6H5)], phase III), and 
iproplatin ([PtCl2(OH)2(NH2iPr)2], abandoned),3 as well as for the activation of 
investigational ruthenium(III) prodrugs like trans-[RuCl4(Hind)2]− (KP1019) and trans-
[RuCl4(Him)(S-DMSO)]− (NAMI-A), both of which have already finished phase I clinical 
trials.4-6 Indeed, an increasing metal-centered redox potential was shown to correlate with 
higher cytotoxicity for a series of platinum(IV)7 and azole-based ruthenium(III) compounds.8 
Metal-centered redox pontenials can be tuned and predicted by application of Lever’s 
parametrization method, facilitating markedly their design as bioreductive drugs.1,9,10 
Although hypoxia-selective organic drugs are under intensive investigation, e.g., 
nitroimidazoles,11 little is known about reductively activated metal-based compounds 
containing electronically non-innocent ligands with physiologically accessible redox 
potentials. One such example is ferrocenyl hydroxytamoxifen, containing a ferrocene-moiety 
attached to a hydroxylated form of the estrogen receptor modulator tamoxifen which shows 
high activity on estrogen receptor positive and negative cell lines.12,13 
 
Thiosemicarbazones are versatile redox non-innocent ligands with a wide range of 
coordination modes in metal complexes, in particular when their binding capacity is further 
increased by condensation with an aldehyde or ketone containing an additional donor atom in 
a suitable position for chelation.14 Beside their exciting coordination chemistry, 
thiosemicarbazones have evoked considerable interest because of their broad spectrum of 
pharmacological activity. In particular, α-N-heterocyclic thiosemicarbazones were found to 
possess antitumor, antimalarial, antibacterial, antifungal and antiviral activity.15 The enzyme 
ribonucleotide reductase (RR) has been identified as the principal molecular target.16 
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Ribonucleotide reductase converts ribonucleotides to deoxyribonucleotides necessary for 
DNA synthesis and is highly expressed in tumor cells making it a suitable and well 
established target in cancer chemotherapy.17 Initially, the inhibition of RR was attributed to 
the ability of thiosemicarbazones as strong chelators to remove iron from the enzyme active 
site, but later it was found that preformed iron chelates of some thiosemicarbazones with a 
terminal NH2 group (4NH2) show higher RR inhibitory activity than the uncomplexed 
thiosemicarbazones.1820 This is in agreement with data of 3-aminopyridine-2-carboxaldeyde 
thiosemicarbazone (Triapine®), an investigational drug currently in phase II clinical trials,21 
where an increase in cytotoxicity upon coordination to iron was reported.  
 
We reported previously that in the presence of the reductant dithiothreitol (DTT) 
iron(III) complexes with 4N-disubstituted α-N-heterocyclic thiosemicarbazone ligands show 
the fastest destruction of the R2 specific tyrosine free radical in mouse RR followed by the 
metal-free ligands and the corresponding gallium(III) complexes.22 In the absence of DTT no 
radical quenching was observed, and the cytotoxicity data for the same compounds tested in 
the cancer cell lines 41M (ovarian carcinoma) and SK-BR-3 (mammary carcinoma) are in 
reversed order: the gallium complexes exhibited slightly higher cytotoxicity in the low 
nanomolar range in comparison to the metal-free ligand, whereas the iron(III) complexes 
displayed a much lower cytotoxicity in the micromolar range. Thus, iron is essential for the 
fast quenching of the tyrosyl radical in RR, but it is not solely responsible for the antitumor 
potency of the 4N-disubstituted thiosemicarbazone derivatives suggesting the existence of 
additional molecular targets. The requirement of an adequate reductant (e.g., DTT) for 
successful radical quenching indicates that the iron(III) complex is reduced to its iron(II) 
form prior radical quenching. Similar observations were reported previously for Triapine23 
and other thiosemicarbazones.19,20 
 
These findings prompted us to prepare a series of gallium(III), iron(III) and 
ruthenium(III) complexes of the general formula [ML2][Y] (M = Ga, Fe and Ru; Y = PF6− or 
FeCl4−), where HL is a chalcogensemicarbazone ligand (Chart 1 and 2) and to investigate the 
effect of coordination to the metal on their metal- and ligand-centered redox properties by 
carrying out detailed electrochemical investigations and quantum chemical calculations. We 
were particularly interested to clarify if the redox properties/potentials of the prepared 
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compounds are of physiological relevance, i.e., to elucidate whether a relation between their 
electrochemical properties and antiproliferative activity or R2 specific tyrosine free radical 
quenching ability can be found. 
 
Chart 1. The chalcogensemicarbazone ligands used in this study 
Y
N
N
N
H
R
X
HLA : X = S, Y = CH, R = N(C4H8)
HLB: X = S, Y = CH, R = N(CH3)2
HLC: X = S, Y = CH, R = NH(C6H5)
HLD: X = S, Y = CH, R = NH(p-C6H4NO2)
HLE: X = S, Y = N, R = N(C4H8) (E)
HLG: X = S, Y = N, R = N(CH3)2
HLF: X = S, Y = N, R = N( C5H10)
HLI: X = S, Y = N, R = NH(p-C6H4NO2)
HLH: X = S, Y = N, R = NH(C6H5)
(G)
HLJ: X = O, Y = CH, R = N(CH3)2
HLK: X = Se, Y = CH, R = N(CH3)2
(J)
(A)
(B)
(C)
(D)
(F)
(H)
(I)
(K)
N
H
N
N
H
N
S
HLM (M)
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Chart 2. The library of metal chalcogensemicarbazonate complexes 
Y
N
N
N
X
Y
N
N
NR
X
M
Z ‾
R
[ML2][Z]
+
M = Fe, L = LA, Z = FeCl4
M = Fe, L = LB, Z = FeCl4
M = Fe, L = LE, Z = FeCl4
M = Fe, L = LF, Z = FeCl4
M = Fe, L = LG, Z = FeCl4
M = Fe, L = LA, Z = PF6
M = Fe, L = LB, Z = PF6
M = Fe, L = LC, Z = PF6
M = Fe, L = LD, Z = NO3
M = Fe, L = LE, Z = PF6
(2'A)
(2'B)
(2'E)
(2'F)
(2'G)
(2A)
(2B)
(2C)
(2D)
(2E)
M = Fe, L = LH, Z = NO3
M = Fe, L = LG, Z = PF6
M = Fe, L = LF, Z = PF6
M = Fe, L = LI, Z = NO3 (2I)
(2H)
(2G)
(2F)
M = Ru, L = LB, Z = PF6 (3B)
M = Ga, L = LA, Z = PF6
M = Ga, L = LB, Z = PF6
M = Ga, L = LC, Z = PF6
M = Ga, L = LD, Z = NO3
M = Ga, L = LE, Z = PF6
(1A)
(1B)
(1C)
(1D)
(1E)
M = Ga, L = LH, Z = NO3
M = Ga, L = LG, Z = PF6
M = Ga, L = LF, Z = PF6
M = Ga, L = LI, Z = NO3 (1I)
(1H)
(1G)
(1F)
M = Ga, L = LK, Z = PF6 (1K)
M = Ga, L = LJ, Z = PF6 (1J)
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V.3. Electrochemical Studies 
 
V.3.1. Ligand-Centered Reduction.  
 
The electrochemical data for the metal complexes and ligands under study are 
summarized in Table 1 and Table S1, respectively, and their electrochemical behavior is 
shown in Scheme 1. In general, all complexes show several redox waves attributable to the 
reduction of the non-innocent thiosemicarbazone ligands at lower potentials (< –0.4 V vs. 
NHE) than the metal-centered redox waves for the iron and ruthenium complexes (> 0 V vs. 
NHE; see below). The cyclic voltammograms of 0.20 M [n-Bu4N][BF4]/CH3CN solutions of 
the gallium thiosemicarbazonate complexes 1A–1I display two consecutive reversible one-
electron (as confirmed by controlled potential electrolysis of 1B) redox waves with oxip /redip = 
1.0 at v > 50 mV/s with ∆Ep = 60 – 70 mV at 0.20 V/s (Scheme 1a, Figure 1). The redox 
potential of the first ligand reduction (wave ILred) occurs between –0.38 and –0.96 V, and the 
second (wave IILred) between –0.62 and –1.25 V vs. NHE depending on the ligand identity 
(Table 2). As expected, complex 1A with the 2-pyridinyl and 4-pyrrolidinyl substituents at 
the thiosemicarbazone ligands shows the most negative redox potentials, whereas complex 1I 
with the more electron–withdrawing moieties p-nitroanilinyl and 2-pyrazinyl (the latter being 
weaker σ-donor and stronger π-acceptor than the 2-pyridinyl moiety) has the most positive 
redox potential for the ligand centered reductions. After these two consecutive reversible 
reduction processes a third irreversible redox wave IIILred is observed for the pyridinyl 
complexes 1A – 1C between –1.63 and –1.81 V vs. NHE, whereas wave IIILred is a reversible 
one-electron reduction process at –1.35 and –1.56 V vs. NHE for the pyrazinyl containing 
complexes 1E – 1H and is followed by a fourth partial quasi-reversible one-electron 
reduction wave, IVLred, at ca. –1.80 V vs. NHE (∆Ep = 100–150 mV) (Figure 2a). For 
complex 1H this fourth reduction wave is irreversible because it overlaps with a further wave 
at ca. –1.95 V vs. NHE. Waves IIILred and IVLred were not detected for 1D and 1I, both 
containing a nitro-group attached to the thiosemicarbazone ligand, but instead a quasi-
reversible (∆Ep = 90–100 mV) reduction of the NO2 group24 at E1/2 = –1.04 and –1.01 V vs. 
NHE was observed, respectively. Complexes with nitro-derivatives are scarcely soluble in 
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CH3CN and were therefore measured in 0.20 M [n-Bu4N][BF4]/DMF. However, no variations 
in redox properties/potentials of the complexes have been observed in DMF or CH3CN 
electrolyte solutions as established for complex 2D. 
 
Table 1. Summary of the Electrochemical Data for the Metal Complexes 
Gallium complexes 
  E1/2 / ILred E1/2 / IILred E1/2 / IIILred 
1A    –0.96 –1.25 –1.81c,e 
1B   –0.93 –1.22 –1.77c,e 
1C   –0.79 –1.05 –1.63c  
1Db   –0.70c –0.84c N/Af 
1E   –0.60 –0.88 –1.56 
1F   –0.58 –0.84 –1.49 
1G   –0.58 –0.85 –1.51 
1H   –0.46 –0.72 –1.35  
1Ib   –0.38d –0.62d N/Af 
1J   –1.03 –1.34 –2.04c 
1K   –0.94 –1.22 –1.73c,e 
Iron complexes 
 
E1/2 / CFered E1/2 / AFered E1/2 / ILred E1/2 / IILred Ep / IIILred 
2A 0.06 – –1.62d –2.01c,g –2.01c,g 
2B 0.08 – –1.61d –1.99c,g –1.99c,g 
2C 0.18 – –1.44d –1.72d –2.15c,e 
2Db 0.27 – N/Af N/A N/A 
2E 0.32 – –1.23 –1.65 –2.12c,e 
2F 0.32 – –1.21 –1.64 –2.09c,e 
2G 0.34 – –1.22 –1.64 –2.13c,e 
2H 0.43 – –1.08 –1.47 –1.97c,e 
2Ib 0.51 – N/Af N/A N/A 
2’A 0.06 0.30 –1.60c
 
  
2’B 0.08 0.30 –1.61d   
2’E 0.31g 0.31g –1.20 c   
2’F 0.31g 0.31g –1.21d   
2’G 0.32g 0.32g –1.22d   
Ruthenium complex 
 
E1/2 / RuIII/II E1/2 / RuIV/III E1/2 / ILred Ep / IILred Ep / IIILred 
3B +0.21 +1.27 –1.56 –2.00c,g –2.00c,e,g 
a) Potentials in V ± 0.01 vs. NHE in 0.20 M [n-Bu4N][BF4]/CH3CN; b) measured in 0.20 M 
[n-Bu4N][BF4]/DMF; c) for the irreversible wave, the Ep values are given; d) oxip / redip 
between 0.6 and 0.8 at 0.2 V/s; e) two or multi electron process (see text); f) for complexes 
with nitro-containing ligands, the reduction of this group at ca. –1.0 V vs. NHE prevented the 
detection of further ligand-centered redox waves (see text); g) could not be detected as 
separate waves. 
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Scheme 1. Schematic overview of the electrochemical behavior of the studied Ga (a), Fe (b) 
and Ru (c) complexes 
 
 
Figure 1. Cyclic voltammograms of (a) 1A and (b) 1F in CH3CN containing 0.20 M [n-
Bu4N][BF4] at a scan rate of 0.20 V s–1 using a platinum working electrode. Square wave 
voltammograms (SWVs; c) of 1.0 mM 1A (black line) and 1F (gray line) electrolyte 
solutions were measured with 2 mV step height, 25 mV pulse and 100 Hz frequency. The 
solid line on the bottom right refers to the current (10 µA) for a–c. For the assignment of 
waves, see text 
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The influence of the chalcogen atom X of the chalcogensemicarbazone ligands (Chart 
1) on the redox potential was studied with complexes 1B, 1J and 1K, which contain a sulfur, 
oxygen or selenium atom, respectively. Complex 1J (X = O) displays the lowest reduction 
potentials at –1.03 and –1.34 V vs. NHE for ILred and IILred, respectively, whereas 1K (X = 
Se) and 1B (X = S) have a similar redox potential at –0.94 to –0.93 and –1.22 V vs. NHE for 
the corresponding redox waves. Thio- and selenosemicarbazone ligands are known to have 
comparable NMR spectra,25 and the gallium complexes 1B and 1K also possess similar 1H 
and 13C NMR chemical shifts with the largest deviation in the 13C NMR spectra of the C–X 
resonance (detected at 176.1 and 173.8 ppm, respectively).22,26 Complex 1J shows a 
considerably different spectrum with the C–X resonance at 167.1 ppm and strong high field 
shifts for both carbon resonances at the CH3C=N moiety (1B: 14.9, 149.0 ppm; 1K: 15.6, 
147.4 ppm; 1J: 12.6, 139.3 ppm); in accordance with the lower redox potential of complex 1J 
(see below). 
 
The ligand-centered reduction of 2A–2I at the iron(II) center (for FeIII→FeII process 
see below) is similar to the gallium analogues, although the corresponding redox potentials 
ILred and IILred are considerably more negative between –1.08 and –1.62 V, and –1.47 and –
2.01 V vs. NHE, respectively (Scheme 1b, Figure 2b, Table 1). In the case of 2A and 2B the 
wave IILred at –2.01 and –1.99 V vs. NHE overlaps with IIILred resulting in two 
indistinguishable redox waves. Complexes 2C–2H are reduced at IIILred between –1.97 and –
2.15, close to the solvent cut-off potential. The much lower redox potentials of the iron(II) 
complexes in comparison to the gallium(III) complexes can be explained at least partially by 
the different charges of the complexes. The uncharged iron(II) posses a higher electron 
density and is therefore harder reducible than the positively charged gallium(III) complex. 
For the nitro group containing complexes 2D and 2I only one irreversible reduction wave at –
0.97 V and –0.93 V vs. NHE was detected which can be attributed to the reduction of the 
nitro group. This is only slightly shifted to more positive potential compared to that in the 
analogous gallium complexes. The presence of the tetrachloridoferrate counteranion in 2’A–
2’G prevented the accurate detection of the second reduction wave IILred in these complexes, 
because the counteranion reacts readily with the ligand radical formed upon reduction at ILred. 
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The ruthenium complex 3B shows the first ligand reduction at E1/2 = –1.56 V vs. NHE 
(Scheme 1c, Figure 2c), whereas IILred, like for the pyridine containing iron complexes 2A 
and 2B, overlaps with IIILred resulting in an irreversible reduction wave at –2.00 V (Figure 3). 
 
Figure 2. Cyclic voltammograms of 1G (a), and 2E (b), and 3B (c) in CH3CN containing 0.20 
M [n-Bu4N][BF4] at a scan rate of 0.20 V s–1 using a glassy carbon working electrode, 
displaying the ligand (Lred), the FeIII/FeII (CFered), and the RuIII/RuII and RuIV/RuIII redox 
couples 
 
 
Figure 3. Cyclic voltammogram of 3B in CH3CN containing 0.20 M [n-Bu4N][BF4] at a scan 
rate of 0.20 V s–1 using a glassy carbon working electrode 
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Increasing electron donor properties of substituents are known to increase the 
effective negative net charge on the corresponding compounds and result usually in a 
decrease of their redox potentials. Plotting the pKa values of the attached amine moieties 
[dimethylamine (10.73), pyrrolidine (11.31), piperidine (11.12), aniline (4.87) and p-
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nitroaniline (1.02)]27 vs. E1/2 results in a linear relationship (Figure 7). By using the resultant 
linear equations (see caption of Figure 4 for the equations of FeIII→FeII and ILred) and the pKa 
values of the attached amine moieties the redox potentials of novel synthesized 2-
acetylpyridine(pyrazine) thiosemicarbazone gallium(III) and iron(III) complexes in CH3CN 
solution can be predicted. The increased redox potential of complexes containing a pyrazine 
(1E–1I, 2E–2I) instead of a pyridine (1A–1D, 2A–2D) moiety can also be rationalized by the 
increased net donor properties of the latter [EL(pyridine) = 0.25 V, EL(pyrazine) = 0.33]9 and 
the different pKa-values [pKa(pyrazine) = 0.65, pKa(pyridine) = 5.23], respectively.27 
 
Figure 4. Plot of pKa values of attached amine moieties on thiosemicarbazone ligands vs. 
ligand- and metal-centered E1/2 values for the gallium (1A–1I, top) and iron (2A–2I, bottom) 
complexes. For the complexes 2D and 2I the reduction of the nitro group prevented the 
detection of the ligand reductions. CFered = FeIII/FeII redox couple of complex cation; Lred = 
ligand-centered reduction; thiosemicarbazonate complexes with pyrazine or pyridine moieties 
are shown separately and indicated with pz or py, respectively. Linear equations: Gallium 
complexes: ILred (pz): E (V) = –0.3592 – 0.0206pKa (r = 0.996); ILred (py): E (V) = –0.6726 – 
0.0247pKa (r = 0.997). Iron complexes: FeIII→FeII (pz): E (V) = 0.5244 –0.018pKa (r = 
0.995); FeIII/→FeII (py): E (V) = 0.2847 – 0.0197pKa (r = 0.995); ILred (pz): E (V) = –0.9692 – 
0.0227pKa (r = 0.998); ILred (py): E (V) = –1.3021 – 0.0284pKa (r = 0.999) 
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The metal-free thiosemicarbazone ligands A–I exhibit an irreversible reduction 
response at –1.01 to –1.47 V vs. NHE (Table S1). The second reduction wave could only be 
observed occasionally and was hardly reproducible indicating the instability of the radical 
formed after the first reduction process. For the p-nitrophenyl ligands D and I a quasi-
reversible nitro reduction wave was detected at –1.04 and –1.03 V vs. NHE, respectively.24 In 
agreement with the remote position of the nitro group in the ligands, these potentials are only 
slightly more negative than those of the corresponding ligands in the gallium and iron 
complexes. In addition, an irreversible pre-wave was observed at Ep = –0.82 and –0.80 V vs. 
NHE, respectively, which was also reported for o-nitrotoluene and m-nitrotoluene in aprotic 
solvents.28 In contrast to the ligand centered reduction of the metal complexes where all 
ligands are forced to adopt the same configuration, the metal-free ligands are present as 
different isomers in solution, therefore showing no conclusive correlation between the Ep and 
pKa values of the amine moieties of the ligand. In particular, for ligand B three different 
isomers were found in DMSO solution,26 two of them with strong intramolecular hydrogen 
bonds, whereas ligand H in the same solvent did not undergo any isomerization (see NMR 
data). The metal-ion stabilizes the reduced ligand radicals preventing their decomposition in 
the time-scale of cyclic voltammetry and allowing for the observation of two or three 
reversible ligand-centered redox waves upon coordination. The gallium-complexes are 
reduced at ~0.3–0.8 V more positive redox potential than the uncoordinated ligands, whereas 
the same ligand centered reductions in the iron(II)- and ruthenium(II)-ions occur at ~0.0–0.4 
V more negative redox potentials than in the metal-free thiosemicarbazones. Therefore 
complexation to different metal ions strongly influences the ligand centered redox potentials 
which offers the possibility to specifically shift the redox potentials into the physiologically 
accessible range. 
 
V.3.2. Metal-Centered Redox Processes. 
 
The cyclic voltammograms of the iron complexes 2A–2I (Figure 5a, Table 1) display 
one reversible single-electron reduction wave, CFered, at 0.06 to 0.51 V vs. NHE, which is 
assigned to the FeIII→FeII process of the cationic complex (oxip /redip = 1.0 for v > 0.05 V/s 
with ∆Ep = 0.60 – 0.70 V at 0.2 V/s). As observed for the ligand-centered redox behavior, an 
increasing net electron-donor character correlates with a decrease in redox potential. The 
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correlation of pKa values with redox potentials for the coordinated thiosemicarbazone ligands 
also holds true for the iron-centered redox couples (Figure 4). Whereas complexes 2A–2I 
showed only one reduction wave (Figure 5a), the analogous complexes 2’A–2’G displayed a 
second wave at 0.31±0.01 V vs. NHE, which is attributed to the reduction of the 
tetrachloridoferrate anion, AFered (Figure 5b). Wave AFered overlaps in 2’E–2’G with the 
reduction wave of the complex cation, and could not be resolved by CV or SVW scans, 
indicating that a set of two tridentate ligands E – G acts as a net electron-donor as strong as 
four tetrahedrally coordinated chlorido ligands. The current height in 2’E–2’G (same 
concentration and experimental conditions) was approximately two-fold compared to 2E–2G 
as confirmed by cyclic voltammetry (Figure 5c). Square wave voltammetry revealed that the 
unresolved wave in 2’E - 2’G arises from an overlap of the FeIII/FeII waves of the cationic 
iron-complex and the tetrachloridoferrate anion indicating the two-electron nature of this 
reduction wave, one from the reduction of the complex cation and one from the 
tetrachloridoferrate anion (Figure 5). The two-electron nature of the overlapped redox wave 
from 2’E - 2’G was confirmed by controlled potential electrolysis of 2’F at 0.14 V vs. NHE. 
 
The ruthenium(III) complex shows two reversible metal centered redox waves with 
the first one at +0.21 V for the RuIII→RuII redox couple and the second at +1.27 vs. NHE 
attributable to the RuIII→RuIV redox process (Figure 2c). The 1.06 V difference for the 
RuIII/RuII and RuIV/RuIII redox couple is narrow compared to the commonly observed 
separation of these two redox waves of ca. 1.6 V for ruthenium complexes with octahedral 
coordination sphere in non-aqueous solvents.29 However, this difference can be explained by 
the distortion of the octahedral geometry by the tridentate thiosemicarbazonate ligands, which 
makes direct comparisons with other sterically non-constrained complexes difficult. 
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Figure 5. Cyclic voltammograms (top) and square wave voltammograms (bottom, 2 mV step 
height, 25 mV pulse, 100 Hz frequency) of (a) 2A (black), (b) 2’A (gray), (c) 2’E (black) in 
0.20 M [n-Bu4N][BF4]/CH3CN at a scan rate of 0.20 V s–1 by using a platinum working 
electrode. CFered indicates the metal-centered reduction of the cathodic complex, and AFered 
the reduction of the [FeCl4]− counteranion 
 
 
V.3.3. Location of Reduction Site. 
 
Most of the literature dealing with electrochemical properties of α-N-heterocyclic 
thiosemicarbazone complexes are exclusively focused on the metal centered redox 
reactions,3033 neglecting the ligand centered redox processes. If reductions are described 
which are associated with the ligand, the position where reduction takes place in the 
thiosemicarbazone moiety is either undefined3436 or changes between the thione portion,37 the 
azomethine part38,39 or both of them,40 whereas no further studies are described to support 
these assumptions. Detailed investigations on the reduction pathway were performed for the 
metal-free 2-formylpyridine thiosemicarbazone in methanol.41 The data showed that the 
ligand will be first protonated at the azomethine nitrogen then cleaved at the N–N bond 
forming thiourea and the 2-pyridinemethaniminium ion which is then further reduced to 
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protonated 2-picolylamine. Two other reduction mechanisms were excluded in this study 
namely the reduction at the pyridine ring resulting in dihydropyridine and the formation of 
the thiol by reduction of the C=S double bond. The direct reduction of the azomethine bond is 
not discussed, but was already described 20 years before for the same ligand in water.42 There 
is only one publication dealing with the metal ion influence on the redox potentials of a 
thiosemicarbazone ligand.43 Although no reference electrode was reported, making a 
quantitative comparison impossible, the reported redox potentials of the perchlorate salt of 
the iron(III) complex 2B and the ligand HLB appeared at considerably different values for all 
reduction waves than observed in the present study. To the best of our knowledge this is the 
first detailed electrochemical study of the influence of metal ions on the redox properties of 
thiosemicarbazones and the influence of the chalcogen donor identity on the reduction 
processes. 
 
There exist two possible locations, where the ligand-centered reduction of the 
complexes takes place: either at the C=N double bond of the 2-acetylpyridine moiety 
(CH3C=N) or at the C=N double bond in close proximity to the chalcogen atom. Comparing 
the 13C NMR data of the gallium complexes 1A – 1I with the E1/2 redox potentials a good 
correlation can be found for both carbon resonance of the CH3C=N moiety (Figure 6 and 
Figure 7); an increasing redox potential at ILred and IILred correlates with enhanced electronic 
deshielding resulting in lower-field chemical shifts for the corresponding 13C nucleus. In 
contrast no correlation could be found for the C–S resonance (1A: 172.9 ppm; 1B: 176.1 
ppm; 1C: 172.5 ppm; 1D: 172.4 ppm). Therefore, we suppose that the one-electron ligand-
centered reduction site is located at the 2-acetylpyridine C=N bond. This is in agreement with 
quantum chemical calculations (see below) and the chemical reduction of this C=N bond for 
the metal-free and coordinated ligands. Addition of NaBH4 to an ethanolic solution of ligand 
HLB resulted in the reduction of the C=N bond and the formation of ligand HLM which 
exhibits its first reduction wave only at –2.10 V vs. NHE. Similarly, reduction of the nitrate 
salt of 1B (obtained by precipitation with diethyl ether prior to the addition of ammonium 
hexafluorophosphate) with NaBH4 yielded a product containing the uncoordinated reduced 
ligand HLM in around 50 % yield. 
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Figure 6. Plot of δ(13C=N) of the CH3C=N moiety vs. E1/2 of complexes 1A–1H 
 
 
Figure 7. Plot of δ(13CH3) of the CH3C=N moiety vs. E1/2 of complexes 1A–1H 
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V.4. Quantum Chemical Studies.  
 
Density functional calculations were performed to elucidate (i) why the ligand 
centered reductions of the iron(II) complexes [FeII(L)2] (formed by reduction of the iron(III) 
complex [FeIII(L)2]+) have a lower standard reduction potential (SRP) than the non-metalated 
thiosemicarbazones (HL) and (ii) to locate the site of reduction at the thiosemicarbazone 
ligands. The reduction of a compound should be strongly facilitated by forming a complex 
with a dicationic metal ion, which should have been reflected by a considerably higher redox 
potential. The one-electron-reduction events involving the species, (LB)−, HLB, [Ga(LB)2]+ 
 143 
and [FeII(LB)2], yielding their reduced forms, (LB)2−, (HLB)−, [Ga(LB)2] and [FeII(LB)2]−, 
respectively, have been investigated and compared. Note that the deprotonated species (LB)− 
shall serve as the intuitive reference compound in our calculations, as the reduction potential 
of (LB)− may be controlled by either protonation (HLB) or metalation ([Ga(LB)2]+ and 
[FeII(LB)2]). Table 2 shows an excellent agreement of our calculated and experimental SRPs, 
validating the computational approach employed for this study. 
 
Table 2. Calculated and experimental standard redox potentials (SRP, in V vs. NHE), 
Hirshfeld partial charges in the oxidized and reduced forms, and LUMO energy level of the 
oxidized species (ELUMO, in eV) 
  partial charges  
 SRP ox red  
compound calc exp Ma L1 L2 Ma L1 L2 ELUMO 
(LB)−/2− –1.65   –1.00   –2.00  1.14 
[Fe(LB)2]0/− –1.56 –1.61 0.02 –0.01 –0.01 0.02 –0.51 –0.51 –2.39 
(HLB)0/− –1.15 –1.21 0.08 –0.08  0.08 –1.08  –3.00 
[Ga(LB)2]+/− –0.94 –0.93 0.32   0.34   0.34 0.32 –0.24 –0.08 –5.84 
a
 H, Ga, and Fe, respectively 
 
Figure 8 displays the predicted structures of the four species and their reduced forms. 
Only the isomers of (LB)− and HLB that are calculated to be most stable in acetonitrile 
solution are shown here, while all isomers and their relative free energies are given in Figure 
9. The predicted bond lengths in HLB and [Ga(LB)2]+ are in good to excellent agreement with 
available X-ray crystallographic structures (Table S5). The calculations reveal structural 
changes in the entire compounds upon reduction. In the free ligand (LB)− (Figure 8, top), the 
C–S bond is elongated (+0.04 Å) upon reduction, the adjacent C=N bond is shortened (–0.04 
Å), the N–N bond is elongated (+0.03 Å), the acetylpyridine C=N bond is elongated (+0.03 
Å), the adjacent C–C bond is shortened (–0.04 Å), and the C=N bond in the pyridine is 
elongated (+0.04 Å). Similar structural changes occur when the protonated species HLB is 
reduced (Figure 8). Upon reduction of [Ga(LB)2]+, such structural changes occur in one of the 
ligands (L1), whereas the distances in the second ligand (L2) do not change significantly 
(Table S5). In [FeII(LB)2], the structural changes occur in both ligands but to a lesser extent 
than those in L1 of [Ga(LB)2]+. The iron complex maintains its C2 molecular symmetry upon 
one-electron reduction, as both ligands remain equivalent, whereas the gallium complex 
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becomes asymmetric. The reduction of the metal complexes is also accompanied by changes 
in the metal-ligand distances (Table 3). Both Ga–N bonds to L1 are significantly shortened (–
0.09 Å each), while all other Ga-ligand bonds are elongated by up to 0.06 Å. In contrast, all 
Fe-ligand bond lengths are either elongated upon reduction or remain constant. 
 
Figure 8. Calculated structures of the oxidized species (LB)−, HLB, [Ga(LB)2]+ and 
[FeII(LB)2] (left) and their reduced forms (right). Bond lengths in Å 
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Figure 9. Calculated relative energies (in kcal/mol) of plausible isomers of 2-acetylpyridine 
N,N-dimethylthiosemicarbazone (HLB) and its deprotonated form (LB)− in acetonitrile 
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Table 3. Calculated metal-ligand bond lengths in Å 
  metal–S metal–N(N–N) metal–
N(py) compound moiety  ox red ox red ox red 
[Ga(LB)2]+/0 L1 2.39 2.43 2.09 2.00 2.18 2.10 
 L2 2.39 2.45 2.09 2.15 2.18 2.21 
[Fe(LB)2]0/− L1 2.36 2.39 1.94 1.94 1.99 1.99 
 L2 2.36 2.39 1.94 1.94 1.99 1.99 
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Table 2 lists the electron-density-based Hirshfeld partial charges on the ligands, the 
metals, and the proton in the four species and their reduced forms. The calculated charges at 
the H, Fe, and Ga atoms in HLB, [FeII(LB)2] and [Ga(LB)2]+ are +0.08, +0.02, and +0.32, 
respectively, while the charge on each ligand is –0.08, –0.01, and +0.34, adding up to a total 
charge of 0, 0, and +1 in these compounds. Upon reduction, the charges at H, Fe, and Ga 
remain constant, while the additional electronic charge is distributed over the ligands. Equal 
charges on both ligands in the reduced iron complex, [FeII(LB)2]−, but different charges on 
both ligands in the reduced gallium complex, [Ga(LB)2], are consistent with the structural 
changes upon reduction and suggest that the one-electron reduction of the iron complex 
occurs on both ligands in a delocalized manner, whereas it occurs in the gallium complexes 
primarily on either ligand. Partial charges calculated using various other approaches are given 
in the Supporting Information (Table S4); note that the basis-function-based Mulliken partial 
charge on the Fe atom would change by –0.8 upon reduction, which would erroneously 
indicate a metal-centered reduction of the iron(II) complex. 
 
Figure 10 displays the semi-occupied molecular orbital (SOMO) of the four reduced 
species (LB)2−, (HLB)−, [FeII(LB)2]−, and [Ga(LB)2]. This orbital corresponds in each case to 
the lowest unoccupied orbital (LUMO) of the oxidized form (Figure 11). The LUMO energy 
levels of the oxidized species are also listed in Table 2 and correlate with the reduction 
potentials: the lower the LUMO energy, the easier the reduction. The SOMO of (LB)2− and its 
conjugate acid (HLB)− are very similar; they are distributed over the entire π system and have 
both bonding and antibonding character leading to the bond distance changes upon reduction 
(see above). For instance, as the SOMO of (HLB)− has a bonding contribution to the C=N 
bond adjacent to the sulfur atom (marked with b in Figure 10), this bond is shortened when an 
electron occupies this orbital. The SOMO of (HLB)− has an antibonding contribution to the 
C=N bond adjacent to the pyridyl group (marked with a in Figure 10), thus elongating this 
bond upon reduction. This result is consistent with the chemoselective hydrogenation of the 
latter C=N bond by NaBH4 (see above). The SOMO of the reduced metal complexes show 
the same bonding and antibonding patterns as those in the SOMO of the free ligand. In the 
gallium complex, the SOMO is mainly distributed over either ligand. The asymmetric 
reduction with the strong shortening of the Ga–N bonds to either ligand maximizes the 
predominantly electrostatic interactions between the metal center and the reduced ligand. In 
contrast, the SOMO of the reduced iron complex is equally distributed over both ligands. It 
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contains a small fraction of a metal d orbital, which combines with the ligand orbitals in an 
antibonding fashion. Note that the Fe–N bond lengths change only insignificantly during 
reduction, indicating an enhanced Pauli repulsion between the ligand orbitals and the partially 
filled d shell in the reduced iron complex. 
 
Figure 10. SOMO of the reduced species 
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Figure 11. LUMO of the oxidized species (LB)−, HLB, [FeII(LB)2] and [Ga(LB)2]+ 
 
 
V.5. Computational Details.  
 
The geometries of the deprotonated 2-acetylpyridine 4N,4N-
dimethylthiosemicarbazone ligand (LB)−, its conjugated acid HLB, the metal complexes 
[Ga(LB)2]+, [FeII(LB)2], and the reduced form of each of these species were optimized using 
the 3-parameter fit of exchange and correlation functionals of Becke44a (B3LYP), which 
includes the correlation functional of Lee, Yang, and Parr (LYP),44b as implemented in 
Gaussian 03.45 The LANL2DZ effective core potentials (ECPs)46 and the corresponding 
valence-basis sets were used on the metals and the 6-31G(d,p) basis sets were used on the 
other atoms. Vibrational frequencies calculated at this level confirm that all structures are 
minima on the potential energy surfaces. Improved energies were calculated by using a 
combination of the exchange functional of Becke47a and the correlation functional of 
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Perdew47b (BP86) together with the same ECPs and valence-basis set on the metal atoms but 
totally uncontracted and augmented with one set of f functions on Fe,48 together with the 6-
311+G(3d) basis set on the S atoms, and the 6-311+G(d,p) basis sets on the other atoms. Free 
energies in vacuo were calculated by adding corrections from unscaled zero-point energy 
(ZPE), thermal energy, work, and entropy evaluated at the B3LYP level at 298.15 K, 1 atm to 
the improved energies. Standard reduction potentials (SRPs) were calculated according to our 
previous approach,49 which was carefully validated for the reduction of 61 ruthenium(III/II) 
complexes (bearing formal charges from 3+/2+ to 1−/2−) in four solvents and shall be readily 
transferable to other metal complexes, as the metal ion is not solvent-exposed in any of those 
Ru complexes. The SRP prediction is based on a thermodynamic cycle and involves the 
calculation of solvation free energies using the Poisson-Boltzmann finite element method50 as 
implemented in Jaguar 751 with dielectric constant of 37.5 representing acetonitrile as the 
solvent. In the present work, the only difference to our previous SRP calculation approach49 
is the use of the BP86 functional for calculating improved energies, which leads to excellent 
agreement with experimental SRPs (see below) and was employed for similar purposes as 
well.52a The overestimation of the contribution of exchange energy by the B3LYP functional 
is well documented52b and may result in the overestimation of the stability of high-
multiplicity spin states in iron complexes. A comparison of the relative energies of the 
electronic states of [FeII(LB)2] and [FeII(LB)2]− and of the SRPs calculated using the BP86 and 
B3LYP improved energies is given in the Supporting Information (Table S2 and Table S3) 
and indicates that multireference approaches would be worth considering if permitted by the 
available computational resources. Other promising methods for this particular purpose 
include the spectroscopy oriented configuration interaction (SORCI) method and a ligand 
field theory (LFT)-based approach.52c Atomic partial charges at BP86 were calculated using 
the Mulliken53a scheme based on basis functions as implemented in Gaussian, the Hirshfeld53b 
scheme based on electron density as implemented in ADF,54 and the ESP53c scheme of fitting 
atomic charges to reproduce the electrostatic potential in Jaguar.51 
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V.6. Conclusions 
 
The electrochemical properties of a series of gallium-, iron-, and ruthenium-
chalcogensemicarbazone complexes are investigated in detail. The electrochemical behavior 
of these complexes can be specified by (i) physiologically accessible metal-centered redox 
potentials for the iron(III) and ruthenium(III) complexes, (ii) formation of stable ligand 
radicals on the time-scale of cyclic voltammetry upon reduction of the non-innocent 
chalcogensemicarbazone ligands in aprotic solvents, (iii) quenching of these reductively 
induced ligand radicals by water, (iv) favorable shift of the ligand-centered redox potential in 
the physiologically accessible range for some gallium complexes when electron-withdrawing 
moieties are incorporated into the ligand, and (v) ligand-reduction for the gallium complexes 
occurs at the CH3C=N double bond. Quantum chemical calculations show that reduction of 
the coordinated and metal-free thiosemicarbazone ligands occurs at a π orbital that spreads 
over the entire thiosemicarbazone moiety with the reduction occurring on both ligands in the 
iron complex [FeII(LB)2] and predominantly on either ligand in the gallium complex 
[Ga(LB)2]+. The ligand-centered reductions ILred and IILred take place at 0.6–0.8 V more 
positive potentials for the gallium complexes than for the uncoordinated (protonated) ligands, 
which on the other hand are easier to reduce than the corresponding iron(II) complexes. The 
redox potentials increasing in the order (LB)− < [FeII(LB)2] < HLB < [Ga(LB)2]+ correlate both 
with the calculated Hirshfeld partial charges on the thiosemicarbazone moieties in these 
compounds and with the energy levels of their LUMO, which becomes semi-occupied upon 
reduction. The intuitive assumption that the reduction of a compound is facilitated when it 
binds to a metal ion appears to be valid only if the free ligand (LB)−, in our case the 
thiosemicarabazonate, is considered as the reference compound, whereas a proton promotes 
the reduction of the thiosemicarbazone more strongly than does the iron(II) ion with its d6 
low-spin electron configuration. 
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V.7. Supporting Information  
 
Table S1. Redox potentialsa of the metal-free ligands HLA–HLM 
Ligand Ep / ILred 
A –1.26 
B –1.21 
Cb –1.47 
Db N/Ac 
E –1.06 
F –1.02 
G –1.01 
Hb –1.31 
Ib N/Ac 
J –1.83 
K –1.13 
M N/A 
a) Potentials in V ± 0.02 vs. NHE in 0.20 M [n-Bu4N][BF4]/CH3CN; b) measured in 0.20 M 
[n-Bu4N][BF4] / DMF; c) for the nitro-containing ligands, only the reduction of this group at 
ca. –1.0 V vs. NHE and a pre-wave at ca. 0.80 V vs. NHE can be observed (see text). 
 
Table S2. Comparison of standard reduction potentials (SRPs, in V vs. NHE) calculated at 
B3LYP and BP86 
Compound B3LYP BP86 exp 
(LB)−/2− –1.81 –1.69  
(HLB)0/− –1.18 –1.12 –1.21 
[Ga(LB)2]+/0 –1.35 –0.86 –0.93 
[Fe(LB)2]0/− –2.00 –1.56 –1.61 
 
Table S3. Relative energies (in kcal/mol) of plausible electronic states of [FeII(LB)2] and 
[FeII(LB)2]− 
 multiplicity B3LYP BP86 
[FeII(LB)2] 1 10.6 0 
 3 5.9 15.0 
 5 0 20.6 
[FeII(LB)2]− 2 13.5 0 
 4 0 6.3 
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Table S4. Calculated partial charges on the ligands and on the metal or hydrogen 
  Mulliken (lb)a Mulliken (sb)b ESP (sb)c Hirshfeldd 
Compound moiety ox red ox red ox red ox red 
(LB)−/2−  –1.00 –2.00 –1.00 –2.00 –1.00 –2.00 –1.00 –2.00 
(HLB)0/− H 0.30 0.29 0.29 0.28 –0.04 –0.01 0.08 0.07 
 L –0.30 –1.29 –0.29 –1.28 0.04 –0.99 –0.08 –1.07 
[Ga(LB)2]+/0 Ga 1.90 1.92 0.94 1.00 0.42 0.48 0.32 0.32 
 L –0.45 –0.96 0.03 –0.50 0.29 –0.24 0.34 –0.16 
[Fe(LB)2]0/− Fe –0.82 –0.84 –0.02 –0.02 –0.16 –0.10 0.02 0.02 
 L 0.41 –0.08 0.01 –0.49 0.08 –0.45 –0.01 –0.51 
a
 Large basis set. Totally uncontracted LANL2DZ on Ga and augmented with one set of f 
functions on Fe, together with the 6-311+G(d,p) basis sets on the other atoms, and the 6-
311+G(3d) on S.  
b
 Small basis set. LANL2DZ on the metal, 6-31G(d,p) on the other atoms.  
c
 Same small basis set, denoted LACVP** in Jaguar.  
d
 Scalar relativistic ZORA, TZV2P basis on the metals and TZVP basis set on the other 
atoms. 
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Table S5. Calculated bond lengths (in Å) 
  C1–S C1–N1 N1–N2 N2–C2 C2-C3 C3–N3 Metal–S Metal–N2 Metal–N3 
Compound  ox red ox red ox red ox red ox red ox red ox red ox red ox red 
(LB)−/2− Calc 1.719 1.757 1.364 1.327 1.340 1.373 1.331 1.356 1.464 1.442 1.373 1.414       
(HLB)0/− Calc 1.713 1.739 1.389 1.343 1.327 1.360 1.328 1.364 1.466 1.428 1.362 1.395       
 X-raya 1.723  1.350  1.353  1.299  1.474  1.352        
[Ga(LB)2]+/− Calc 1.755 1.759 1.362 1.346 1.338 1.355 1.331 1.343 1.464 1.445 1.370 1.387 2.412 2.453 2.089 2.057 2.141 2.119 
 X-rayb 1.741  1.342  1.356  1.304  1.465  1.361  2.373  2.032  2.131  
[Fe(LB)2]0/− Calc 1.747 1.752 1.349 1.336 1.358 1.369 1.344 1.355 1.442 1.428 1.383 1.400 2.318 2.341 1.902 1.902 1.942 1.944 
C3
N3 
C2
N2
N1
C1
N
S
C3
N3 
C2
N2
N1
C1
N
S H
HLB
(LB)-
C3
N3 
C2
N2
N1
C1
N
S
C3
 N3
C2
N2
N1
C1
N
S
M[M(LB)2]
 
a
 Kowol, C. R.; Eichinger, R.; Jakupec, M. A.; Galanski, M.; Arion, V. B.; Keppler, B. K. J. Inorg. Biochem. 2007, 101, 1946. 
b
 Arion, V. B.; Jakupec, M. A.; Galanski, M.; Unfried, P.; Keppler, B.K. J. Inorg. Biochem. 2002, 91, 298. 
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